

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 21, 2003, 18:39:49 ; Search time 27 Seconds
(without alignments)
1150.584 Million cell updates/sec

Title: US-09-913-955a-1

Perfect score: 3958
Sequence: 1 MEATGSSVETGKANKRQTR.....AFNCPNSTNRGMDSCLRW 749

Scoring table: BLOSUM62
Gapop 10.0, Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Database: SwIsProt_40.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3952	99.8	749	1 PEX_HUMAN	P78662 homo sapien
2	3837	96.9	749	1 PEX_MOUSE	P70669 mus musculu
3	1283.5	32.4	749	1 NEP_HUMAN	P08473 homo sapien
4	1270.5	32.1	749	1 NEP_RABIT	P08049 oryctolagus
5	1263.5	31.9	749	1 NEP_RAT	P07861 rattus norve
6	1262.5	31.9	749	1 ECEL_CAVPO	P97739 cavia porce
7	1259.5	31.8	749	1 NEP_MOUSE	P61391 mus musculu
8	1257	31.8	770	1 ECEL_HUMAN	P42892 homo sapien
9	1243.5	31.4	762	1 ECEL_RAT	P42893 rattus norve
10	1241.5	31.4	754	1 ECEL_BOVIN	P06344 homo sapien
11	1221	30.8	787	1 ECEL_HUMAN	P01071 bos taurus
12	1184	29.9	787	1 ECEL_MOUSE	P01071 mus musculu
13	992	25.1	775	1 ECEL_RAT	P01071 mus musculu
14	977	24.7	775	1 ECEL_HUMAN	P01071 mus musculu
15	969.5	24.5	775	1 ECEL_HUMAN	P01071 mus musculu
16	949	24.0	769	1 ECEL_HUMAN	P01071 mus musculu
17	597.5	15.1	732	1 ECEL_HUMAN	P01071 mus musculu
18	586	14.8	647	1 ECEL_HUMAN	P01071 mus musculu
19	495	12.5	626	1 ECEL_HUMAN	P01071 mus musculu
20	494	12.5	626	1 ECEL_HUMAN	P01071 mus musculu
21	365	9.2	564	1 ECEL_HUMAN	P01071 mus musculu
22	135.5	3.4	2077	1 ECEL_HUMAN	P01071 mus musculu
23	135	3.4	853	1 ECEL_HUMAN	P01071 mus musculu
24	126.5	3.2	2077	1 ECEL_HUMAN	P01071 mus musculu
25	126	3.2	1545	1 ECEL_HUMAN	P01071 mus musculu
26	121	3.1	490	1 ECEL_HUMAN	P01071 mus musculu
27	120	3.0	863	1 ECEL_HUMAN	P01071 mus musculu
28	117	3.0	408	1 ECEL_HUMAN	P01071 mus musculu
29	116.5	2.9	700	1 ECEL_HUMAN	P01071 mus musculu
30	116.5	2.9	1270	1 ECEL_HUMAN	P01071 mus musculu
31	116.5	2.9	1616	1 ECEL_HUMAN	P01071 mus musculu
32	116.5	2.9	1790	1 ECEL_HUMAN	P01071 mus musculu
33	116	2.9	725	1 ECEL_HUMAN	P01071 mus musculu

34	116	2.9	3587	1 SRFL_BACSU	P27206 bacillus su
35	115	2.9	882	1 RA50_PYREU	P58301 pyrococcus
36	114.5	2.9	3061	1 POLG_PYTTH	P02963 p genome po
37	114	2.9	762	1 MNML_YEAST	P39106 saccharomyc
38	114	2.9	2059	1 TEGU_HSV7J	P52362 human herpe
39	113.5	2.9	986	1 EPIL-STREP	P30195 staphylococ
40	112.5	2.8	1826	1 SUTS_RABIT	P07768 oryctolagus
41	112	2.8	1295	1 BXA2_CIOBO	P45894 clostridium
42	111.5	2.8	1056	1 SPS_SPIOT	P31928 splinacia ol
43	111.5	2.8	1230	1 SMC3_YEAST	P47037 saccharomyc
44	111	2.8	1328	1 EXO2_SCHPO	P40383 schizosacch
45	110	2.8	1638	1 BRM_DROME	P25439 drosophila

ALIGNMENTS

RESULT 1	ID	PEX_HUMAN	STANDARD:	PRT:	749 AA.
AC	P78562	Q00678; Q99827; Q13646; Q93032;			
DT	01-NOV-1997	(Rel. 35, Created)			
DT	01-NOV-1997	(Rel. 35, Last sequence update)			
DT	15-JUN-2002	(Rel. 41, Last annotation update)			
DE	Phosphate regulating neutral endopeptidase (EC 3.4.24.-)				
DE	(Metalloendopeptidase homolog PEX) (X-linked hypophosphatemia protein).				
DE	(HYP) (Vitamin D-resistant hypophosphatemic rickets protein).				
GN	PHX OR PEX.				
OS	Homo sapiens (human).				
OC	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;				
OC	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.				
OX	NCBI_TaxID=9606;				
RN	SEQUENCE FROM N.A., AND VARIANTS HYP ARG-85; LEU-534; ARG-579 AND				
RP	PRO-651				
RA	MEDLINE=97343325; PubMed=9199930;				
RA	Francis F., Strom T.M., Hennig S., Boeddrich A., Lorenz B.,				
RA	Brandau O., Mohlke K.L., Cagnoli M., Steffens C., Klages S.,				
RA	Borzum K., Pohl T., Oudet C.L., Econs M.D., Rowe P.S.N., Reinhardt R.,				
RA	Mellinger T., Lehrach H.;				
RT	"Genomic organization of the human PEX gene mutated in X-linked				
RT	dominant hypophosphatemic rickets.";				
RT	Genome Res. 7:573-585(1997).				
RN	[2]				
RP	SEQUENCE FROM N.A.				
RA	MEDLINE=97232252; PubMed=9077527;				
RA	Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C.,				
RA	Goodyer C.G., Tenenhouse H.S.;				
RT	"Pex/pep tissue distribution and evidence for a deletion in the 3'				
RT	region of the Pex gene in X-linked hypophosphatemic mice.";				
RT	J. Clin. Invest. 99:1200-1209(1997).				
RN	[3]				
RP	SEQUENCE FROM N.A.				
RA	TISSUE=bone;				
RA	MEDLINE=97343443; PubMed=9199999;				
RA	Guo R., Quarles L.D.;				
RT	"Cloning and sequencing of human PEX from a bone cDNA library:				
RT	evidence for its developmental stage-specific regulation in				
RT	osteoblasts.";				
RT	J. Bone Miner. Res. 12:1009-1017(1997).				
RN	[4]				
RP	SEQUENCE FROM N.A.				
RA	Lipman M.L., Panda D., Henderson J.E., Shen Y., Goltzman D.,				
RA	Katipis A.C.;				
RA	Submitted (JAN-1997) to the EMBL/GenBank/DBJ databases.				
RN	[5]				
RP	SEQUENCE FROM N.A.				
RA	MEDLINE=97224400; PubMed=9070861;				
RA	Grieff M., Mumm S., Waelitz P., Mazzarella R., Whyte M.P.,				
RA	Thakker R.V., Schlesinger D.;				
RT	"Expression and cloning of the human X-linked hypophosphatemia gene				
RT	cDNA.";				
RT	Biochem. Biophys. Res. Commun. 231:635-639(1997).				

[6]
 RN SEQUENCE OF 4-641 FROM N.A.
 RP MEDLINE-96024647; PubMed-7550339;
 RA Francis F., Hennig S., Korn B., Reinhardt R., de Jong P., Poustka A.,
 RA Leirach H., Rowe P.S.N., Goulding J.N., Summerfield T., Mountford R.,
 RA Econs M.J., Popowska E., Pronicka E., Davies K.E., Orlordan J.L.H.,
 RA Hanaauer A., Strom T.M., Melndi A., Lorenz B., Cagnoli M.,
 RA Monmale K.L., Murken J., Mellingner T.;
 RT "A gene (PEX) with homologues to endopeloidases is mutated in
 RT patients with X-linked hypophosphatemic rickets. The HYP
 RT Consortium";
 RL Nat. Genet. 11:130-136(1995).
 RP [7]
 RP SEQUENCE OF 1-116 FROM N.A.
 RA Webster R.;
 RN Submitted (JAN-1999) to the EMBL/GenBank/DBJ databases.
 RP [8]
 RP VARIANTS HYP TYR-85; CYS-166; SER-252; ILE-253 AND VAL-579.
 RX MEDLINE-97260404; PubMed-9106524;
 RA Holm I.A., Huang X., Kunkel L.M.;
 RT "Mutational analysis of the PEX gene in patients with X-linked
 RT hypophosphatemic rickets";
 RL Am. J. Hum. Genet. 60:790-797(1997).
 RP [9]
 RP VARIANTS HYP SER-77; PRO-138; LEU-534 AND ARG-579.
 RX MEDLINE-97252387; PubMed-9097956;
 RA Rowe P.S.N., Oudet C.L., Francis F., Standing C., Pannetter S.,
 RA Econs M.J., Strom T.M., Mellingner T., Garabedian M., David A.,
 RA Mochizuki A., Gorioux E., Popowska E., Pronicka E., Read A.P.,
 RA Goulding J.N., Orlordan J.L.H.;
 RT "Distribution of mutations in the PEX gene in families with X-linked
 RT hypophosphatemic rickets (HYP)";
 RL Hum. Mol. Genet. 6:539-549(1997).
 RP [10]
 RP VARIANT HYP PRO-555.
 RX MEDLINE-98439582; PubMed-9768646;
 RA Econs M.J., Friedman N.E., Rowe P.S.N., Speer M.C., Francis F.,
 RA Strom T.M., Oudet C.L., Smith J.A., Nimomiya J.T., Lee B.E.,
 RA Bergen H.;
 RT "A PEX gene mutation is responsible for adult-onset vitamin
 RT D-resistant hypophosphatemic osteomalacia: evidence that the disorder
 RT is not a distinct entity from X-linked hypophosphatemic rickets";
 RL J. Clin. Endocrinol. Metab. 83:3459-3462(1996).
 RP [11]
 RP VARIANTS HYP F-317; L-534; R-579; R-621; N-680 DEL; T-720; Y-731 AND
 RP R-749.
 RX MEDLINE-98439610; PubMed-9768674;
 RA Dixon P.H., Christie P.T., Wooding C., Trump D., Gieff M., Holm I.A.,
 RA Gertner J.M., Schmidke J., Shah B., Shaw N., Smith C., Tau C.,
 RA Schlesinger D., Whyte M.P., Thakker R.V.;
 RT "Mutational analysis of PEX gene in X-linked hypophosphatemia";
 RL J. Clin. Endocrinol. Metab. 83:3615-3623(1996).
 RP [12]
 RP VARIANTS HYP S-80; F-142; G-237; C-530; D-573; S-733 AND W-746.
 RX MEDLINE-99368844; PubMed-10439911;
 RA Filisetti D., Ostermann G., von Bredow M., Strom T.M., Filler G.,
 RA Ehrlich J., Pannetter S., Garnier J.-M., Rowe P.S.N., Francis F.,
 RA Julienne A., Hanaauer A., Econs M.J., Oudet C.L.;
 RT "Non-random distribution of mutations in the PEX gene, and
 RT under-detected missense mutations at non-conserved residues";
 RL Eur. J. Hum. Genet. 7:615-619(1999).
 RP [13]
 RP VARIANTS HYP F-85; P-141; V-341 DEL; P-567; K-680 AND Y-693.
 RX MEDLINE-20202840; PubMed-10737991;
 RA Tyymismaa H., Kattila I., Naentoe-Salonen K., Ala-Houhala M.,
 RA Alitalo T.;
 RT "Identification of fifteen novel PEX gene mutations in Finnish
 RT patients with hypophosphatemic rickets";
 RL Hum. Mutat. 15:383-384(2000).
 RP [14]
 RP VARIANTS HYP ARG-160 AND ASN-444 INS.

RX MEDLINE-20461419; PubMed-11004247;
 RA Sato K., Tajima T., Nakae J., Adachi M., Asakura Y., Tachibana K.,
 RA Suwa S., Katsumata N., Tanaka T., Hayashi Y., Abe S., Mutsaers M.,
 RA Okhara K., Shinohara N., Fujieda K.;
 RT "Three novel PEX gene mutations in Japanese patients with X-linked
 RT hypophosphatemic rickets";
 RL Pediatr. Res. 48:536-540(2000).
 CC -1- FUNCTION: PROBABLY INVOLVED IN BONE AND DENTIN MINERALIZATION
 CC AND RENAL PHOSPHATE REABSORPTION.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein (potential).
 CC BRAIN, PLACENTA, SKELETAL MUSCLE, AND PANCREAS; NOT IN ADULT AND
 CC FETAL HEART, LUNG, LIVER, AND KIDNEY.
 CC -1- DISEASE: DEFECTS IN PEX ARE A CAUSE OF X-LINKED HYPOPHOSPHATEMIC
 CC RICKETS (HYP), A DOMINANT DISORDER CHARACTERIZED BY IMPAIRED
 CC PHOSPHATE UPTAKE IN THE KIDNEY, WHICH IS LIKELY TO BE CAUSED BY
 CC ABNORMAL REGULATION OF SODIUM PHOSPHATE COTRANSPORT IN THE
 CC PROXIMAL TUBULES. CLINICAL MANIFESTATIONS INCLUDE SKELETAL
 CC DEFORMITIES, GROWTH FAILURE, CRANIOSYNDROSIS, PARAVERTEBRAL
 CC CALCIFICATIONS, PSEUDORACTURES IN LOWER EXTREMITIES, AND MUSCULAR
 CC HYPOTONIA WITH ONSET IN EARLY CHILDHOOD. X-LINKED HYPOPHOSPHATEMIC
 CC RICKETS IS THE MOST COMMON FORM OF HYPOPHOSPHATEMIA WITH AN
 CC INCIDENCE OF 1 IN 20000.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC -1- DATABASE: NAME=PEXdb; WWW="http://data.mcgill.ca/pexdb/".
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL: Y10196; CA671258.1; -
 DR EMBL: U75645; AAB47749.1; -
 DR EMBL: U82970; AAC24487.1; -
 DR EMBL: U87284; AAB47562.1; -
 DR EMBL: Y08111; CA669326.1; -
 DR EMBL: Y08112; CA669326.1; JOINED.
 DR EMBL: Y08113; CA669326.1; JOINED.
 DR EMBL: Y08114; CA669326.1; JOINED.
 DR EMBL: Y08115; CA669326.1; JOINED.
 DR EMBL: Y08116; CA669326.1; JOINED.
 DR EMBL: Y08117; CA669326.1; JOINED.
 DR EMBL: Y08118; CA669326.1; JOINED.
 DR EMBL: Y08119; CA669326.1; JOINED.
 DR EMBL: Y08120; CA669326.1; JOINED.
 DR EMBL: Y08121; CA669326.1; JOINED.
 DR EMBL: Y08122; CA669326.1; JOINED.
 DR EMBL: Y08123; CA669326.1; JOINED.
 DR EMBL: Y08124; CA669326.1; JOINED.
 DR EMBL: Y08125; CA669326.1; JOINED.
 DR EMBL: Y08126; CA669326.1; JOINED.
 DR EMBL: Y08127; CA669326.1; JOINED.
 DR EMBL: Y08128; CA669326.1; JOINED.
 DR EMBL: Y08129; CA669326.1; JOINED.
 DR EMBL: Y08130; CA669326.1; JOINED.
 DR EMBL: Y08131; CA669326.1; JOINED.
 DR EMBL: Y08132; CA669326.1; JOINED.
 DR EMBL: Y08133; CA669326.1; JOINED.
 DR EMBL: Y08134; AAB42219.1; JOINED.
 DR EMBL: Y08135; AAB42219.1; JOINED.
 DR EMBL: Y08136; AAB42219.1; JOINED.
 DR EMBL: Y08137; AAB42219.1; JOINED.
 DR EMBL: Y08138; AAB42219.1; JOINED.
 DR EMBL: Y08139; AAB42219.1; JOINED.
 DR EMBL: Y08140; AAB42219.1; JOINED.
 DR EMBL: Y08141; AAB42219.1; JOINED.
 DR EMBL: Y08142; AAB42219.1; JOINED.
 DR EMBL: Y08143; AAB42219.1; JOINED.
 DR EMBL: Y08144; AAB42219.1; JOINED.
 DR EMBL: Y08145; AAB42219.1; JOINED.
 DR EMBL: Y08146; AAB42219.1; JOINED.
 DR EMBL: Y08147; AAB42219.1; JOINED.
 DR EMBL: Y08148; AAB42219.1; JOINED.
 DR EMBL: Y08149; AAB42219.1; JOINED.
 DR EMBL: Y08150; AAB42219.1; JOINED.

Query Match 99.8%; Score 3952; DB 1; Length 749;
 Best Local Similarity 99.9%; Pred. No. 2,76-258;
 Matches 748; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

OY 1 MEATGSSVETGKKKRRGRIALVYFVGSTLVLGTLFVLSGGLSLDAKOEYCLKPECI 60
    |||||
DB 1 MEATGSSVETGKKKRRGRIALVYFVGSTLVLGTLFVLSGGLSLDAKOEYCLKPECI 60
OY 61 EAAATISKVNLSDPCDNEFFRACDGMISNNIPEDMPSGVFWLRYNDLKELLE 120
    |||||
DB 61 EAAATISKVNLSDPCDNEFFRACDGMISNNIPEDMPSGVFWLRYNDLKELLE 120
OY 121 KSISRRTDTEAIQAKILYSSCNNEKAIEKADAKPLHLIRSPFPMPLSEINIGPEGW 180
    |||||
DB 121 KSISRRTDTEAIQAKILYSSCNNEKAIEKADAKPLHLIRSPFPMPLSEINIGPEGW 180
OY 181 SERKFSLLQTLATFRGQYNSVFIRLYVSPDDKASNEHLLKLDQATLSLAVREDYLDNST 240
    |||||
DB 181 SERKFSLLQTLATFRGQYNSVFIRLYVSPDDKASNEHLLKLDQATLSLAVREDYLDNST 240
OY 241 EAKSYDALIKFVNDTVLLGANSRRHEHDKSVLRLEIKIATIMIPHEKRSSEAMYNKM 300
    |||||
DB 241 EAKSYDALIKFVNDTVLLGANSRRHEHDKSVLRLEIKIATIMIPHEKRSSEAMYNKM 300
OY 301 NISLSAMIPQDMIGYIKKVIDRPLPHLKDIPSENVVYVPOYFKDLFRLLSEKRR 360
    |||||
DB 301 NISLSAMIPQDMIGYIKKVIDRPLPHLKDIPSENVVYVPOYFKDLFRLLSEKRR 360
OY 361 TIANLVWRYYSRIPLNSRRQYRLLEFSVYIOGTTLLPOMDKCVNFLESALPYVGK 420
    |||||
DB 361 TIANLVWRYYSRIPLNSRRQYRLLEFSVYIOGTTLLPOMDKCVNFLESALPYVGK 420
OY 421 MEVDYFQEDDKKEMEELVEGVRAFIIDMLEKENMDAGTKRRAKAKAVLAKVYPE 480
    |||||
DB 421 MEVDYFQEDDKKEMEELVEGVRAFIIDMLEKENMDAGTKRRAKAKAVLAKVYPE 480
OY 481 FIMNDTHVNEDLKAIKFSADYFGVNLQTKRYLAOSDFEMLRKAVPTKEMTNTPTVNAF 540
    |||||
DB 481 FIMNDTHVNEDLKAIKFSADYFGVNLQTKRYLAOSDFEMLRKAVPTKEMTNTPTVNAF 540
OY 541 YSASTQIIFPAGELQKPFVNGTEPRSLSYGALVIGVHEFTGFDNNGKRYDKNGMD 600
    |||||
DB 541 YSASTQIIFPAGELQKPFVNGTEPRSLSYGALVIGVHEFTGFDNNGKRYDKNGMD 600
OY 601 PAMSTSESEKFEKTKCMINQISNYWKAGLNVKGRKTLGENTADNGLEAPAFAYKRW 660
    |||||
DB 601 PAMSTSESEKFEKTKCMINQISNYWKAGLNVKGRKTLGENTADNGLEAPAFAYKRW 660
OY 661 INDRQGLEPPLPGITFTNNOLFSLYAHVRCNSYRPREAREVOYIGAHSPQPRVNGA 720
    |||||
DB 661 INDRQGLEPPLPGITFTNNOLFSLYAHVRCNSYRPREAREVOYIGAHSPQPRVNGA 720
OY 721 ISNSEFOKAFNCPNPNSTNRMGDSCLW 749
    |||||
DB 721 ISNSEFOKAFNCPNPNSTNRMGDSCLW 749
  
```

RESULT 2

PEX_MOUSE STANDARD; PRT; 749 AA.

AC P70669; P97439; (Rel. 35, Created)
 DT 01-NOV-1997 (Rel. 35, Last sequence update)
 DT 01-NOV-1997 (Rel. 41, Last annotation update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Metalloendopeptidase homolog Pex (EC 3.4.24.-) (Phosphate regulating
 DE neutral endopeptidase) (X-linked hypophosphatemia protein) (HYP)
 DE (Vitamin D-resistant hypophosphatemic rickets protein).
 GN PHEX OR PEX OR HYP.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxId=10090;

```

RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=96411643; PubMed=8812412;
RA Du L., Desbarats M., Viel J., Giorieux F.H., Cawthorn C., Ecarot B.,
RT "CDNA cloning of the murine Pex gene implicated in X-linked
RL hypophosphatemia and evidence for expression in bone."
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=97217775; PubMed=9063736;
RA Strom T.M., Francis F., Lorenz B., Beedrich A., Econs M.J.,
RT "Pex gene deletions in Gy and Hyp mice provide mouse models for
RN X-linked hypophosphatemia."
RN [3]
RP SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; PubMed=9077527;
RA Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C.,
RT "Pex/PEX tissue distribution and evidence for a deletion in the 3'
RN region of the Pex gene in X-linked hypophosphatemic mice."
RL J. Clin. Invest. 99:1200-1209(1997).
CC -1- FUNCTION: PROBABLY INVOLVED IN BONE AND DENTIN MINERALIZATION
CC AND RENAL PHOSPHATE REABSORPTION.
CC -1- SUBCELLULAR LOCATION: Type II membrane protein (Potential).
CC -1- TISSUE SPECIFICITY: BONE.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: U49908; AAC3502.1; -
CC EMBL: U73910; AAC25862.1; -
CC EMBL: U73912; AAC25964.1; -
CC EMBL: U73913; AAC25965.1; -
CC EMBL: U73914; AAC25966.1; -
CC EMBL: U73915; AAC25967.1; -
CC EMBL: U75646; AAB47750.1; -
CC HSSP: P08473; 1DMT.
CC MEROPS: M13.091; -.
CC MGD: MGI:107489; PheX.
CC InterPro: IPR000718; Peptidase_M13.
CC InterPro: IPR001230; Prenyl_site.
CC InterPro: IPR000130; Zn_MTpeptidse.
CC Pfam: PF01431; Peptidase_M13; 1.
CC PRINTS: PR00786; NEPRILYSIN.
CC PROSITE: PS00142; ZINC_PROTEASE_1.
CC HydroLase: Metalloprotease; Zinc; Glycoprotein; Transmembrane;
CC Signal-anchor.
CC KX DOMAIN 1 20
CC FT TRANSMEM 21 37
CC FT DOMAIN 38 749
CC FT METAL 580 580
CC FT ACT_SITE 581 581
CC FT METAL 584 584
CC FT METAL 642 642
CC FT ACT_SITE 646 646
CC FT CARBOHYD 71 71
CC FT CARBOHYD 238 238
CC FT CARBOHYD 263 263
CC FT CARBOHYD 290 290
CC FT CARBOHYD 301 301
CC FT CARBOHYD 377 377
CC FT CARBOHYD 484 484
  
```

FT CARBOHYD 736 736 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CONFLICT 430 430 D -> V (IN REF. 3).
 SQ SEQUENCE 749 AA: A88FA481C376C18A CRC64;
 Query Match
 Best Local Similarity 96.9%; Score 3837; DB 1; Length 749;
 Matches 718; Conservative 20; Mismatches 11; Indels 0; Gaps 0;
 QY 1 MEATGSSVETKANGRTIAVAVGGTLYGLTFLVSGGLSLQAKOBYCCKPCCI 60
 DB 1 MEATGSSVETKANGRTIAVAVGGTLYGLTFLVSGGLSLQAKOBYCCKPCCI 60
 QY 61 EAAALISKVNLSDPCDNFEPACDGMISNNPIEDMPSYGVYWLHNNDLKELLE 120
 DB 61 EAAALISKVNLSDPCDNFEPACDGMISNNPIEDMPSYGVYWLHNNDLKELLE 120
 QY 121 KTSRRRDTEALQAKIILSSCMNEKALEKADAKPLHLRHSRPMPLVLSNIGEGW 180
 DB 121 KTSRRRDTEALQAKIILSSCMNEKALEKADAKPLHLRHSRPMPLVLSNIGEGW 180
 QY 181 SERKESLQTLATFRGOYSNSVYFIRLYVSPDDKASNEHLKLDQATSLANREDYDNT 240
 DB 181 SERKESLQTLATFRGOYSNSVYFIRLYVSPDDKASNEHLKLDQATSLANREDYDNT 240
 QY 241 EAKSYRDALYKPMVTAVILGANSRAHDMKSVLRLEIKIAEIMPHENTSEAMNKA 300
 DB 241 EAKSYRDALYKPMVTAVILGANSRAHDMKSVLRLEIKIAEIMPHENTSEAMNKA 300
 QY 301 NISELSAMIPQPDWLGITKIVYIDRLYPLHLDISPENYVRYQYKDFRLGSRKK 360
 DB 301 NISELSAMIPQPDWLGITKIVYIDRLYPLHLDISPENYVRYQYKDFRLGSRKK 360
 QY 361 TIANTLVRYMYSRIPNLSRREORYRLSESVYIGTTLTPQWDKCVNFIESALPYVVK 420
 DB 361 TIANTLVRYMYSRIPNLSRREORYRLSESVYIGTTLTPQWDKCVNFIESALPYVVK 420
 QY 421 MEVYVYQEOCKEMMEELVEGVMAFLDMLEKEMEMDAGTKKAKERAVIATKYGE 480
 DB 421 MEVYVYQEOCKEMMEELVEGVMAFLDMLEKEMEMDAGTKKAKERAVIATKYGE 480
 QY 481 FIMNDTVNEDLAIKIFSEADYFGNYLQTKYLAOSDFWLRKAVKTEMTPTVNAF 540
 DB 481 FIMNDTVNEDLAIKIFSEADYFGNYLQTKYLAOSDFWLRKAVKTEMTPTVNAF 540
 QY 541 YSASTNIRPAGELQKPFWGTETPRSLSYGALGVYGHETFGDNNGRKYDNGMID 600
 DB 541 YSASTNIRPAGELQKPFWGTETPRSLSYGALGVYGHETFGDNNGRKYDNGMID 600
 QY 601 PMSSESEKFEKTKCMINQYSNYWKAGANVAGKRTIGENIADNGCLREAFRAYRKW 660
 DB 601 PMSSESEKFEKTKCMINQYSNYWKAGANVAGKRTIGENIADNGCLREAFRAYRKW 660
 QY 661 INDRGGLLEPLPGITFTNNOLFELSYAHVNCNSYREPEARREOYIGAHSPROFVNGA 720
 DB 661 INDRGGLLEPLPGITFTNNOLFELSYAHVNCNSYREPEARREOYIGAHSPROFVNGA 720
 QY 721 ISNSEEFOAFNCPNPTNNRGMDCRLM 749
 DB 721 ISNSEEFOAFNCPNPTNNRGMDCRLM 749
 RESULT 3
 NEP_HUMAN
 ID NEP_HUMAN STANDARD: PRT: 749 AA.
 AC P08473;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-AUG-1988 (Rel. 08, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Neprilysin (EC 3.4.24.11) (Neutral endopeptidase) (NEP)
 DE (Enkephalinase) (Common acute lymphocytic leukemia antigen) (CALLA)
 DE (Neutral endopeptidase 24.11) (CD10).
 GN MME OR EFN.
 OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 OX NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE OF 2-749 FROM N.A.
 RC TISSUE=Placenta;
 RX MEDLINE=88152222; PubMed=3162217;
 RA Malfroy B., Kuang W.-J., Seeburg P.H., Mason A.J., Schofield P.R.;
 RT "Molecular cloning and amino acid sequence of human enkephalinase
 (neutral endopeptidase).";
 RL FEBS Lett. 229:206-210(1988).
 RP SEQUENCE FROM N.A.
 RC TISSUE=Kidney;
 RX MEDLINE=89010526; PubMed=2971756;
 RA Letarte M., Vera S., Tran R., Addis J.B.L., Onizuka R.J.,
 RT Quackenbush E.J., Jongeneel C.V., McInnes R.R.;
 RT "Common acute lymphocytic leukemia antigen is identical to neutral
 endopeptidase.";
 RL J. Exp. Med. 168:1247-1253(1988).
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=88263038; PubMed=2968607;
 RA Shipp M.A., Richardson N.E., Sayre P.H., Brown N.R., Masteller E.L.,
 RT Clayton L.K., Ritz J., Reinherz E.L.;
 RT "Molecular cloning of the common acute lymphoblastic leukemia antigen
 (CALLA) identifies a type II integral membrane protein.";
 RL Proc. Natl. Acad. Sci. U.S.A. 85:4819-4823(1988).
 RN [4]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=89386688; PubMed=2528730;
 RA D'Amato L., Shipp M.A., Masteller E.L., Reinherz E.L.;
 RT "Organization of the gene encoding common acute lymphoblastic
 leukemia antigen (neutral endopeptidase 24.11): multiple minexons
 and separate 5' untranslated regions.";
 RL Proc. Natl. Acad. Sci. U.S.A. 86:7103-7107(1989).
 RN [5]
 RP ACTIVE SITE ASP-650.
 RX MEDLINE=94222095; PubMed=8168535;
 RA Le Moual H., Dion N., Roques B.P., Crine P., Boileau G.;
 RT "Asp650 is crucial for catalytic activity of neutral endopeptidase
 24-11.";
 RL Eur. J. Biochem. 221:475-480(1994).
 RN [6]
 RP X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
 RX MEDLINE=20135972; PubMed=1068592;
 RA Oefner C., D'Arcy A., Hennig M., Winkler F.K., Dale G.E.;
 RT "Structure of human neutral endopeptidase (Neprilysin) complexed with
 phosphoramidon.";
 RL J. Mol. Biol. 296:341-349(2000).
 CC -1- FUNCTION: THERMOLYSIN-LIKE SPECIFICITY, BUT IS ALMOST CONFINED ON
 ACTING ON POLYPEPTIDES OF UP TO 30 AMINO ACIDS. BIOLOGICALLY
 IMPORTANT IN THE DESTRUCTION OF OPIOID PEPTIDES SUCH AS MET-
 AND LEU-ENKEPHALINS BY CLEAVAGE OF A GLY-PHE BOND.
 CC -1- CATALYTIC ACTIVITY: Preferential cleavage at the amino group of
 hydrophobic residues in insulin, casein, hemoglobin, and a number
 of other proteins and polypeptides.
 CC -1- COFACTOR: BINDS 1 ZINC ION.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -1- DISEASE: IMPORTANT CELL SURFACE MARKER IN THE DIAGNOSTIC OF HUMAN
 ACUTE LYMPHOBLASTIC LEUKEMIA.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 or send an email to license@isb-sib.ch.
 CC -----
 DR EMBL: X07166; CAA30157.1; ALT_INIT.
 DR EMBL: Y00811; CAA68752.1; -.

[illegible]

RA Crine P., Boilleau G.;
 RL EMBL J. 6:2506-2506(1987).
 RN [3]
 RP SEQUENCE OF 205-273 FROM N.A.
 RX MEDLINE-87241344; PubMed-3297057;
 RA Kahn P.H., Powell J.F., Beaumont A., Roques B.P., Mallet J.J.;
 RT "An antibody purified with a lambda cII1 fusion protein precipitates
 RL encephalinase activity";
 RN Biochem. Biophys. Res. Commun. 145:488-493(1987).
 RP NOTAGNESIS
 RX MEDLINE-88196403; PubMed-3162886;
 RA Dervault A., Sales V., Nault C., Beaumont A., Roques B., Crine P.,
 RA Boilleau G.;
 RT Exploration of the catalytic site of endopeptidase 24.11 by site-
 RT directed mutagenesis. Histidine residues 583 and 587 are essential
 RL for catalysis";
 RN FEBS Lett. 231:54-58(1988).
 CC -1- FUNCTION: THERMOLYSIN-LIKE SPECIFICITY, BUT IS ALMOST CONFINED ON
 CC ACTING ON POLYPEPTIDES OF UP TO 30 AMINO ACIDS. BIOLOGICALLY
 CC IMPORTANT IN THE DESTRUCTION OF OPIOID PEPTIDES SUCH AS MET-
 CC AND LEO-ENKEPHALINS BY CLEAVAGE OF A GLY-PHE BOND.
 CC -1- CATALYTIC ACTIVITY: Preferential cleavage at the amino group of
 CC hydrophobic residues in insulin, casein, hemoglobin, and a number
 CC of other proteins and polypeptides.
 CC -1- COFACTOR: BINDS 1 ZINC ION.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL: X05338; CAA28950.1; -
 DR EMBL: M16593; AAA53694.1; -
 DR PIR: A29451; HYRBN.
 DR HSSP: P08473; 1DMT.
 DR MEROPS: M13.001; -
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR001230; Ptenylsite.
 DR InterPro: IPR000130; Zn_Metpeptase.
 DR Pfam: PF01431; Peptidase_M13; 1.
 DR PRINTS: PR00786; NEPRILYSIN.
 DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 DR HydroLase; Metalloprotease; Zinc; Transmembrane; Glycoprotein;
 KW Signal-anchor.
 KW INIT_MET 0
 FT DOMAIN 1 27
 FT TRANSMEM 28 50
 FT DOMAIN 51 749
 FT DOMAIN 15 22
 FT BINDING 102 102
 FT METAL 583 583
 FT ACT_SITE 584 584
 FT METAL 587 587
 FT METAL 646 646
 FT ACT_SITE 650 650
 FT CARBOHYD 144 144
 FT CARBOHYD 284 284
 FT CARBOHYD 310 310
 FT CARBOHYD 324 324
 FT CARBOHYD 627 627
 SQ SEQUENCE 749 AA; 85450 MW; E60B04357B0BAB9 CRC64;
 Query Match 32.1%; Score 1270.5; DB 1; Length 749;
 Best Local Similarity 36.1%; Pred. No. 6.9e-78;
 Matches 273; Conservative 149; Mismatches 290; Indels 45; Gaps 19;

QY 13 KKANGRIALVYVGGLVIGLILFVSQGLISDAKOE--CYKPECTEANAALISKV 70
 Db 18 KKGQWVPLELISLV---LVL--LTVIAVTALVATYDDIDCKSSCIKSAALIGNM 72
 QY 71 NLSVDCDFNEFRPADGWSINNPIDEDPSYGVYPMLRNVDLTKLELLEISRRPTE 130
 Db 73 DATAEPCTEFKXACGGMKRVNIPETSSRYNPFILNDELVLKDVQ--PRTEIV 130
 QY 131 AIQAKIIVSSCKNEKATKADAPLHLIRSPFRRVLESNIGPEGWSE---RRFSL 187
 Db 131 AVQKATILRVSCVNEALDSDRGQPLKIL--PDYVGWVAATON-----MFQYGTGWSA 183
 QY 188 LQIATFRQOYSNVFIRLYSPDDKASNEHLKDQATISLAVREDYLDNSTEAKYRD 247
 Db 184 EKSIQILNSNGKRVILNFEVGTDDKSNMNIHIDQRLGLPSR--DIYECTGYEACT 242
 QY 248 ALYKEMVDTAVL-----LGANSSRAEHDAKSVLRLEIKAEIMIPHEPTSE--AMYNKA 300
 Db 243 AYVDEMIAVAKILRQEBGLPIDENQISVENKRVLEKEITANNTYSESDNDPMILYNKM 302
 QY 301 NISELSAMT-----PODWLGYIKVYIDRLVPHLKDIPSENVYVRYPOYKDLFRIL 354
 Db 303 TLAQIQQNFSLKNGKPEFSMNFTEIMSTVNI-----NIPNEDVYVYAPETILKLPIL 358
 QY 355 GSERKTIANYLVNRYSTRIPNLSRRFOYRMLEFSVIOGTTLLPQWDKCVNIESAL 414
 Db 359 TKYPRDFQNLFSWRFIMDLVSSLSKRYKDSNAKFAKLYGTTSSEATWRRCANVYNGNM 418
 QY 415 PYVYKAFVYVFOEDKKEEMELVEGVRAFTDMLKEKEMWMDGTRKAKERAVILA 474
 Db 419 ENAVGRLYVEAFRAGEKHVEDLIAQIREVFIQIOTD-DLTMMDAETKKAEEKALAKE 477
 QY 475 KVGVP--EFINDTHVEDLKAIFSEADYFGVNLQRTKLAOSDFEWMKRAVPKTEPTN 533
 Db 478 RIGYPDIVSNDKLNNEVLELNYLKYDETFEYNIQWLKFSQSKOLKRLREYVDKDEWITG 537
 QY 534 PTIVNAFYSASTQVQIPEPAGLQKPEFMTGEXPRSLISYGAIGVYGHFTGPNNNGRY 593
 Db 538 AALVNAFYSSGRQVIVFPAGIILPPEF--SAQOSNLNLTGGIGMVIHGHITTHGFDNGRNF 596
 QY 594 DKNGNLDPMWSTSEEEKFEKTKCMINQYSNYMKKA--GLVKKKRLGLENIAADNGLRE 652
 Db 597 NKGGDLVDWMTQGSANNFREDSQCMVYQYGNFSDWLAGGQHLNINLTGENIADNGSIGQ 656
 QY 653 ARFVAKWINDRQGLEPILPGITFTNNQLEFSLVAHVRNSYRPAREROVIGAHSP 712
 Db 657 AYRAIQTNTV--RKNQ--EKKLPGIDLNHKLQFLFNFAQVQMGYRPREYAVNSIKTDVHSP 713
 QY 713 PQRVNGAISNSEERQKAFNCPNSTNMGDSQRLW 749
 Db 714 GNFRTIGSLQNSVSEAFQCPKNSYNN--PEKKCRWV 749
 RESULT 5
 NEP_RAT
 ID NEP_RAT STANDARD; PRT; 749 AA.
 AC P07861;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-AUG-1988 (Rel. 08, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Neprilysin (EC 3.4.24.11) (Neutral endopeptidase) (NEP)
 GN MHE.
 OS Rattus norvegicus (Rat).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_Taxid-10116;
 RN [1]
 RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
 RX MEDLINE-87213218; PubMed-3555489;
 RA Maltby B., Schofield P.R., Kuang W.-J., Seeburg P.H., Mason A.J.,
 RA Henzel W.J.;

"Molecular cloning and amino acid sequence of rat enkephalinase.";
 RT Biochem. Biophys. Res. Commun. 144:59-66(1987).
 RN [2]
 RA ACTIVE SITE ARG-102.
 RX MEDLINE:89197908; PubMed-2703483;
 RA Bateman R.C. Jr., Jackson D., Slaughter C.A., Umiltan S., Chai Y.G.,
 RA Moonaw C., Hersh L.B.;
 RT "Identification of the active-site arginine in rat neutral
 RT endopeptidase 24.11 (enkephalinase) as arginine 102 and analysis of a
 RT glutamine 102 mutant.";
 RT J. Biol. Chem. 264:6151-6157(1989).
 CC -1- FUNCTION: THE MOLECULAR-LIKE SPECIFICITY, BUT IS ALMOST CONFINED ON
 CC ACTING ON POLYPEPTIDES OF UP TO 30 AMINO ACIDS. BIOLOGICALLY
 CC IMPORTANT IN THE DESTRUCTION OF OPIOID PEPTIDES SUCH AS MET-
 CC AND LEU-ENKEPHALINS BY CLEAVAGE OF A GLY-PHE BOND.
 CC -1- CATALYTIC ACTIVITY: Preferential cleavage at the amino group of
 CC hydrophobic residues in insulin, casein, hemoglobin, and a number
 CC of other proteins and polypeptides.
 CC -1- COFACTOR: BINDS 1 ZINC ION.
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL: M15944; AAA41116.1; -
 CC DR PIR: A29295; HYRN.
 CC DR HSSP: P08473; IDMT.
 CC DR MEROPS: M13.001; -
 CC DR InterPro: IPR000718; Peptidase_M13.
 CC DR InterPro: IPR001330; Prenyl_site.
 CC DR InterPro: IPR000130; Zn_Mpeptidase.
 CC DR Pfam: PF01431; Peptidase_M13; 1.
 CC DR PRINTS: PR00786; NEPRILYSIN.
 CC DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 CC DR Hydroxylase; Metalloprotease; Zinc; Transmembrane; Glycoprotein;
 CC KW Signal-anchor; 0
 CC FT INIT_MET 0
 CC FT DOMAIN 1 27
 CC FT TRANSMEM 28 50
 CC FT DOMAIN 51 749
 CC FT BINDING 102 22
 CC FT METAL 583 583
 CC FT ACT_SITE 584 584
 CC FT METAL 587 587
 CC FT METAL 646 646
 CC FT ACT_SITE 650 650
 CC FT CARBOHYD 144 144
 CC FT CARBOHYD 210 210
 CC FT CARBOHYD 284 284
 CC FT CARBOHYD 310 310
 CC FT CARBOHYD 324 324
 CC FT CARBOHYD 627 627
 CC FT SEQUENCE 749 AA; 85663 MW; 89B0EC50A9016447 CRC64;
 CC
 CC Query Match 31.9%; Score 1263.5; DB 1; Length 749;
 CC Best Local Similarity 35.7%; Pred. No. 2e-77;
 CC Matches 270; Conservative 151; Mismatches 291; Indels 45; Gaps 19;
 CC
 CC QY 13 KKANSGRIALVVEGTLVLTILFVSGLLSLQAKOE--VCLKECEIAAAALISKV 70
 CC DB 18 KKKQWTFLEISLV---LVL--LITIAVMIALVAYDGIKSSDCIKSAARLQNM 72
 CC QY 71 NLSVPCDNFPRACDGMISNPIDPMPSYGVFWLHNVDLKLLEKLSISRRDTE 130
 CC DB 73 DASAEPTDFFKACGMLKRNVPIDPISRSNFDLDELVELIKDLVDE--PKTDIV 130

QY 131 AIQAKIITYSSCMEKAEKADAPLHLIHSFRRWPLESNGPBGVSE---RRTSL 187
 DB 131 AVQAKTIYRSICINSAIDSREGQPLTL--PDITGMFVASQ-----MQDTGTSMTA 183
 QY 188 LQTLAFRGQYSNVFIRLYSPDDKASNEHLKLDQATLSLAVREDYLDNSTEAKSYRD 247
 DB 184 ESIAGLNSKYLKGLVINFVGTGDKNSQHIHPDQPLGPSR-DYEECTGYKRACT 242
 QY 248 ALTKFWDYAVL-----LGANSRAEDMKSVLELKIKEMIMPHENRSE-AMYNKM 300
 DB 243 AYVDPMISAVARLROBORLPIDENDLSLENNVMELESIANATTKPRDRNDPHILVNM 302
 QY 301 NISLSMT-----PQPMIGYIKKVIDTRLYPHLKDISPSENVVVRPOYFKDLFIL 354
 DB 303 TLAKLONNSELINGKPFNSNTFNIMSTVMI---NIONEEVAVVAPELTIRKIDIL 358
 QY 355 GSEKRTIANYLVWRYSRIPULSRFQYRLERFVYQGTITLLPQMDKCVNFESAL 414
 DB 359 TKSPYRDLQIMSGWRFIMDLVSSLSRYKESRNAFKALYGTSETATYRRCANVNGNM 418
 QY 415 PYVVGKFFVDYVYQEDKEMAEIVGVRWAFIDMLEKENEMWDACTKRKAKAVLIA 474
 DB 419 ENAVGRLYVEAEFGESKHYVEDLIAQIRVFIQTLD-DLTMADATKKKAEKALALE 477
 QY 475 KVGP-EFIMNDTVNEDLAKIFSEADYGNVLOTRKYLAOSDFWLKRAVKTEMTFN 533
 DB 478 RIGYDDIISNENKLNNEYLELNKKEEYENIIONLKFSQOLKKLREKDKDEMISG 537
 QY 534 PTVNAFISASNTQIRPAGLOKPFPGMTEYPRSLSYGAIYVGHETHFGDNNGRY 593
 DB 538 AAIVNAFYSNGNOITVPAAGILOPFF-SARQSLNLYGVGIVGHEITHGPDGGRNF 596
 QY 594 DKGNMIDPMWSTSESEKERTKCMINOYSNYTKKA-GLNVKGRKLGINDNGLRE 652
 DB 597 NKGDLVDMWQIQSANPKDQSQCVYQYGNFTMDLGGQHLNINLTGINLNGDGIQ 656
 QY 653 AFPRATKRNIDRQGLEPILPGITFTNNOLFYSYAHVRCNSYRPAREROYQIGASP 712
 DB 657 AVRAYQNVY--KRG-EKKLDGLDLNKHOLFELNFAQVWGCTRPVAVNSIKTDVHSP 713
 QY 713 PGRVNGAISNSEFOKAFNCPPNSTNMGDSCRW 749
 DB 714 GNFRIITGIQNSAEFADAFHCRKNSYMPDER-KCVRW 749
 CC
 CC RESULT 6
 CC ECCL_CAVPO STANDARD: PRT: 754 AA.
 CC ID ECCL_CAVPO
 CC AC P97739;
 CC DT 01-NOV-1997 (Rel. 35, Created)
 CC DT 01-NOV-1997 (Rel. 35, Last sequence update)
 CC DT 15-JUN-2002 (Rel. 41, Last annotation update)
 CC DE Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1).
 CC GN ECCL
 CC OS Cavia porcellus (Guinea pig).
 CC CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC CC Mammalia; Eutheria; Rodentia; Hystriocognathi; Cavidae; Cavia.
 CC CC NCBI_TaxID=10141;
 CC RN [1]
 CC RP SEQUENCE FROM N.A.
 CC RX MEDLINE:96192242; PubMed-8624482;
 CC RA Shima H., Yamanouchi M., Omori K., Sugitara M., Kawashima K.,
 CC Sato T.;
 CC RT "Endothelin-1 production and endothelin converting enzyme expression
 CC by guinea pig airway epithelial cells.";
 CC RL Biochem. Mol. Biol. Int. 37:1001-1010(1995).
 CC CC -1- FUNCTION: CONVERTS BIG ENDOTHELIN-1 TO ENDOTHELIN-1.
 CC CC -1- CATALYTIC ACTIVITY: Forms endothelin 1 by cleavage of the 21-
 CC CC TRP-Val-22 bond in the precursor
 CC CC -1- ENZYME REGULATION: INHIBITED BY PHOSPHORAMIDON (BY SIMILARITY).
 CC CC -1- SUBUNIT: HOMODIMER (BY SIMILARITY).
 CC CC -1- SUBCELLULAR LOCATION: Type II membrane protein.

CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

DR EMBL: S82653; AAB46734.1; -

DR HSSP: P08473; IDMT.

DR MEROPS: M13.002; -

DR InterPro: IPR000718; Peptidase_M13.

DR InterPro: IPR000130; Zn_Mpeptidase.

DR Pfam: PF01431; Peptidase_M13; 1.

DR PRINTS: PRO0786; NEPRILYSIN.

DR PROSITE: PS00142; ZINC_PROTEASE; 1.

KW Hydrolase; Metalloprotease; zinc; Glycoprotein; Transmembrane;

KW Signal-anchor.

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

FT TRANSMEM 53 73

FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)

FT DOMAIN 1 52

SEQUENCE 754 AA; 85772 MW; F064657F2BA8A0 CRC64;

Query Match

Best Local Similarity 38.0%; Score 1262.5; DB 1; Length 754;

Matches 284; Conservative 128; Mismatches 270; Indels 65; Gaps 22;

QY 23 LVFVGGTVLVTITLVVSGGLISLQAKQCYLKEPCIEAAALSKVNLVSDPCDNFR 82

DB 53 LTVLV-ALAAAGLVACTLALGIQYRTPTPCVLEACVSVSSILSNMNPVPCQDFE 111

QY 83 FADGWNISNPPEDPSPYGVYRWLRHNDLKLKLEKISRRDTEALOKATLYSSC 142

DB 112 YACGWMKANKPVDDGSRMGAFSNLWENHQAIIKHLNSTA--SVSEAERKQVYRAC 169

QY 143 MNEKAIEKADAPLHLIHRSPFVPLESNIGPVSSEKFSLLDTLAFRRQYSNV 202

DB 170 MNETRIEELRAPLMLLEIKLG-GWNI-----TGPAKKNFQ--DILQVTAHYTSP 219

QY 203 FTRLVSPDDKSNHILKLDQATLSAVREDYIDNSTEAKSYDALYKEMVDTAVLGA 262

DB 220 FSVSYVSDSKSNMNVHVQSGGLPESRDYLT-NKTEENKVLNGVLTMYDGLKLLG 278

QY 263 ---NSRAEDHDKSVLRLEIKIAEIMPHENRTSEAM-YKMNISELSAIIPOFDMGLY 318

DB 279 GDENAIRAO--MOQILDEPETAANITIPQEKRRDEELIYKVAEIQGTAPAINMLPF- 335

QY 319 KKVIDRLYPLKDISBENVVAVPOYFDLFRILGSEKRTIANYLVWRMYSRIPNL 378

DB 336 ---LNTIYTP--VEINSEPIVYDKKEYLVQVSTLINTDKCLANNYMLMNLVTRKSSPL 390

QY 379 SRRPQYMLEFSRYIGT-TTLFQMDKCVNFESALPYVYGMFADYVFOEDKEMEE 437

DB 391 DQFQDADEKFMVYMGTKTCLPRKFCVSDTENNLGGLGFMFKATFADSKNIASE 450

QY 438 LVESGRAPFIDMLEKEMENDACTKKRANERAVLAKYVEFTI-----NDTHV 488

DB 451 IIEIKKAFESL-STLKWDEDTKRSKAKEDAIYNMIGYDFIMDKREIDKYNDDTA 509

QY 489 NEDLKAIKSEADYFENVLQTRKYLQSDFF-----LRKAVTEFTNPTVNAVS 542

DB 510 VPLD-----YFNMAHF-----FNSKRVTAEOURLRAPNDQMSMPPMVNAVS 554

QY 543 ASNNOIRFAPAGELQKPFENGTETPSLSYGAIVTIGHEFTHGPDNNGRKYDKNGNDPW 602

DB 555 PINKNEIVFPAGLIPAFYTRSS-PRALNFGIGVYVGHETLHARDQGREIDKNGNRPW 613

QY 603 WTESESEKFEKTKKINQYSNYWKKAGLVKGRITGEMIANGLREAFRAYRWIN 662

DB 614 WKNSVSEAFKQTECMEVDYSN--SVNGEYVNGRHITGENIADNGILKAYRAYQMWV- 670

QY 663 DRQGLIEFLGLGITFTNNQLEFSLYAHVKNSTYRPEAARQVIGASPPQFVNGAIS 722

DB 671 -KNGAEF-TLETJGLTNNQLEFGLFAQVCSVTRPSSHEGLTDPHSRRRVIGSIS 728

QY 723 NSEFQKAFNCPNPSTNMRGMDSCRLW 749

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

QY 729 NSKESEHFQCPSPSPM-PRHKEVW 754

DB 729 NSKESEHFQCPSPSPM-PRHKEVW 754

InterPro: IPR001230; Prenyl-site.
 InterPro: IPR000130; Zn_MTPeptide.
 DR Pfam: PF01431; Peptidase_M3; 1.
 DR PRINTS: PR00786; NEPRILysin.
 DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 DR HydroLase: Metalloprotease; Zinc; Transmembrane; Glycoprotein;
 KW Signal-anchor.
 FT INIT-MET 0 0 BY SIMILARITY.
 FT DOMAIN 1 27 CYTOPLASMIC (POTENTIAL).
 FT TRANSMEM 28 50 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 (POTENTIAL).
 FT DOMAIN 51 749 EXTRACELLULAR (POTENTIAL).
 FT BINDING 15 22 STOP-TRANSFER SEQUENCE (POTENTIAL).
 FT BINDING 102 102 FREE CARBOXYLATE OF SUBSTRATE
 (BY SIMILARITY).
 FT METAL 583 583 ZINC (CATALYTIC) (BY SIMILARITY).
 FT ACT_SITE 584 584 ZINC (CATALYTIC) (BY SIMILARITY).
 FT METAL 587 587 ZINC (CATALYTIC) (BY SIMILARITY).
 FT METAL 646 646 ZINC (CATALYTIC) (BY SIMILARITY).
 FT ACT_SITE 650 650 PROTON DONOR (BY SIMILARITY).
 FT CARBOHYD 144 144 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 210 210 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 284 284 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 310 310 N-LINKED (GLCNAC...) (BY SIMILARITY).
 FT CARBOHYD 324 324 N-LINKED (GLCNAC...) (POTENTIAL).
 FT CARBOHYD 627 627 N-LINKED (GLCNAC...) (BY SIMILARITY).
 SQ SEQUENCE 749 AA; 85509 MW; 5FE1AC6685FDEE30 CRC64;
 Query Match 31.8%; Score 1259.5; DB 1; Length 749;
 Best local similarity 35.8%; Pred. No. 3.8e-77;
 Matches 272; Conservative 149; Mismatches 289; Indels 49; Gaps 20;

13 KRANRT--RIALVVGVTIVGLTFLVSGLLIOAKOE--YCLNPECIEAAALIS 68
 18 KKKKQRTPELISLVY----LTKTIANV---MALATATYDDGCKSSDCIKSARLIQ 70
 69 KVALSYDCDFEFACDGMISNIPEDMPSYGYPMIRHNVADKLKLEKTSRRRD 128
 71 NMDASVEPTDFPKYACGGLKRNVPETSSRSNDILRDELYLKVDOE--PKED 128
 129 TEALQKAKILYSSCMENKAEKADAPLILHSPFMPVLESNIGEGVWSE--RKF 185
 129 IVAQKAKKILYSCINSAIDSRGQPLKL--PDLYGMPVASDN-----MDQYGTGW 181
 129 SILOTLATFGQYSNFIILVYSPDKASNEHILKDOATLSIAREDYDINSFEAKSY 245
 186 TAESIAQNSKYGKVLINFEVGTQDKNSTOHIIHDDPRLGLPSR--GYECTGITYKA 240
 246 RDALYKRVDTAVL-----IGANSSRAEDHMSVLEIKIAEIMIPHENTSE--AMYN 298
 241 CTAAVDEMTISVARLIROBOSIPIDENOLSLKMKVMELEIANATTKPEDRNDPMLLYN 300
 299 KMNISELSAMT-----POEDWILGYIKVDTIRLYPHUKISSENVVAVPOYFDLFR 352
 301 KWTILAKLQNNFSLEVNGKFSMSNFTNEMSTVNI---MIONEVEVVAPELTKIKP 356
 333 ILGSRKRTINNYLVWRVRYRIPNLRRFOYRWLEFSRYIOGTTTLTPOMDKVNFIES 412
 357 ILTKYSPDOLKMSWRIIMLYVSLSNKYKESNAPFRKALYGTSTETATMRCANYNG 416
 413 ALPYVVGKMFVDVYFQEDKKEMELVGVFMALIDMEKENEMMDAGTRKAKERARAV 472
 417 NNENAVGRILYDAFAEGSKHVEEDLIAQIREVFLOTLD--DLTWMDLTKKAEKALAI 475
 473 LAKVGP--EFIMNDTHVNDLKAIFESEADYFAGNVLQTRKYLAAOSDFWLRKAVKTEWF 531
 476 KERIGPDDIISNENKLNIEYLINREDYENITQMLKSQSOQLKREKVDKDEMI 535
 532 TNPFTVNAFYASINOIRPAGELOKPFEWGTETYSRISYGAISYIVHEHETGPDNNGR 591
 536 SGAAYVNAFYSSGRNQIVPAGILPPFP--SAQOSNSLNYGGIGIVHETLHGGDDNGR 594
 592 KYDKNGMLDPWMTSESEKFKETKCMINQYNSYWKKA--GLNVAGKRTLGENIADNGGL 650

DB 595 NFNKDDDLVDWMTQOSANNEKDQSOQMYIYQENESWDLAGOCHLNGINTLEIADNGGI 654
 QY 651 REAFRAYRKWINDRROGLEBEPLIGITFTNNQLFSLVAHYRCSYREAPAREVOYQCAH 710
 DB 655 GQAFRAIQNTY--KNGG-BEKLLPGDLNHLKQLEFLNFAQWCGTYREBYAVNSIKTDVH 711
 QY 711 SPDFRVNGAISNSEEPQKAFNCPPNSYNNRGMDSORLW 749
 DB 712 SPGNFRITGLTQNSAEFADFHCRCRKNYMPER-KCRVW 749

RESULT 8
 ECCEL_HUMAN STANDARD; PRT: 770 AA.
 ID ECCEL_HUMAN
 AC P42892; Q14217; Q9U006; Q9UPF4; Q9UPM4; Q9Y501;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1).
 GN ECEL.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 OX NCBI_Taxid=9606;
 RN [1]
 RP SEQUENCE OF 7-770 FROM N.A. (ISOFORM B).
 RC TISSUE-Placenta;
 RX MEDLINE-95104423; PubMed-7805846;
 RA Schmidt M., Kroeger B., Jacob E., Seuberger H., Subkowski T.,
 RA Oltner R., Meyer T., Schmalzing G., Hillen H.;
 RA "Molecular characterization of human and bovine endothelin converting
 RT enzyme (ECE-1).";
 RT FEBS Lett. 356:238-243(1994).
 RL [2]
 RN SEQUENCE FROM N.A. (ISOFORM B).
 RP MEDLINE-95209687; PubMed-7695628;
 RA Yoritatsu K., Moroi K., Inagaki N., Satou T., Masuda Y.,
 RA Masaki T., Seto S., Kimura S.;
 RA "Cloning and sequencing of a human endothelin converting enzyme in
 RT renal adenocarcinoma (ACHN) cells producing endothelin-2.";
 RL Biochem. Biophys. Res. Commun. 208:721-727(1995).
 RN [3]
 RP SEQUENCE FROM N.A. (ISOFORMS A AND B).
 RC TISSUE-Placenta;
 RX MEDLINE-96102029; PubMed-8530372;
 RA Valdenaire O., Rohrbacher E., Mattei M.-G.;
 RA "Organization of the gene encoding the human endothelin-converting
 RT enzyme (ECE-1).";
 RT J. Biol. Chem. 270:29794-29798(1995).
 RL [4]
 RN SEQUENCE FROM N.A. (ISOFORM A).
 RP MEDLINE-95169128; PubMed-7864876;
 RA Shimada K., Matsushita Y., Wakabayashi K., Takahashi M., Matsubara A.,
 RA Iijima Y., Tazawa K.;
 RA "Cloning and functional expression of human endothelin-converting
 RT enzyme cDNA.";
 RL Biochem. Biophys. Res. Commun. 207:807-812(1995).
 RN [5]
 RP SEQUENCE FROM N.A. (ISOFORM C).
 RC TISSUE-Umbilical vein endothelial cells;
 RA Takeyanagi R.;
 RA "Human endothelin-converting enzyme-1c.";
 RA submitted (AUG-1999) to the EMBL/Genbank/DBJ databases.
 RN [6]
 RP SEQUENCE FROM N.A. (ISOFORM B).
 RA Pearce A.;
 RA submitted (JUN-1998) to the EMBL/Genbank/DBJ databases.
 RL [7]
 RP SEQUENCE OF 1-132 FROM N.A. (ISOFORM D), AND TISSUE SPECIFICITY.
 RX MEDLINE-99421637; PubMed-10491078;
 RA Valdenaire O., Lepailleur-Bonnot D., Egidy G., Thouard A., Barret A.,
 RA Vranckx R., Tougard C., Michel J.-B.;

[illegible]

FT ETLRESVTLALQMSYKRRATLDEEDLVDSLSGDIYPMG
(IN ISOFORM D).
SQ SEQUENCE 762 AA; 86125 MW; D6B8253BC67CCAD8 CRC64;

Query Match 31.4%; Score 1243.5; DB 1; Length 762;
Best Local Similarity 37.5%; Pred. No. 4.6e-76;
Matches 277; Conservative 120; Mismatches 284; Indels 49; Gaps 19;

QY 23 LVFVGGTIVLGLITFLVSGSLSLQAKOEYCLKPECIEAAAILSKVNSVDPQCNFR 82
DB 61 LVVIV-ALLAAGLVACIALGIQYRTFRPPVCLTEACVSTSLSSMDPTVDPQCFDS 119
QY 83 FACDGMISNNPIEDMPSGYVYPMRLHNDLKLKELLSISRRDTEAIOAKILYSSC 142
DB 120 YACGGMITANVPDGSRRGTSNLMHNOAILKLHLENSTASA--SEAEKRAQYVYRAC 177
QY 143 MNEKAIEKADAKPLHLIRHSPRPVLESNIGPVGSEKRSFSLQTLATRGQYSNV 202
DB 178 MNEIRIELKAKPLMELIEKLK-GNNI-----TGPMKDNFQ--DTLQVYVTAHRTSP 227
QY 203 FIRLYSPDOKASNEHLKIDQATLSLAVREDYLDNSTEAKSYRDALYKFNVDYAVL-G 261
DB 228 FFSYVASDSKSNNSVNTQVDSGLDPSRDYLL-NKTENEKVLGYLNYVQLKGLGG 286
QY 262 ANSSRAEHDKSVLRLEIKAEIMIPHENRTSEAM-YNKMNISLSAMIPQDWTGYTK 320
DB 287 GDEDSIRPQMOQILDEFETALANTIPQEKRBDELTYHKAVALQTLAPALNMLPFLNA 346
QY 321 VITRILYPLHAKOISBSENVYVRYPOYFQDLERILGSEKRTIANYLVNRYYSRIPNSR 380
DB 347 I-----FYP--VEINSEPIVYVDEKLYRQVSTLINSCLKLNNYMMNLVRAKSSFLDQ 400
QY 381 RFOYRLMFSRVIOGT-TLLPOMDKCVFISALPYVYGKFDVYFQEKKEMEELV 439
DB 401 RFQDADEKFMEMWYGTKKICLRKMFQVSDTENNGFALGPEYKAFPAEDSKNIAEII 460
QY 440 EGYRAFTIMLEKENEMMDAGTKRKAARAVLAKVGPFFIM-----NDTHVNE 490
DB 461 LKTKAFEEEST-STLKWDEDETRRSKAKADAIYNMIGPYFIMDPKELDVFEDYDAVP 519
QY 491 DKAIKFSEADYFNVLTQRYKLQSDFFMLRKAPKTEMTNTTNYAFYASTNOIRF 550
DB 520 DL-----YFENAMFENFSLVTVADQLRKAPNRQOMSMPTPMVNAYSPTKNEIV 570
QY 551 PGELOKPEFPGTEYPSLSYGAIGVYGHETFGFNNGSKYKNGNLDPWSTSEEEK 610
DB 571 PAGIIQAEFFYRSS-PNALNFGGIGVYGHETLHAFDQGRYDKDNLPMKNSVEA 629
QY 611 FEKTKMINOYSNYWKAGLANKGKRTIGENTADNGLEAFRAYRKVINDROGLEE 670
DB 630 FKQTECHAVQOINNT--SVNGEPVNGRRITIGENTADNGGLKAAVRAVQNNV--KKNGADQ 685
QY 671 PLLRGITFTNNQVLEFSLYAHRCNSYRPEAROEVOIGASPOOFNRNGAISSEEFQA 730
DB 686 -ILPFLIGLISNQLPFLGPAQWCVSRTPRESSHEGLITDPHSRFRVIGLSNKESESH 744
QY 731 FNCPPNSTMGMSDSCRLM 749
DB 745 FRCPLGSPMN-PRHKEVW 762

RESULT 10
ECEL BOVIN STANDARD; PRT; 754 AA.

AC P42891;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, last sequence update)
DT 15-JUN-2002 (Rel. 41, last annotation update)
DE Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECC-1).
GN ECEL.
OS Bos taurus (Bovine).
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euteria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;

OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;

RN [1]
RP SEQUENCE FROM N.A. AND PARTIAL SEQUENCE.
RX MEDLINE=95104423; PubMed=7805846;

RA Schmitt M., Kroegeer B., Jacob E., Seuburger H., Subkowski T.,
RA Otter R., Meyer T., Schmalzing G., Hillen H.;
RT "Molecular characterization of human and bovine endothelin converting
enzyme (ECE-1).";

RL FEBS Lett. 356:238-243(1994).
CC -1- FUNCTION: CONVERTS BIG ENDOTHELIN-1 TO ENDOTHELIN-1.
CC -1- CATALYTIC ACTIVITY: Forms endothelin-1 by cleavage of the 21-
CC -1- tripeptide bond in the precursor.
CC -1- ENZYME REGULATION: INHIBITED BY PHOSPHORAMIDON.
CC -1- SUBUNIT: HOMODIMER.
CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).

CC EMBL: Z35306; CAA84547.1; -.
CC HSSP: P08473; IDMT.
CC MEROPS: M13.002; -.

DR InterPro: IPR000718; Peptidase_M13.
DR InterPro: IPR000130; Zn_Mpeptidase.
DR Pfam: PF01431; Peptidase_M13; 1.
DR PRINTS: PR00786; NEPRILYSIN.
DR PROSITE: PS00142; ZINC_PROTEASE; 1.

KW Hydrolase; Metalloprotease; Zinc; Glycoprotein; Transmembrane;
KW Signal-anchor.

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

FT DOMAIN 1 52
FT TRANSMEM 53 73

[illegible]

Db 236 DNF--MEVLAAGVATYRATPEFYIVISADSKSSNSVNIQDQGLPLPSRDYLL-NRTAN 292
 Qy 243 KSYRDALYKEMVADAVALLGANSRAEDMKSVLRLEIKIAEIMPH-ENRTSEAMYNKN 301
 Db 293 EKVLTAYIDMEELGMLGGRPTSTRBQOVLELEIOLANTIVPQDRDEEKIKYHKS 352
 Qy 302 ISELISAMIPQFDMLGYIKKVIDTRLYPHLKDIPSPVAVRVQYKDFRILGSRKKT 361
 Db 353 ISELQALAPSMWMLFSLFLSP-----LELSDSEPVVYGYMDYIQOYSELINTEPSI 406
 Qy 362 IANLVWRYMYSRIPNLSRFPQRYLWLEFSRVIOGT-TLLPQMDKCVNFIESALPYVYG 420
 Db 407 LANVLNNLVQKTTSSIDRFESAOEKLLETLYGTGKSCVPMQOCISNTDALCFALGS 466
 Qy 421 MFVDVYFQEDKEMMEELVEGVWAFIDMLEKENEMMDAGTRKAKKARAVLAVGYPE 480
 Db 467 LFVKAIEDRQSKRIAGMSIETRAFEEL-GQLYWMDKTRQAKKEADAIYMDIGFPD 525
 Qy 481 FIMNDTHVNDLKAIFESADYFGVYLOTRKYLAQSDFFWLKRAVKTETMPTVNAF 540
 Db 526 FILEPEKEDDYDGYEISDSFQNMMLYNFSAKYMAQDLRKPPSRDQWMTQVYNA 585
 Qy 541 YSASTNOIRFPAGELQKPFMGTEPRSLSYGALGVYGHETGFDNNGKKYKNGLD 600
 Db 586 YLPTKNEIVFPAQILQAPFY-ARNHPKALNFGIGVWGHETLTHAFDQGEYDKGNLR 644
 Qy 601 PMWSTSEKKEKTKKCHINOYSYWKAGLVNKKRTLTGENTADNGSLREAFRAYRW 660
 Db 645 PMWQESLAAEFNHTACCEEDYNDY--OVNGERLNGRGTGENTADNGSLREAFRAYRW 702
 Qy 661 INDRROGLEEPLLPGITPTNNQLEFISYAHGCSYRPEARREVOYGASPPQFRYNGA 720
 Db 703 L--RKHG--EQOQLPAVGLTNQLPFGVGAQWCVSRPESHSBELVTPDPSPARFVLTG 759
 Qy 721 ISNSEFOKAPNCPNSTMNGMDSCLW 749
 Db 760 LSNRDLFHFHFCVPSPMNG-QLCFVW 787

RESULT 12

ECE2_BOVIN STANDARD; PRT; 787 AA.

AC 01-OCT-1996 (Rel. 34, Created)
 DT 01-OCT-1996 (Rel. 34, Last sequence update)
 DE 15-JUN-2002 (Rel. 41, Last annotation update)
 GN ECE2.
 OS Bos taurus (Bovine).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 OC Bovidae; Bovinae; Bos.
 OX NCBI_TaxId=9913;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=95318093; PubMed=779512;
 RA Emoto N., Yanagisawa M.;
 RT Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-
 sensitive metalloprotease with acidic pH optimum.";
 RL J. Biol. Chem. 270:15262-15268(1995).
 CC 1- FUNCTION: CONVERTS BIG ENDOTHELIN-1 TO ENDOTHELIN-1. OPTIMUM PH IS
 CC 5.5. INACTIVE AT NEUTRAL PH.
 CC 1- CATALYTIC ACTIVITY: Forms endothelin 1 by cleavage of the 21-
 CC Trp-1-Val-22 bond in the precursor.
 CC 1- ENZYME REGULATION: INHIBITED BY PHOSPHORAMIDON.
 CC 1- SUBCELLULAR LOCATION: INHIBITED BY PHOSPHORAMIDON.
 CC 1- SIMILARITY: BELONGS TO TYPE II membrane protein.
 CC 1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See [http://www.isb-sib.ch/](http://www.isb-sib.ch/announce/))
 CC or send an email to license@isb-sib.ch)
 CC -----
 Db EMBL: U27341; AAA82927.1;
 Dr HSSP: P08473; 1DMT.
 Dr MEROPS: M13.003; --.
 Dr InterPro: IPR000718; Peptidase_M13.
 Dr InterPro: IPR000130; Zn_MTPeptidase.
 Dr Pfam: PF01431; Peptidase_M13; 1.
 Dr PRINTS: PR00786; NEPRILysin.
 Dr PROSITE: PS00142; ZINC_PROTEASE; 1.
 Dr HydroLase; Metalloprotease; Zinc; Glycoprotein; Transmembrane;
 Dr Signal-anchor.
 FT DOMAIN 1 82
 FT TRANSMEM 83 103
 FT METAL 104 787
 FT ACT_SITE 624 624
 FT METAL 625 625
 FT METAL 628 628
 FT ACT_SITE 684 684
 FT CARBOHYD 164 164
 FT CARBOHYD 183 183
 FT CARBOHYD 187 187
 FT CARBOHYD 228 228
 FT CARBOHYD 288 288
 FT CARBOHYD 333 333
 FT CARBOHYD 400 400
 FT CARBOHYD 456 456
 FT CARBOHYD 549 549
 FT CARBOHYD 657 657
 FT SEQUENCE 787 AA; 88957 MW; F085C2921DAF0BF2 CR664;
 Query Match 29.9%; Score 1184; DB 1; Length 787;
 Best Local Similarity 35.1%; Pred. No. 4.9e-72;
 Matches 265; Conservative 138; Mismatches 313; Indels 38; Gaps 18;

Qy 4 ETGSSVETGKANKGRIRIALVFGGLVLTILF--LYSQGL-LSIAQKQCYCKPSCI 60
 Db 64 EAGFRKTSRLGLHQLQLELV-AGVSLALLALGLCVALGVQVHRPSSHCTLENCI 122
 Qy 61 EAAAILSKVNLVSDQDNFERRACDQWISNPIDPMSYGVFWLRHNVDLKLELLE 120
 Db 123 RVAGKILFSLDRVSCEDYFQSCGWTTRNPLPDGGRSMNNSLMDQALIKHLE 182
 Qy 121 KSISSRRDTEALQAKIILYSCMNEKALEKADAKPLHLRSPRMVYLSNG---PE 177
 Db 183 NT-TFNSSSEAEKQRFYLSCLQVERIEELGA-----HALD-----LDKIGMNV 230
 Qy 178 GVWSEKRFSLQTLATFRQOYNSVFILYSPDDKASNEHILKLDATYLSLAVREYLD 237
 Db 231 GPWDDQNF--MEVLAAGVATYRATPEFYIVSASKSNSNINQDQGLPLPSRDYLL- 287
 Qy 238 NSTEAKSYDALYKEMVADAVALLGANSRAEDMKSVLRLEIKIAEIMPH-ENRTSEAM 296
 Db 288 NNTAEKVLTAVIDAMELGLGQPTSTRBQOVLELEIOLANTIVPQDRDEEKI 347
 Qy 297 YKKNMISELSAMIPQFDMLGYIKKVIDTRLYPHLKDIPSPVAVRVQYKDFRILGSRKKT 356
 Db 348 YHKMSIAELQALAPSMWMLFSLFLSP-----LELSDSEPVVYGYMDYIQOYSELINTEPSI 401
 Qy 357 EKKTIANYLVWRYMYSRIPNLSRFPQRYLWLEFSRVIOGT-TLLPQMDKCVNFIESALP 415
 Db 402 TEPVANNYLLVNNLVQKTTSSIDRFESAOEKLLETLYGTGKSCVPMQOCISNTDALG 461
 Qy 416 YVVGMPVDYFQEDKEMMEELVEGVWAFIDMLEKENEMMDAGTRKAKKARAVLAK 475
 Db 462 FALSLFVKAIEDRQSKRIAGMSIETRAFEEL-GHLYWMDKTRQAKKEADAIYMD 520
 Qy 476 VGPEFTINDTHVNDLKAIFESADYFGVYLOTRKYLAQSDFFWLKRAVKTETMPTVNAF 535

Db 521 IGFPELLEPEKELDDVDYDGYVSEDSFFQNMNLNYSKAVMDOLRKPSPRDQMSMTQ 580

QY 536 YVNAFASSTNOIRPAGELQKPEFWGTEPRISYALIVYIGHETHEFDNGKRYDK 595

Db 581 YVNAFVLPKKNIVPAGILQAFY-TCNHQALNFGGIVGMKHELTHAFDQGNREYK 639

QY 596 NGMLDWMTSESEKPEKTEKCMINQYNYWKRAGLNVKGRITLGENIADNGGLREAR 655

Db 640 EGNIRFWMNESLAFKRNHTACIEQYISOY--QVNGEKLNRQRTIGENIADNGGLKAYN 697

QY 656 AYKRWINDRROGLEPELPGITFTNNQFLFSLYAHRCNSYRPREARROVQIGASPPQF 715

Db 698 AYKAWL--RRHG-EEQQLAVAGLTLNHLFVGFAGVWCSVTPRESSHGLVTDHSHARF 754

QY 716 RVNGAISNSEFQKAFNCPPNSFMNGKMDSCRLM 749

Db 755 RVLTGLTNSRDLRFHFGCPVGSFPMNSG-QLCEYV 787

RESULT 13

ECCEL_MOUSE STANDARD: PRT; 775 AA.

AD Q9UMIO: 15-JUN-2002 (Rel. 41, Created)

DT 15-JUN-2002 (Rel. 41, Last sequence update)

DT 15-JUN-2002 (Rel. 41, Last annotation update)

DE Endothelin-converting enzyme-like 1 (EC 3.4.24.-) (Xce protein)

DE (Damage-induced neuronal endopeptidase).

GN ECCEL OR XCE OR DINE.

OS Mus musculus (Mouse).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus;

OX NCBI_TaxID=10090;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=Brain;

RX MEDLINE=20226106; PubMed=10759559;

RA KIRIYU-Seo S., Sasaki M., Yokohama H., Nakagomi S., Hirayama T.,

RA Aoki S., Wada K., Kiyama H.;

RT "Damage-induced neuronal endopeptidase (DINE) is a unique

RT metalloproteinase expressed in response to neuronal damage and

RT activates superoxide scavengers."

RL Proc. Natl. Acad. Sci. U.S.A. 97:4345-4350(2000).

CC -1- FUNCTION: May contribute to the degradation of peptide hormones

CC and be involved in the inactivation of neuronal peptides.

CC -1- COFACTOR: Binds 1 zinc ion (By similarity).

CC -1- SUBCELLULAR LOCATION: Type II membrane protein (By similarity).

CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@sib-sib.ch).

CC -----

CC EMBL; AB026294; BAA95005.1; -

CC DR HSSP; P08473; IDMT.

DR MEROPS; M13.007; -

DR MGD; MGI:1343461; Eccl1.

DR InterPro; IPR000718; Peptidase_M13.

DR InterPro; IPR000130; Zn_MTPeptide.

DR Pfam; PF01431; Peptidase_M13; 1.

DR PRINTS; PR00786; NEPRILYSIN.

DR PROSITE; PS00142; ZINC_PROTEASE; 1.

DR PROSITE; PS00142; ZINC_PROTEASE; Metal-binding; Zinc;

KW Glycoprotein; Transmembrane; Signal-anchor.

FT DOMAIN 1 61

FT TRANSSEM 62 82

FT DOMAIN 83 775

FT METAL 612 612

ZINC (CATALYTIC) (BY SIMILARITY).

ACT SITE 613 613 BY SIMILARITY.

METAL 616 616 ZINC (CATALYTIC) (BY SIMILARITY).

FT METAL 672 672 ZINC (CATALYTIC) (BY SIMILARITY).

FT CARBOHYD 255 255 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 322 322 N-LINKED (GLCNAC. . .) (POTENTIAL).

FT CARBOHYD 656 656 N-LINKED (GLCNAC. . .) (POTENTIAL).

SO SEQUENCE 775 AA; 87993 MW; 5344595D/C5F34B9 CRC64;

Query Match 25.1%; Score 992; DB 1; Length 775;

Best Local Similarity 30.7%; Pred. No. 3.9e-59;

Matches 241; Conservative 159; Mismatches 290; Indels 94; Gaps 22;

QY 11 TGRKANRGTAL-----VVFVGTLYGLTLLFVSGLLSLQ-----AKQ 52

Db 41 SGRSAS-GRSGSLPRMRNRREVCLLSG-LYFAGICALIILAMALTKLIGPAAAGGACPE 98

QY 53 YCLKEPCIEAAAILLS-KVNLSDVPCNFRPCQDQMSNPFIPEDPSYGVYPMLRHV 111

Db 99 GCPERKAFARARFLSAMIDASIDPCDFYSFGGMLRHAIIPDKLTGTITATIGEQN 158

QY 112 DLKKELEKLSISRRDR-----EAIQKAKLTVSCNNEKAIKADAKPLHILRSPR 166

Db 159 EERLRRL-----ARPTGPGGAQKRVAFRSCIDMRLEIRGPMLVEIQC----- 209

QY 167 WPLIESNIGPEGW-----SERKSLQTLATPRGYSNSVFTRLVSPDDKASNE 217

Db 210 -----GGMDLGGADRPGAARDNLRLYKAGYSAALSLTVSILDDRSSR 258

QY 218 HILKQATSLAVRDYDNDNSTEAKSYRDALRYKRVDTAVLLGANSRREHDMKSLRL 277

Db 259 YVRIIDQGLTLPRLTYLAQDESEKILAAVYRMORILLGLADA--VQKQELTQL 316

QY 278 EIKTAEIMPHEN---RTSEAMTKMNISELSAMIPOFDMGLYIKKYIDTRYLHLKDIS 334

Db 317 EORLANISVEYDLDKRDVSSATNKVTLQLOKIIPHLOMKWLLQIPI-----EDFS 369

QY 335 PSENVVYRVPOFKDLFRILIGSERKTIANYLVKRWYSRIPIPLSRPOYMLSESVYIQ 394

Db 370 EEEVYVLTATYMQVYQQLRTPRRLIHYLVWVAVVLSLHSPREALHELAKEME 429

QY 395 GTTLLPQWDR-----CVNFIESALPYVVGKMFVDVYFOEDKEMMEELVEYKMAFI 447

Db 430 GN-----DKPOLARVYCLQANRHMALGALFHEHRSASKAKVOQLVEDIKYILG 482

QY 448 DLEKENEMDAGTTRKAKKERAVALKVGYPETIMDTVYNDLKAIFSEADIFGNVL 507

Db 483 ORLE-ELDMMDAQTFARAKIQLYMWVGYPDILKPEAVDKYE-FEVHEKTYPKNL 540

QY 508 QTRKYLAQSDFWLKKAPKTEMTPTNTVNAFASSTNOIRPAGELQKPEFWGTEYR 567

Db 541 NSIRFSTIQLSVKRIQEVKSTWLLPQALNAYLLPKNGVYVYAGILO-PLTYLDPDFQ 599

QY 568 SLISYGAIVGVGHEFTGFDNNGRRYKNGNLDPWMTSESEKPEKTEKCMINQYSNY-- 625

Db 600 SLVYGGIGITLGHGELHGYDWDGQYDRSGNLIHMTASTSRFLHACIVRLYDNFV 659

QY 626 YMKRAGLVNKGKTIENIADNGGLREAFRAVKKWINDRROGLEPILPGITFTNNQFL 665

Db 660 YNCR---VNGKRTLGENTADMGKLAYVAQKV--REHGEHP-LHRKYTHNQLFF 712

QY 686 LSYAHVRCNSYRPREAREVOYIGASHPPOFRYNGAISNSEEFQKAFNCPPNSFMNGDS 745

Db 713 IAFQNMCKIRRSQSYLYVLTLDKHAPEHYRVLYGSVQFEERGRAFHCPKPSPMN-PVHK 771

QY 746 CRWL 749

Db 772 CSYV 775

RESULT 14

ECCEL_MOUSE STANDARD: PRT; 775 AA.

ID Q9JHD3: 09JH192;


15-JUN-2002 (Rel. 41, Created)
 15-JUN-2002 (Rel. 41, Last sequence update)
 15-JUN-2002 (Rel. 41, Last annotation update)
 Endothelin-converting enzyme-like 1 (EC 3.4.24.-) (Xce protein)
 (Damage-induced neuronal endopeptidase).
 GN ECCL1 OR XCE OR DINE.
 OS Rattus norvegicus (Rat).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NIH3T3; TISSUE=Brain;
 RX MEDLINE=20226106; PubMed=10759559;
 RA Kiyama S., Sasaki M., Yokohama H., Nakagomi S., Hiyama T.,
 RT "Damage-induced neuronal endopeptidase (DINE) is a unique
 RT metalloproteinase expressed in response to neuronal damage and
 RT activates superoxide scavengers." Proc. Natl. Acad. Sci. U.S.A. 97:4345-4350(2000).
 RL [2]
 RP SEQUENCE OF 431-632 FROM N.A.
 RX MEDLINE=99132387; PubMed=9931490;
 RA Valdenaire O., Richards J.G., Pauli R.L.M., Schweizer A.;
 RT "XCE, a new member of the endothelin-converting enzyme and neutral
 RT endopeptidase family, is preferentially expressed in the CNS." Brain Res. Mol. Brain Res. 64:211-221(1999).
 RL [1]
 CC -1- FUNCTION: May contribute to the degradation of peptide hormones
 CC and be involved in the inactivation of neuronal peptides. Cleaves
 CC the synthetic substrate Z-Gly-Gly-Leu-PNA and releases PNA. May
 CC protect against C2-ceramide-induced apoptosis.
 CC -1- COFACTOR: Binds 1 zinc ion (By similarity).
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -1- TISSUE SPECIFICITY: Highly expressed in the CNS, in particular in
 CC neurons of the caudate putamen, diagonal band, the paraventricular
 CC nucleus of the thalamus, part of the hypothalamus, in cranial
 CC spinal tract trigeminal nucleus, and substantia gelatinosa of the
 CC hippocampus and cerebellum.
 CC -1- INDUCTION: By mechanical damage to nerve cells.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL: AB026293; BAA95004.1;
 DR EMBL: AB023896; BAA95006.1;
 DR EMBL: Y16188; CAA76114.1;
 DR HSSP: P08473; IDMT.
 DR MEROPS: M13.007;
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR000130; Zn_MTPeptide.
 DR Pfam: PF01431; Peptidase_M13; 1.
 DR PRINTS: PRO0786; NEPRILysin.
 DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 KW Hydrolase; Protease; Metalloproteinase; Metal-binding; Zinc;
 KW Glycoprotein; Transmembrane; Signal-anchor.
 FT DOMAIN 1 61 82
 FT TRANSMEM 62 82
 FT SIGNAL-ANCHOR (POTENTIAL).
 FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT LUMENAL (POTENTIAL).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT BY SIMILARITY.
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 656 656
 FT CARBOHYD 656 656

FT CONFLICT 536 536 L -> F (IN REF. 2).
 SQ SEQUENCE 775 AA; 87944 MW; 0823091F98A41556 CRC64;
 Query Match 24.7%; Score 977; DB 1; Length 775;
 Best Local Similarity 30.5%; Pred. No. 4e-58;
 Matches 239; Conservative 158; Mismatches 293; Indels 94; Gaps 22;
 11 TGRKARNGRIAL-----VIVGGLVLTGLTFLVSGLLSLQ-----AKOE 52
 Db 41 SGRSAS-GARSGLRMRKREVCILSG-LVPAAGCALIAMAALATKYLRGGAAGGACGACPE 98
 QY 53 YCLPECELEAAALIS-KVNLVSDPCDNFEEACDGMISNIPIDMSYGVYRWLRNRY 111
 Db 99 GCEPKKAPARARFLSANIDASIDPCQDFYSFACGGMRLRAHAPDKLTGLTAIEON 158
 QY 112 DLKLEKLEKISRRDPT-----EATOKAKIYSSCEKAEKADAKPLHLIRHSPFR 166
 Db 159 EERLRRL-----ARPTGGPGAARQKRAFRKSCIDMRERIEIRGPRMVEIYEDC--- 209
 QY 167 WPLVLSNIGPEGV-----SERKESLLQTLATFERGQYSNVSFIRLYSPDDKASNE 217
 Db 210 -----GWDLGGAADPGGAARDLNRLLYKAQGYSAALFSLVSDDDNSSR 258
 QY 218 HILKIDATLSLAVEDYLDNSTEAKSYRDLTFPMDTAVLIGANSSRAEDMKSVRL 277
 Db 259 YVIRIDODGLTLPRTVLTADDESEKVALAKYMERLRLIGADA--VEOKAQRIQL 316
 QY 278 EIKIKEMIPHEN--RSEAMKKNMISLSAMIPDFMLGIKKYIDTRLYPHLKDIS 334
 Db 317 EGRANISVSEIDLRKRVSSVYKVTGLQITPHLQKMLLDQIRQ-----EDPS 369
 QY 335 PSENVYVVPQYFEDLRILSEKRTIANYLYRWVYRIRPLSRQYRMLESRYIQ 394
 Db 370 EEEVYVLTADYMQVYQSLIRSPRLNHYLYRWVYVLSHLSPPREALHEIAKEME 429
 QY 395 GTTTLTPQMDK-----CVNFIESALPYVYGKMEVDYVFOBKKEEMELVEGVRNAFI 447
 Db 430 GN-----DKPQELAVVCLGQANRRFGMALGALFVHEHFSASAKAYQQLVEDIKIILG 482
 QY 448 DMLEKEMNDAGTKRKAKERAVLAKYGEPEFTINPTVHVEDKAKKSEADYFSGNL 507
 Db 483 QRE-ELDMVMDAGTKAARAKLQYVMVVGYPDLTKAEVADKEE-PEVHEKYYLNL 540
 QY 508 QTRKYLAOSDFEYLKRAVPTKEMFNPTVNAFYSASTNQIRFAGELORPFWGTEYPR 567
 Db 541 NSIRFSIQSYKKIRQEVKSTWLLPQALNAYVLPNKNQVFPAGILQ-PTLYDDDFQ 599
 QY 568 SLISYGAIVYVHEFTHGFGNNGKRYDKNGNLDPMWSTSESEKKEKTKCMINQSYN-- 625
 Db 600 SLNYGGIGITIGHELTHGDDMGQGYDRSGNLLHWTEASYSRLHKAECIVRLXDNFTV 659
 QY 626 YWKAGLANKGKRTGENIADNGGLRFAFRYKRWINDRQGLEEPLDGLFTNNQLEF 685
 Db 660 YNOR-----VNGHTLIGENIADMGGLKLAAYAYOKW--REHGPEHD-LRLRYTHNQLEF 712
 QY 686 LSYAVRNSYRPEARBOVIGASHPPQFVNGAITSNSEEPQKAPCNPNSTANRGDS 745
 Db 713 IAFANMCKIKRRSOSIYVLTLDKHAPEHYRVLGSVQGEERGRAPHCXKPSPN-PVKH 771
 QY 746 CRLW 749
 Db 772 CSWV 775
 RESULT 15
 ECCL_HUMAN
 ID ECCL_HUMAN STANDARD; PRT; 775 AA.
 AC 095672; Q9NY95;
 DT 15-JUN-2002 (Rel. 41, Created)
 DT 15-JUN-2002 (Rel. 41, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)
 DE Endothelin-converting enzyme-like 1 (EC 3.4.24.-) (Xce protein).
 GN ECCL1 OR XCE
 OS Rattus norvegicus (Rat).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.
 OX NCBI_TaxID=10116;
 [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=NIH3T3; TISSUE=Brain;
 RX MEDLINE=20226106; PubMed=10759559;
 RA Kiyama S., Sasaki M., Yokohama H., Nakagomi S., Hiyama T.,
 RT "Damage-induced neuronal endopeptidase (DINE) is a unique
 RT metalloproteinase expressed in response to neuronal damage and
 RT activates superoxide scavengers." Proc. Natl. Acad. Sci. U.S.A. 97:4345-4350(2000).
 RL [2]
 RP SEQUENCE OF 431-632 FROM N.A.
 RX MEDLINE=99132387; PubMed=9931490;
 RA Valdenaire O., Richards J.G., Pauli R.L.M., Schweizer A.;
 RT "XCE, a new member of the endothelin-converting enzyme and neutral
 RT endopeptidase family, is preferentially expressed in the CNS." Brain Res. Mol. Brain Res. 64:211-221(1999).
 RL [1]
 CC -1- FUNCTION: May contribute to the degradation of peptide hormones
 CC and be involved in the inactivation of neuronal peptides. Cleaves
 CC the synthetic substrate Z-Gly-Gly-Leu-PNA and releases PNA. May
 CC protect against C2-ceramide-induced apoptosis.
 CC -1- COFACTOR: Binds 1 zinc ion (By similarity).
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein.
 CC -1- TISSUE SPECIFICITY: Highly expressed in the CNS, in particular in
 CC neurons of the caudate putamen, diagonal band, the paraventricular
 CC nucleus of the thalamus, part of the hypothalamus, in cranial
 CC spinal tract trigeminal nucleus, and substantia gelatinosa of the
 CC hippocampus and cerebellum.
 CC -1- INDUCTION: By mechanical damage to nerve cells.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC
 DR EMBL: AB026293; BAA95004.1;
 DR EMBL: AB023896; BAA95006.1;
 DR EMBL: Y16188; CAA76114.1;
 DR HSSP: P08473; IDMT.
 DR MEROPS: M13.007;
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR000130; Zn_MTPeptide.
 DR Pfam: PF01431; Peptidase_M13; 1.
 DR PRINTS: PRO0786; NEPRILysin.
 DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 KW Hydrolase; Protease; Metalloproteinase; Metal-binding; Zinc;
 KW Glycoprotein; Transmembrane; Signal-anchor.
 FT DOMAIN 1 61 82
 FT TRANSMEM 62 82
 FT SIGNAL-ANCHOR (POTENTIAL).
 FT SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT (POTENTIAL).
 FT LUMENAL (POTENTIAL).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT BY SIMILARITY.
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 656 656
 FT CARBOHYD 656 656

OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
 NC NCBI_TaxID=9606;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Caudate, and Spinal cord;
 RX MEDLINE=99132387; PubMed=9931490;
 RA Valdenaire O., Richards J.G., Faull R.L.M., Schweizer A.;
 RT "XCE, a new member of the endothelin-converting enzyme and neutral
 endopeptidase family, is preferentially expressed in the CNS.";
 RL Brain Res. Mol. Brain Res. 64:211-221(1999).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=20164043; PubMed=10698686;
 RA Valdenaire O., Rohrbacher E., Langeveld A., Schweizer A., Meijers C.;
 RT "Organization and chromosomal localization of the human ECE1 (XCE)
 gene encoding a zinc metallopeptidase involved in the nervous control
 of respiration.";
 RL Biochem. J. 346:611-616(2000).
 CC -1- FUNCTION: May contribute to the degradation of peptide hormones
 and be involved in the inactivation of neuronal peptides.
 CC -1- COFACTOR: Binds 1 zinc ion (By similarity).
 CC -1- SUBCELLULAR LOCATION: Type II membrane protein (By similarity).
 CC -1- TISSUE SPECIFICITY: Highly expressed in the CNS, in particular in
 putamen, spinal cord, medulla and subthalamic nucleus. A strong
 signal was also detected in uterine subepithelial cells and around
 renal blood vessels. Detected at lower levels in amygdala,
 caudate, thalamus, pancreas and skeletal muscle. Detected at very
 low levels in substantia nigra, cerebellum, cortex, corpus
 callosum and hippocampus.
 CC -1- PTM: N-glycosylated.
 CC -1- SIMILARITY: BELONGS TO PEPTIDASE FAMILY M13.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation-
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See http://www.isb.ch/announce/
 or send an email to license@isb-sib.ch).
 CC -----
 DR EMBL: Y16187; CAA76113.1; .
 DR EMBL: AJ130734; CAB86601.1; .
 DR HSSP: P08473; IDMT.
 DR MEROPS: M13.007; .
 DR Genew: HGNC:3147; ECE1.
 DR MIM: 605896; .
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR001230; Prenyl_site.
 DR InterPro: IPR000130; Zn_MTpeptidase.
 DR Pfam: PF01431; Peptidase_M13; 1.
 DR PRINTS: PR00786; NEPRILYSIN.
 DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 DR PROSITE: PS00142; ZINC_PROTEASE; 1.
 DR Hydroxylase; Protease; Metalloprotease; Metal-binding; zinc;
 KW Glycoprotein; Transmembrane; Signal-anchor; Polymorphism.
 KM DOMAIN 1 59
 FT DOMAIN 1 59
 FT TRANSMEM 60 82
 FT LUMENAL (POTENTIAL).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT BY SIMILARITY.
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT ZINC (CATALYTIC) (BY SIMILARITY).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT H -> Q (IN DBSNP:2741281).
 FT /FTID=VAR_012813.
 FT Y -> H (IN DBSNP:1529874).
 FT /FTID=VAR_012814.
 FT V -> I (IN REF. 2).
 FT VL -> AF (IN REF. 2).
 FT CONFLICT 286 286
 FT CONFLICT 757 758

FT CONFLICT 763 763 V -> D (IN REF. 2).
 SQ SEQUENCE 775 AA; 87781 MW; 5B43E0F11C5B55C CRC64;
 Query Match 24.58; Score 969.5; DB 1; Length 775;
 Best Local Similarity 30.7%; Pred. No. 1.3e-57;
 Matches 231; Conservative 157; Mismatches 297; Indels 67; Gaps 19;
 QY 23 LVEVGGTLVGLTILFVSOGSLSL--QAKQCYLKEPCEYFAAAAIL-SKYNLSVDPDCLN 79
 DB 66 LVFAAGCALIILAAALTYLGPVAAAGGACGCEGPEKAFARARFLAANLADSIDPCOD 125
 QY 80 FEFACDGMISNNPIEDMPSYGVYVWLRHNVDDLKLELLEKTSISRRDTEALOKATLY 139
 DB 126 FYFACGGWMLRHAIIPDDKLTGTGTAIGQNEERILRLARP-GGGPGGAQRVAF 184
 QY 140 SSCANEKAIERKADAPLHLIRHSFRRPVLESNGPGVY-----SER-----KFSILQ 189
 DB 185 RSLDMREIERLGRPRMLEVIEDC-----GGMDLGAEERPGVAARWDLNR 230
 QY 190 TLATFRGQYSNVEFRLYVSPDDKASNEHILKLDQATLSLAVREDYLDNSTEAKSYDAL 249
 DB 231 LLYKAGVYSAALSLTYVSLDDRSRVYRIDDGLTLPERLYLAQDDESEKVLAAV 290
 QY 250 YFPMVDYAVLGANSRAEHDKSVLRLEIKAEIMIHEN--RTSAMYNKNISLTS 306
 DB 291 RYFMERVLSILGADA--VEQKAQELQVQOLANTVSEYDRLRDVSMINKYTLGLO 348
 QY 307 AMIPQDMYGLTKVYIDTLYPLHLKDIPSENVVYVQVQKDLPRILGSEKKTIANYL 366
 DB 349 KITPHLRKMWLDQIFQ-----EDFSEEEVVLATDYMQVQSOLIRSFHRLVNYL 401
 QY 367 VWRVYSRIPNLSRRFQYMWLEFSRYIGTITLLQWOK-----CYNFIESALPYVG 419
 DB 402 VWRVYVVLSEHSPPRREALHELAQEMEGS-----DKPOLANVCYQANRHEGMAIG 454
 QY 420 KMYVDYVQEDKKEMEEELVEGVRAFIIDLKEMEMDAGTKRKAKERARVLAQVGP 479
 DB 455 ALVHHFHSASAKAQQLVEDIKYTLGRLRLE-ELDDMAEFRAARAKLYMMVAVGVP 513
 QY 480 EFTLNDTHVNEDLKAIKESADYFGVNLQTKRYLAOSDFWLKRAVKTENFTNPTVVA 539
 DB 514 DFLKPDADVDEYE-FEVHEKTYFKNLIINSIRSIQLSVYKRIQEVKSTWLLPQALNA 572
 QY 540 FYGASINQIRFPAGELQKPFMGTEYPRSLSGAIGVIGHEFTGFDNNGKRYDKGNL 599
 DB 573 YLDPNKNQVFPAGILO-PTLYDPDPQSLNGIGITIIIGHELTHGYDDMGQOYDRSGNL 631
 QY 600 DPMWSTSESEKFEKTKCMINQYSNY--YWKAGLVNKGKRTLGENIADNGIGREAFRAY 657
 DB 632 LHMWTEASYSRFLKAKCIVRLDNFTVYNQR-----VNGKHITGEMINADMGKIKLAYHAY 687
 QY 658 RKMVINDRQGLLEPLPGITFTNNQFLFSLAHVNRNSYRPEARAOYDGAHSPQGFVY 717
 DB 688 QKWV--REHGPENP-LRLKTYTHDQLEFLAFAQNMCKKRSOSITLYLVLTDKHAPHYRYV 744
 QY 718 NGATSNSEEFQKAFNCPNPNSTNMGDSCRLL 749
 DB 745 LGSYSQFEHGRVYACPKVPMNA-HKCSYV 775

Search completed: May 21, 2003, 18:48:18
 Job time : 31 secs



Query Match	96.58;	Score 3819;	DB 11;	Length 749;
Best Local Similarity	95.38;	Pred. No. 3.1e-256;		
Matches 714; Conservative	22;	Mismatches 13;	Indels 0;	Gaps 0

QY 1 MEAGTSSVETGKANKGRTRIALVFWGGVLTLLFVSGGLSLQAKOETCLKPCPI 60
 DB 1 MEAGTSSVETGKANKGRTRIALVFWGGVLTLLFVSGGLSLQAKOETCLKPCPI 60
 QY 61 EAAALISKVNLVSDPCDNFEPACDGMWISNNPDEMPSYGVFWLRHNDLKLKELLE 120
 DB 61 EAAALISKVNLVSDPCDNFEPACDGMWISNNPDEMPSYGVFWLRHNDLKLKELLE 120
 QY 121 KTSIRRRDEALQAKITVSSCNEKATIKAKAPLHLRLSPRRMVLNLSNIGESGV 180
 DB 121 KTSIRRRDEALQAKITVSSCNEKATIKAKAPLHLRLSPRRMVLNLSNIGESGV 180
 QY 181 SEKESLDTLATFRGOYSNSVFIKLYSPDDKASNEHLKIDQATISLAVREDYLDNST 240
 DB 181 SEKESLDTLATFRGOYSNSVFIKLYSPDDKASNEHLKIDQATISLAVREDYLDNST 240
 QY 241 EAKSYDALKFMPVPAVLILGANSRAHDMKSVLRLEIKIAETIMIPHEMTSEAMTKM 300
 DB 241 EAKSYDALKFMPVPAVLILGANSRAHDMKSVLRLEIKIAETIMIPHEMTSEAMTKM 300
 QY 301 NISELSAMIPDFMLGYIKVYIDTRYLPHLKDISENVVYRVQYKDFRILIGSRKK 360
 DB 301 NISELSAMIPDFMLGYIKVYIDTRYLPHLKDISENVVYRVQYKDFRILIGSRKK 360
 QY 361 TIANTLVNMYSRIPNLSRROVYHLEFSVYIGTTLTPQMDKCVNFTESALPYVVGK 420
 DB 361 TIANTLVNMYSRIPNLSRROVYHLEFSVYIGTTLTPQMDKCVNFTESALPYVVGK 420
 QY 421 MEVDVYFQEDKKEMMELVEGVNAFIDMLEKENMDAGTKRKAKARAVLAKYCYPE 480
 DB 421 MEVDVYFQEDKKEMMELVEGVNAFIDMLEKENMDAGTKRKAKARAVLAKYCYPE 480
 QY 481 FIMNDTYNEDLKIKSEADYEGNVLOTKRYLAQSDPEFWLRAVPTKTEFTNPTVNAF 540
 DB 481 FIMNDTYNEDLKIKSEADYEGNVLOTKRYLAQSDPEFWLRAVPTKTEFTNPTVNAF 540
 QY 541 YSASTNOIRFAGELQKPFMGTEYPRSLSYGALVYGHGHEFTGHDNGRKDKNGND 600
 DB 541 YSASTNOIRFAGELQKPFMGTEYPRSLSYGALVYGHGHEFTGHDNGRKDKNGND 600
 QY 601 PMSSESEKPEKTKCMINOYSNYTKKAGLVKGRITGENIADNGILREAFRAYRK 660
 DB 601 PMSSESEKPEKTKCMINOYSNYTKKAGLVKGRITGENIADNGILREAFRAYRK 660
 QY 661 INDRQGLIEBLLPGITFTNNOLFSLYAHVRCNSYRPEARQVOIGAHSPQRYVNGA 720
 DB 661 INDRQGLIEBLLPGITFTNNOLFSLYAHVRCNSYRPEARQVOIGAHSPQRYVNGA 720
 QY 721 ISNEEFQKAFNCPNSTANRGADSCRW 749
 DB 721 ISNEEFQKAFNCPNSTANRGADSCRW 749
 RESULT 2
 QYERK3 PRELIMINARY: PRT: 742 AA.
 ID QYERK3: PRELIMINARY: PRT: 742 AA.
 AC QYERK3: PRELIMINARY: PRT: 742 AA.
 DT 01-MAR-2001 (Tremblrel. 16, Created)
 DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE Neprilysin-like peptidase alpha.
 GN ME11.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 NCBI_TaxID=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=21293028; PubMed=11278416;
 RA Shirotsani K., Tsubuki S., Iwata N., Takaki Y., Harigaya W.,
 RA Maruyama K., Kiyu-Seo S., Kiyama H., Iwata H., Tomita T.,
 RA Iwatsuno T., Saito T.C.;

RT "Neprilysin Degrades Both Amyloid beta Peptides 1-40 and 1-42 Most
 RT Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive
 RT Endopeptidases."
 RL J. Biol. Chem. 276:21895-21901(2001).
 DR EMBL: AF302075; MAG18446.1; -.
 DR HSSP: P08473; 1DMT.
 DR MEROPS: M13.008; -.
 DR MGD: MG1.1351603; Me11.
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR001230; Prenyl_site.
 DR pfam: PF01431; Peptidase_M13; 1.
 DR PRINTS: PR00786; NEPRILYSIN.
 DR PROSITE: PS00294; PRENYLATION; UNKNOWN.1.
 DR PROSITE: PS00142; ZINC_PROTEASE; UNKNOWN.1.
 SQ SEQUENCE 742 AA; 8593 MW; 4444EAD211B2499F CRC64;
 Query Match 34.9%; Score 1380; DB 11; Length 742;
 Best Local Similarity 38.8%; Pred. No. 3.6e-87;
 Matches 291; Conservative 148; Mismatches 267; Indels 44; Gaps 17;
 QY 18 GTRIALVFWGGVLTLLFVSGGLSLQAKOETCLKPCPIEAAALISKVNLVSDPC 77
 DB 19 GLAVLILLLGLAVTLGV---FYSIALRDSLSKSDITTPSCVYAAARILNMDQSRNFC 75
 QY 78 DNEFFACDGMISNNPDEMPSYGVFWLRHNDLKLKELLEKTSIRRRDEALQAKI 137
 DB 76 EEFYVACGWLRRHVIVLETNSRYSVFIDILRDELVEILKGLDSDISQHR--PAVEKAT 133
 QY 138 LYSSCNEKATEKADAPLHLRLSPRRMVLNLSNIGESGVSR---KFSLLDTLATF 194
 DB 134 LYSSCNOVSYLEKRDSELSVLK--MVGMPVAMDK-----WNEYGLKWELEQLAVL 186
 QY 195 RGOYSNSVFIKLYSPDDKASNEHLKIDQATISLAVREDYLDNSTEASYPDALYKCY 254
 DB 187 NSQFNRRVLLDLFTWMDQNSSRHVYIYIDPTLGMPSEREYFQEDNNH--VKAYLEMT 245
 QY 255 DTAVL-----LGANSRAHDMKSVLRLEIKIAETIMIPHEMTS--EAYNNANISLSA 307
 DB 246 SVATMLRKQDNLSEKSMVREAEVLELTHANATVPEQRHVDYALYHMDLMELOE 305
 QY 308 M--IPQDMLGYIKV---IDTRYLPHLKDISENVVYRVQYKDFRILIGSRKTI 362
 DB 306 RFGIKGFNMTLFTONLSSVEVELF-----PDEEVVYGIPLYLELIDISYARTM 358
 QY 363 ANYLVNMYSRIPNLSRROVYHLEFSVYIGTTLTPQMDKCVNFTESALPYVVGMAF 422
 DB 359 ONYLVNMYSRIPNLSRROVYHLEFSVYIGTTLTPQMDKCVNFTESALPYVVGMAF 418
 QY 423 VDYVYFQEDKKEMMELVEGVNAFIDMLEKENMDAGTKRKAKARAVLAKYCYPEFI 482
 DB 419 IKRAFSDSKSVYRELIERISVFDNDELN--WMDSESKKAQKANNINEQIGDPTI 477
 QY 483 M--NDTHVEDLKIKFSEADYEGNVLOTKRYLAQSDPEFWLRAVPTKTEFTNPTVNAF 540
 DB 478 LEDNNKHDEBEVSSLTFTYDLYFENGLOLNKNAQSRSLKRLREKVDOMLTIGAAVNAF 537
 QY 541 YSASTNOIRFAGELQKPFMGTEYPRSLSYGALVYGHGHEFTGHDNGRKDKNGND 600
 DB 538 YSPNRQIVFPAIGLQPPF--SKDQPSLNGIGMVGIVGHITITGFDNGRNFENKSNMML 596
 QY 601 PMSSESEKPEKTKCMINOYSNYTKKAGLVKGRITGENIADNGILREAFRAYRK 659
 DB 597 DMKSNFSAHFQOQOOCMTIYOGNFSWILADONVNGSTIGENIADNGVRAQYKAYLR 656
 QY 660 WINDRQGLIEBLLPGITFTNNOLFSLYAHVRCNSYRPEARQVOIGAHSPQRYVNG 719
 DB 657 WLAD---GKQDRLPGLMLTYAQLFEITNAYAGWGSTIRPEAVOSIKTVVHSPKRYVIG 713
 QY 720 AISNEEFQKAFNCPNSTANRGADSCRW 749
 DB 714 SIQNLPGFSEAFHCPRGSPM--PMKRCRIW 742

[illegible][illegible]


```

Db 249 SDRYACTGPAEACR-AYEKEMIDLAKLIRIDRGILNISTEDTIREKRYMDLERDIANA 307
Qy 285 MIPENRTSEA-MYKKNMISLSAMT-----POFDWLGIRKVIDTRLYPHLKDISPE 337
Db 308 TDTEEDRNNPVLLKMKELGDLNANFTLEVESQVFDMSYETAKIMTVI-----SVPDTE 363
Qy 338 NVAVRVQYKDFRILGSEKRTIANTLYVMRVYRIRPLRSRQYRMLEFSRYIQGT 397
Db 364 KVIYSPNYRRLNLLIARYNKRDILONYMVRAMMNVGLSRYSYDFRKAARKALSGT 423
Qy 398 TLDPOMKCVNFIESALPIYVGKMFVDYVFOEDKEMELEVEGVMAFIDMLEKENEM 457
Db 424 SEAAVMQCALYVNNMNDNAVGLYQVQEAFFSEKSEKLEMEMLKODIRFISILD-DLTM 482
Qy 458 DAGTKRAKAKARAVLAKGYPEEIMNDPHVEDLKAIFSDYFGVGLQTRKYLQSD 517
Db 483 DAETKRAAEKAKAIREIRGIDYDNKIDKYLNNENYDLAYSSEYFENILNLEYVOKR 542
Qy 518 FEMLRKAVKTEWFTNPTVNAFYASTNQIRFPAGELQKFFWGTETPRSLGAYGVI 577
Db 543 LRKLRYKKEEYVGAAYVNAFYSSKNQIVFPAGILQPEFF-SKGAQSLNGLGIGV 601
Qy 578 VGEHTGFDNNGRKYKNDLPWMSTSESEKFEKTKKMINOYSNYAKKA-GLNVKG 636
Db 602 IGHETIGHFDNGRNYDKDGLKMTGTSTDRFLDSKCTVNOYGNFSDLANGLHLNG 661
Qy 637 KRTIGENTADNGLEAPRAVRYKRTNDRQGLEPPLPGITFTNNQLFYSYAHVRCNS 696
Db 662 NNTLENTADNGIRQAQAYKNYV--EKHG-EEPSLPGILSHNOJFPLNFQVWCGTH 718
Qy 697 REAPAREVOIGAHSPPOFRVNGAISNSEEFQAFNCPSPSTNRKGDSCRIM 749
Db 719 REQAVNSIKYDVHSPGKFRVYLSLQNPPEAKAFKCKNSYMPA-NICRVW 770

RESULT 8
Q96P9 PRELIMINARY; PRT; 770 AA.
AC Q96P9;
DT 01-DEC-2001 (TREMBLrel. 19, Created)
DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
DE 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
OS Homo sapiens (human).
OC Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE-21444797; PubMed-11560781;
RT "Molecular cloning, tissue distribution, and chromosomal localization
RT of MME2, a gene coding for a novel human member of the neutral
RT endopeptidase-24.11 family."
RL DNA Cell Biol. 20:493-498(2001).
DR EMBL; AF336981; AAL08942.1.
DR MEROPS; M13.008;
DR InterPro; IPR000718; Peptidase_M13.
DR InterPro; IPR001230; Prenyl_site.
DR InterPro; IPR000130; Zn_MTPeptide.
DR Pfam; PF01431; Peptidase_M13; 1.
DR PROSITE; PS00294; PRENYLATION; UNKNOWN_1.
DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
SQ SEQUENCE 770 AA; 88523 MW; DP9C08F4A56A3B CRC64;

```

Query Match 33.7%; Score 1332.5; DB 4; Length 770;
 Best Local Similarity 39.2%; Pred. No. 7.4e-84;
 Matches 284; Conservative 145; Mismatches 258; Indels 37; Gaps 17;

Qy 42 QGLSLAKQKQCYCKPCEIAAAAILSKVLSYDPCDNFRFRACDGMISNPNIPEDMPSY 101
 Db 68 RGIREAGEVEVCTTCPCVIAAARILQNMDDPTTEPCDDFYQFACGGLMRHRYIPEINSKY 127

```

Qy 102 GYVPLRHNVDLKLLEKLSRRRDTEAIOAKILYSSCMKEAKIEKAKPLHLIR 161
Db 128 SIFVRLDELEVLITKAVLENST--KDRAVEAKRLYSCNNOYIEKRGQPLDIL 184
Qy 162 HSPFRMPVLESNIGPEWSER--KFSLLQTLAEFRGYSNVEIRLYVSPDKASNEH 218
Db 185 EYVGGMFVANDR-----NNEVIGLEWELERQALAMNSQFNRRVILDLFINMDQNSRH 238
Qy 219 ILALDQATLSIAREDYLDNSTEAKSYRDLAKKEDVAVIL--GANSR-----AEDMK 272
Db 239 IIVIDQPTLGMPEREYFFGGSNRK-VREAYIQFVAVATLLREDANLPRSCVQEDMV 297
Qy 273 SVLRLEKIALEIMIPENRTSE-AMYNKNMISLSAM--IPQFDWLGIRKVIDTRLYPH 329
Db 298 QVLEETQIAKATVQEEHHVDIALYHMGLEIQSGGLGFWMTLFIQVLS-----352
Qy 330 LR-DISPEENVVVRVQYKDFRILGSEKRTIANTLYVMRVYRIRPLRSRQYRMLE 388
Db 353 VRIKILPDEEVVYGIPLQNLNENIDITYSARTIQNLVWRLVLDRLGSLQSEFKDTRVN 412
Qy 389 FSRVIGTTLTPQWDKCVNFIESALPIYVGKMFVDYVFOEDKEMELEVEGVRAFTD 448
Db 413 YKALFGRVVEERKRECVGVNSNMENAVGSLYREAFPGDSKSMVRELIDKRYVYV 472
Qy 449 MLEKENEMDAGTKRAKAKARAVLAKGYPEEIMNDTH--VVEDLKAIFSDYFGV 506
Db 473 TLD-ELGMDEESKKKQEKAMSIREQIGHPDYLEMNRRLDEEYSNFSEDLFEENS 531
Qy 507 LOTRKYLAQSDFFMLRKAVPTEWFTNPTVNAFYASTNQIRFPAGELQKFFWGTETPR 566
Db 532 LONLKVAGQBSLRKLREKVPDNLITGAAYVNAFYSPNRQIVFPAGILQPEFF-SKEP 590
Qy 567 RSLSYGAIYVGEHTGFDNNGRKYKNDLPWMSTSESEKFEKTKKMINOYSNY 626
Db 591 QALNFGIGVYGHETIGHFDNGRNFDPKGNMMDMWSNFSTQHREOSECMIYQGYNS 650
Qy 627 WKAG-LNVKGRKRTIGENTADNGLEAPRAVRYKRTNDRQGLEPPLPGITFTNNQLEF 685
Db 651 WDLADEQNVGENTIGENTADNGVQAVKAYLKW--AEGKQDQPLGDLTHEQLEF 707
Qy 686 LSYAHVRCNSYREAPAREVOIGAHSPPOFRVNGAISNSEEFQAFNCPSPSTNRKGD 745
Db 708 INYAQWCGSYREPAIQSIKTDVHSPKRYVGLSLQNLAAFDTHCARCTPMH-PKER 766
Qy 746 CRM 749
Db 767 CRM 770

```

```

RESULT 9
Q9DGN6 PRELIMINARY; PRT; 752 AA.
AC Q9DGN6;
DT 01-MAR-2001 (TREMBLrel. 16, Created)
DT 01-MAR-2001 (TREMBLrel. 16, Last sequence update)
DE 01-DEC-2001 (TREMBLrel. 19, Last annotation update)
DE Endothelin converting enzyme-1.
GN ECE-1.
OS Gallus gallus (Chicken).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Eukaryota; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;
OC Gallus.
OX NCBI_TaxID=9031;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE-20363660; PubMed-10903177;
RA Takebayashi-Suzuki K., Yanagisawa M., Gourdi R.G., Kanawa N.,
RA Mikawa T.;
RT "In vivo induction of cardiac Purkinje fiber differentiation by
RT co-expression of preproendothelin-1 and endothelin converting enzyme-
RL Development 127:3523-3532(2000).

```


Db 173 APPSPDELPVYTKAKNLKSCLETDMDARGIDYKOWLSSTIGEWPLISS-----AFN 226
 Qy 182 ERKESLQTLAFNGQYNSVFIIRLYSPDOKASNEHLIKLDOATLSAVERDL--DNS 239
 Db 227 ESEFPTTAIRK-ANIVPGVVAFTVGTDDKNSKTLKLDQAFGLPGQRYRVRPND 285
 Qy 240 TEANSYRDALYKFWNDPAVLG-ANSSRAEHDMKSVLNLKIAEIMI-PHENRTSEAMY 297
 Db 286 TYKAYETLYR---VAELGFPDPAEAKDADVDFEMQIAQISVRAIRRNANAVF 341
 Qy 298 NKNMISELSA--MIPQFWLGIKKYIDTLYPHLK-DISSENVYVVRVPOYFQDLRIL 354
 Db 342 NPMTLAIDQDSSPELNFSLITTVMSA---PEVAVSGDELTIMNSPEYFNLDL 398
 Qy 345 GSEKRTIANTLVNMYVSRIPNLSRROQYRWLESRVIOGTTLTPQMDKCVNFISAL 414
 Db 399 RNTFKRTIANTYIKRITISYIGTLQYFKDREFETKATYIEIVQPELFCISFVRNV 458
 Qy 415 PYVVGKMFVDYVFOEDKKEMBELVEGRVAFIMLEKENEMMDAGTKRKAERAVLA 474
 Db 459 GFILSKPVDKFEPSPEADVALEMISGLQSAFNEIYD-EVEMDDETKVYAREKNDAYS 517
 Qy 475 KVGYPEFIMNDTHVNEIDKAIKFSADYFGVLOTRTKLAOSDFFWLKAAPKTEWTPN 534
 Db 518 KIGYEFYINSTRLELTYNTYTGNDTYFENILSKNKVNVDSFERSLRELYDKQWERSP 577
 Qy 535 TVVNAFYASTNQIRFPAGELQKPFEMGTEKPRSLSYGAIGVYIHEFTHGDNNGRYD 594
 Db 578 PTVNAVYKAGNEIYFPGIIGSPYF-HYDPKTLNIGSIVITIGHETTFEDDKGRLYD 636
 Qy 555 KNGNIDPMWSTSEBEKEKTKCMINQSYNYWKAGLNVKGRKTLGENIADNG----- 648
 Db 637 KNGNIDPMWSTSEBEKEKTKCMINQSYNYWKAGLNVKGRKTLGENIADNGSVKSL 696
 Qy 649 GLREAFRAYRWINDRQGLEPILPGITTEFNNOLEFISYAHVRCNSYRPAAREQVIG 708
 Db 697 GRTKAGOSTRK-----BEPLIPGLQYTNDOLEFISYQTCNMTRDALISSIRSG 747
 Qy 709 AHSPPQFVNGAISNSEEFQAFNCPNPNSTNNRGDSCRLW 749
 Db 748 VHSPPQYRVIGSLQNSDEFAFVENCPSYMN-AANKQVW 787
 RESULT 13
 Q9BLH1 PRELIMINARY; PRT; 772 AA.
 ID Q9BLH1
 AC Q9BLH1
 DT 01-JUN-2001 (Tremblrel. 17, Created)
 DT 01-JUN-2001 (Tremblrel. 17, Last sequence update)
 DT 01-MAR-2002 (Tremblrel. 20, Last annotation update)
 DE Neutral endopeptidase 24.11.
 GN BMBEP-L.
 OS Bombyx mori (Silk moth).
 OC Eukaryota; Metazoa; Arthropoda; Tracheata; Hexapoda; Insecta;
 OC Pterygota; Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia;
 OC Bombycoidea; Bombycidae; Bombyx.
 OC NCBL_taxid=7091;
 OX [1]
 RN SEQUENCE FROM N.A.
 RA Kawasaki H., Zhao X.;
 RL Submitted (SEP-2000) to the EMBL/GenBank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RA Zhao X., Mita K., Shimada T., Okano K., Quan G., Kanke E.;
 RT "Isolation of a 20-hydroxycyclohexanone inducible nepilysin (neutral
 endopeptidase 24.11)-like gene and its expression in wing discs during
 metamorphosis of Bombyx mori."
 RL Submitted (MAR-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AB048208; BAB33300.1; -.
 DR HSSP; P08473; IDMT.
 DR InterPro; IPR000718; Peptidase_M13.
 DR InterPro; IPR001230; Ptenyl-site.
 DR InterPro; IPR000130; Zn_MTPeptide.

DR Pfam; PF01431; Peptidase_M13; 1.
 DR PRINTS; PRO0786; NEPRILYSIN.
 DR PROSITE; PS00294; NEPRYLATION; UNKNOWN.1.
 DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN.1.
 DR SOURCE 772 AA; 87763 MW; B0D3336EAF4F0D56 CRC64;
 Query Match 30.8%; Score 1219; Db 5; Length 772;
 Best Local Similarity 37.6%; Pred. No. 5,5e-76;
 Matches 264; Conservative 137; Mismatches 276; Indels 26; Gaps 16;
 Qy 52 EYCLKPECEIAAAAILSKYNLSVDCDNEFRFACDGMISNPIPEDMSTGYPMIRNAV 111
 Db 91 EYCSAPCIIHTAARLLINDEKVDPCDNEFDGCSGLNTRIRPGDKTSVNFISITDOL 150
 Qy 112 DLKIKELLEKSIRRRDTEALQKALILYSCMNEKAEKADKPLHLIRHSPRPVYE 171
 Db 151 QEOIRSLDEPVT-PEPPRPVYAKTLQYQCMKRTAIEARGVPLDMLKRLG-GMPVLD 208
 Qy 172 SNIGPEGVMSERFSLQTLATER-GQYSNVFIIRLYSPDOKASNEHLIKLDOATLSIA 230
 Db 209 GQ-----SMDENSFMSQSYTKFRDAGSYVDYLDPSISVDYVKNSTRVYIDDOASLGIS 263
 Qy 231 VREDYLDNSTEAKSYRDALYKFWNDPAVLIGANSSRAEHDMKSVLLEIKIAEIMPE- 289
 Db 264 --REYLNRGFSDLVQ-AVEYVWDIALILGADKRTATELKSLOPEMKLANISIDPLEK 320
 Qy 290 NRTSEAMYNKNMISELSAMIPQFDWIGYIKKYIDTLYPHLNDISSENVYVVRVPOYFD 349
 Db 321 RNNATSLYNMTIAELQOKPKPWLLEYIKRL---LAPHI-IVDVNELIYSVPKTYTD 375
 Qy 350 LFRILGSEKRTIANTLVNMYVSRIPNLSRROQYRWLESRVIOGTTLTPQMDKCVNF 409
 Db 376 LEALIEKTPRQVQANYVMHVRVAGASYLTDLDRQLAVITLISGKTERESRMRKCAJDT 435
 Qy 410 IESGLPYVVKMFDVYFQEDKKEMBELVEGRVAFIMLEKENEMMDAGTKRKAERKA 469
 Db 436 TSMSIAVVALYIRKFNENSRANALEVNDIRQOFRTYIKV-DWMDMTRQOELEKA 494
 Qy 470 RAVLAKYGVDFEIMNDTHVNEIDKAIKFSADYFGVLOTRTKLAOSDFFWLKAAPKTE 529
 Db 495 DAMASHAYASEMLDNNRLLEFYSGLEMSSEHLMESVINTLTFTTYLGLKLRPEPNKD 554
 Qy 530 WFTN--PTVNAVYSASTNOIRFPAGELQKPFEMGTEKPRSLSYGAIGVYIHEFTHGPD 587
 Db 555 WYTHGRPAIYNAVYSSISNIOFPAGILOGAF-SAKRPAYMNYGAIQVYIGHEITHGPD 613
 Qy 588 NNGKRYKNGNIDPMWSTSEBEKEKTKCMINQSYNYWKAGLNVKGRKTLGENIADN 647
 Db 614 DQGRQFDKNGNLDVWQWQEMTKERYLDKACIIDQYSNYVKEGLKLVNGVNTGENIADN 673
 Qy 648 GLREAFRAYRWINDRQGLEPILPGI-TFTNNOLEFISYAHVRCNSYRPAAREQVIG 706
 Db 674 GGIKKAYATVQANTH--RHG-EEARLPGLEKYEPRQLFWLSAANTWCAYYRNALILRIT 730
 Qy 707 IGASPPQFVNGAISNSEEFQAFNCPNPNSTNNRGDSCRLW 749
 Db 731 TGFHAPGRFRVIGPMSNMEEFASDFKCPMGSPMNP-DKCKVW 772
 RESULT 14
 O16796 PRELIMINARY; PRT; 848 AA.
 ID O16796
 AC O16796
 DT 01-JAN-1998 (Tremblrel. 05, Created)
 DT 01-MAY-2000 (Tremblrel. 13, Last sequence update)
 DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)
 DE Hypothetical 97.1 kDa protein.
 GN F18A12.8.
 OS Caenorhabditis elegans.
 OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditioidea;
 OC Rhabditidae; Pelodierinae; Caenorhabditis.
 OC NCBL_taxid=6239;
 OX [1]

RP SEQUENCE FROM N.A.
 RC STRAIN-BRISTOL N2;
 RX MEDLINE=9069613; PubMed=9851916;
 RA None;
 RT "genome sequence of the nematode C. elegans: a platform for
 investigating biology. the C. elegans Sequencing Consortium.";
 RL Science 282:2012-2018(1998).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN-BRISTOL N2;
 RA Waterston R., Ozersky P., Le T.T.;
 RT "The sequence of C. elegans cosmid F18A12.";
 RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP SEQUENCE FROM N.A.
 RC STRAIN-BRISTOL N2;
 RA Waterston R.;
 RT "Direct Submission";
 RL Submitted (JUN-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF016688; AAB66079.2; -;
 DR HSSP; P08473; 1DMT.
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR001230; Prenyl_site.
 DR InterPro: IPR000130; Zn_MTPeptide.
 DR Pfam: PF01431; Peptidase_M13; 1.
 DR PRINTS; PR00786; NEPRILYSIN.
 DR PROSITE; PS00294; PRENYLATION; UNKNOWN_1.
 DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
 DR Hypothetical protein.
 SQ SEQUENCE 848 AA; 97061 MW; 4548FFEE5A915DA4 CRC64;

Query Match 30.5%; Score 1209; DB 5; Length 848;
 Best Local Similarity 35.4%; Pred. No. 3.1e-75;
 Matches 254; Conservative 140; Mismatches 277; Indels 46; Gaps 15;

QY 52 EYCLAPRECIATAAIIISKVLSDPCDNFRACDGMISNNRPEDMPSGYVPMRLAHNV 111
 DB 159 EVGTFPCVRAATHFLAAMTSDPCDFEFACGQMNQDHPIDDMYGTFAYAREOV 218
 QY 112 DLKIKLEKSISSRRDTEAIQAKILYSSCMNEKAIKADAKPLHLIHLSPRPVLE 171
 DB 219 RQGLRVLEGEV--TESESINMARATYRSCMKTKQDELMTGPLETLELG-EMPLIQ 275
 QY 172 SNIGESVSEKFSLLQTLATRGQYSNSVETRLVSPDDKASNEHIILKQDQATLSA- 230
 DB 276 EN-----MDKTFENFSLVNSGRROYGVDFQLYIYADSKNTSNTLTIDQSTLALGR 329
 QY 231 VREDYLDNSTEAKSYNDALTKENVDVAVL--GANSRAEH-----PMKSLRLKTIKAI 284
 DB 330 GTRDYIANTLTFSSHMTAYRKYLQJIAHLKTDGNTLRSESENNADIEKIIDIELEAKI 389
 QY 285 MIPH-ENRTSEAMYNNKINISELSAMIPQEDMLGYIKKVIDTRLYPHLKDISPSE----- 337
 DB 390 IYADEDERNNTRLYNKRQIDQVNLDPQVDMV-----PFGQSLAPSDLHLHLP 437
 QY 338 ----NVVVRVQYRKDLFRILIGSERKKTIANIYLRMYTSLIPNLRSRFOYRLSESRVIO 394
 DB 438 NETEIIICELEYLQHVSELIEKTDVGLINIVYLMRVVQSVVRLDERFEDIKDLEKVMY 497
 QY 395 GTTTLDPQMDKCVNFIESALPYVVGKMFVDVYFOEDKKEMMELVGVWRAFMLEKKN 454
 DB 498 GQOOSPRKMDCAQVSTVPLAAGAIYVOAHFOESDKHEALRMILHNRSPADLV-RON 556
 QY 455 ENMDAGTKRKAERARAVLAKVGPPEFINMDTHVNEDLKAIFSEADYGVNLOTREKYLA 514
 DB 557 DMWDEERKAVAIKANSMINNIGYPPVTDNLPKLDQYIGLSTSDDYIYIMKKVYVM 616
 QY 515 QS-DEFWLKAAYKTEWTFNPTVNAFYASSTQIIRPAGELQKPPFWGTETPRKSLSYA 573
 DB 617 QSRHEFKLTKRPDKHEFDISPAVNAFYSPKNAITFPAGIILQPPFSGT-PPKAVNYGA 675
 QY 574 IGTVGHEFHGFDNNGRKDKNGNLDPMWSTSESEKFFEKTRCMINQSNYYWKAGLN 633

DB 676 IGAVIGHEITTHGFDGQSDYDKDGNLHMWSESSINSFDTERRRCIVEGYGVTPKTNFR 735
 QY 634 VNGKFTIGENTDNGGLRAFRAYRKWINDRQGLEEPLLTGI-TEFNNOLEFPLSYAHVR 692
 DB 736 VNGKLTGENTDNGGVAEFAFOYKQYVENG--EEPRLEQLQOYTHEQIFFYSAHFV 792
 QY 693 CNSYREARQEOYQIGASPPQFRVNGCAISNSEEFQAFNCPPNSTNRGDSCLW 749
 DB 793 CGKKKEAAMQVLTDEHSPEYFRVIGVLSNMQAFADVYKCPBRNAPVMD-HKCIW 848

RESULT 15
 Q923T6 PRELIMINARY; PRT; 763 AA.

ID Q923T6
 AC Q923T6;
 DT 01-DEC-2001 (TREMBLrel. 19, Created)
 DT 01-DEC-2001 (TREMBLrel. 19, Last sequence update)
 DT 01-JUN-2002 (TREMBLrel. 21, Last annotation update)
 DE Endothelin converting enzyme-2.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OX NCBI_Taxid=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/
 RA Pan H., Mahavira N., Devi L.A.;
 RT "Mouse Endothelin Converting Enzyme-2 cDNA.";
 RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AF396999; AAK83919.1; -;
 DR MEROPS; M13.003; -;
 DR InterPro: IPR000718; Peptidase_M13.
 DR InterPro: IPR000221; Protamine_P1.
 DR InterPro: IPR000130; Zn_MTPeptide.
 DR Pfam: PF01431; Peptidase_M13; 1.
 DR PROSITE; PS00048; PROTAMINE_P1; UNKNOWN_1.
 DR PROSITE; PS00142; ZINC_PROTEASE; UNKNOWN_1.
 SQ SEQUENCE 763 AA; 86205 MW; 4B5180E9FBE549 CRC64;

Query Match 30.5%; Score 1208; DB 11; Length 763;
 Best Local Similarity 35.4%; Pred. No. 3.1e-75;
 Matches 267; Conservative 134; Mismatches 312; Indels 42; Gaps 16;

QY 4 ETGSSVETGKRNKRTIALV---VFVGGTLVLTGTLIFVSGLLSLQAKQEYCLAPREC 59
 DB 42 EVGFQKRRQLFGSHQTELVLAGLIVLALGLCVALL---WVNRDPAHSCTVTEAC 97
 QY 60 IEAAILISKVLSDPCDNFRACDGMISNNRPEDMPSGYVPMRLAHNVDLKLEL 119
 DB 98 IRVAKGILIESLDRGVSPQDGYFQSCGWMIRNPLPNGRSRWNTFNSLMDQNALHL 157
 QY 120 EKSISSRRDTEAIQAKILYSSCMNEKAIKADAKPLHLIHLSPRPVLESNIP-- 176
 DB 158 ENF-TFNSSSEKERTIFLYSLQSEKIEKLGAKPLRLDI-----DKIGWNT 205
 QY 177 EGVSEKFSLLQTLATRGQYSNSVETRLVSPDDKASNEHIILKQDQATLSAVRDYL 236
 DB 206 TGPMDDESF--MDVLKAVAGTYRATPEFTYVVASDKSSNSNITQVQSGFLPSRDYL 263
 QY 237 DNSTAKYRQALYKFMVDVAVILGANSRAEHDKSVLRLEIKAIEMIPH-ENRSESA 295
 DB 264 -NRINAEVLTAVLYWELVGLVGGOPTSTREMQOVLLEIQLANITYVQDQDRBEK 322
 QY 296 MYNNKINISELSAMIPQEDMLGYIKKVIDTRLYPHLKDISPENVVVVRPQYKFLPLIG 355
 DB 323 IYHKKISIELQALAPAVDMLEFLSLSP-----LEIGDSEPVVYVGTETLQOYSELIN 376
 QY 326 SERKKTIANIYLRMYTSLIPNLRSRFOYRLSESRVIOGT-TTLDPQMDKCVNFIESAL 414
 DB 377 RTEPSILNNYILWNVQKTSLLDQRFETAQEKLETLTYGKCKSPRMQTCISNTDAL 436
 QY 415 PYVVGKMFVDVYFOEDKKEMMELVGVWRAFMLEKKNRMDAGKRRKAKERARVLA 474

```

Db 437 GFALGSLFVKATFDROSKIEAEGMINEIRSAFEETL-GDLVWMDKTRFLAKERADAIYD 495
Oy 475 KVGYPEFTMNDTHVNEDEKAIKFSADYFCGVNLOTRKTLAOSDEFFWLKRAVPTKTEWETNP 534
Db 496 MIGEPDETLPEKRELDVDYDGYEVSEDSFFQNMNLNFSAKVMADQLNKPPSRDQWSMTP 555
Oy 535 TTVNAFYSASTNOLRFPAGELQKPEFMGTXYPRSLSYGAIGVIGHEFTHGFDNNGRKYD 594
Db 556 QTVNAIYLPKNEIYFPAGIILQAPFH-AHNHPKALNFGIGVYMGHELTHAFDDOGRKYD 614
Oy 595 KNGNLDPMWSTSESEKEKTKCMINQYSNYYWKKAGLNVKGRKTLGENTLADNGGLREAF 654
Db 615 KEGNLRPMWQNESLTAFOHNTACMEQYQY--QVNGERLNGLOTLGENTLADNGGLKAY 672
Oy 655 RAYRKWINDRROGLEEPLPGITFTNNQLEFLSYAHVRCNSYRPPAAREQVQIGAHSPQ 714
Db 673 NAYKAWL--RKHGEQF-LPAVGLTNHOLFVGFQVWCYVTPRESSHEGLVTDPHSPAR 729
Oy 715 FRVNGAISNSEEFOKAFNCPPNSTWNRGMDSCRLW 749
Db 730 FRVLGTLNSRDFLHRFGCPVGPSPMNPB-QLCEYVW 763

```

Search completed: May 21, 2003, 18:49:07
 Job time : 46 secs

Thu May 22 07:48:40 2003

us-09-913-955a-1.rag

Page 1

GenCore version 5.1.4-p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 21, 2003, 18:39:14 ; Search time 79 Seconds
(without alignments)
1263.351 Million cell updates/sec

Title: US-09-913-955a-1

Perfect score: 3958
Sequence: 1 MEAEFGSSVEYTKKANKRGR.....AFNCPNSTNMGDSCLRW 749

Scoring table: BLOSUM62
Gap 10.0, Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

1: /SID52/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
2: /SID52/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
3: /SID52/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
4: /SID52/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
5: /SID52/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
6: /SID52/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
7: /SID52/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
8: /SID52/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
9: /SID52/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
10: /SID52/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
11: /SID52/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
12: /SID52/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
13: /SID52/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
14: /SID52/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
15: /SID52/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
16: /SID52/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
17: /SID52/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
18: /SID52/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
19: /SID52/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
20: /SID52/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
21: /SID52/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
22: /SID52/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
23: /SID52/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3958	100.0	749	21	Human PHX.
2	3952	99.8	749	21	Human PHX.
3	3928	99.2	749	21	Human PHX.
4	1375.5	34.8	753	22	Human PHX.
5	1362	34.4	753	22	Human PHX.
6	1352	34.2	753	22	Human PHX.
7	1351	34.1	753	22	Human PHX.
8	1343.5	33.9	779	22	Human PHX.
9	1333.5	33.7	779	22	Human PHX.
10	1332.5	33.7	779	22	Human PHX.

11	1332.5	33.7	779	23	ABR79521
12	1332.5	33.7	779	23	AAE17799
13	1332.5	33.7	779	23	AAE17799
14	1326.5	33.5	702	22	AAE17799
15	1322.5	33.4	742	22	AAE17799
16	1321	33.3	746	23	AAE17799
17	1317	33.1	743	23	AAE17799
18	1310.5	32.4	743	22	AAE17799
19	1283.5	32.4	743	22	AAE17799
20	1283.5	32.4	743	22	AAE17799
21	1283.5	32.4	743	22	AAE17799
22	1283.5	32.4	743	22	AAE17799
23	1283.5	32.4	743	22	AAE17799
24	1275.5	32.2	748	15	AAE17799
25	1270.5	32.1	748	15	AAE17799
26	1270	32.1	748	15	AAE17799
27	1265.5	32.0	750	9	AAE17799
28	1263.5	31.9	750	9	AAE17799
29	1263.5	31.9	750	9	AAE17799
30	1257	31.8	753	16	AAE17799
31	1257	31.8	753	16	AAE17799
32	1257	31.8	753	16	AAE17799
33	1257	31.8	753	16	AAE17799
34	1257	31.8	753	16	AAE17799
35	1257	31.8	753	16	AAE17799
36	1256	31.7	753	16	AAE17799
37	1248.5	31.5	758	19	AAE17799
38	1241.5	31.4	754	16	AAE17799
39	1241.5	31.4	754	16	AAE17799
40	1223	30.9	736	20	AAE17799
41	1223	30.9	736	20	AAE17799
42	1223	30.9	736	20	AAE17799
43	1221	30.8	766	23	AAE17799
44	1212	30.6	766	23	AAE17799
45	1205.5	30.5	661	22	ABE1898

ALIGNMENTS

RESULT 1	AA196190	standard: protein; 749 AA.
ID	AA196190	
AC	AA196190	
XX	19-DEC-2000 (first entry)	
XX	Human PHX.	
XX	PHX, human; metalloproteinase; x chromosome;	
XX	x-linked hypophosphatemia; hyperparathyroidism;	
XX	renal osteodystrophy; phosphaturia; diagnosis.	
XX	Homo sapiens.	
XX	Key	Location/Qualifiers
XX	Peptide	21.40
XX		/label= Transmembrane_domain
XX	WO2000050580-A2.	
XX	31-AUG-2000.	
XX	24-FEB-2000; 2000WO-CA00201.	
XX	24-FEB-1999; 99CA-2262056.	
XX	(UYMO-) UNIT MONTREAL.	
XX	Crine P, Bouleau G;	
XX	WPI: 2000-565455/52.	

Novel soluble human PHEX enzyme useful for treating phosphaturia and/or hypophosphatemia, is a gene product of phosphate-regulating gene having homology to endopeptidase on X chromosome

Disclosure: Fig 2; 64pp; English.

The present sequence is that of human PHEX (a gene product of phosphate-regulating gene with homology to endopeptidase on X chromosome). Absence of a functioning PHEX gene is associated with hypophosphatemia. PHEX is a type II integral membrane glycoprotein. To produce a soluble form of PHEX, the transmembrane anchor domain was modified with a signal peptidase coding sequence (see AAY96188 and AAY96189). The soluble PHEX thus comprised the active ectodomain. An inactive PHEX can also be constructed by replacement of the Glu-382 residue by a hydrophobic amino acid residue, especially valine. Soluble and inactive mutant forms of PHEX can be used to screen ligands to PHEX. These ligands are used as substrates or inhibitors of PHEX. Since PHEX is phosphaturic, an inhibitor can be used to treat phosphaturia and/or hypophosphatemia. A substrate for PHEX, or PHEX itself, can be used to treat hypophosphatemia, including its most frequent manifestations, secondary hyperparathyroidism and renal osteodystrophy.

Sequence 749 AA:

Query Match 100.0%; Score 3958; DB 21; Length 749;
Best local similarity 100.0%; Pred. No. 0;
Matches 749; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 MEAEFGSSVETGKKANRGTALVYVVGTLGTLFLVSGGLSLQAKQECLEKCEI 60
1 MEAEFGSSVETGKKANRGTALVYVVGTLGTLFLVSGGLSLQAKQECLEKCEI 60
61 EAAAIILSVNLSVPCNPFACDGIISNNIPEDMPSYGVYVWLRHNDLKLKELLE 120
61 EAAAIILSVNLSVPCNPFACDGIISNNIPEDMPSYGVYVWLRHNDLKLKELLE 120
121 KSISSRDTLEAIQAKILYSSCMNEKAIKADAKPLHLIRHSPRPVLESNIGEGVW 180
121 KSISSRDTLEAIQAKILYSSCMNEKAIKADAKPLHLIRHSPRPVLESNIGEGVW 180
181 SERKFSLLQTLATFRGVSNSVETRLVSPDKASNHILKLDQATLSLAVREDYDINST 240
181 SERKFSLLQTLATFRGVSNSVETRLVSPDKASNHILKLDQATLSLAVREDYDINST 240
241 EAKSTRDALYKFNVDVAVLLGANSRAEHDMKSVLRLEIKIAEIMLPHEHRSSEAYANKM 300
241 EAKSTRDALYKFNVDVAVLLGANSRAEHDMKSVLRLEIKIAEIMLPHEHRSSEAYANKM 300
301 NISLSAMIFQFQDLGIRKVIDTRLYPHLKDLSPEENVVVRVPOYKDLFRILSERKK 360
301 NISLSAMIFQFQDLGIRKVIDTRLYPHLKDLSPEENVVVRVPOYKDLFRILSERKK 360
361 TIANYLWRAVYSRIPNLSSRFQYRWLEFSRVIGQTTLLPQMDKCVNTEISALPYVVGK 420
361 TIANYLWRAVYSRIPNLSSRFQYRWLEFSRVIGQTTLLPQMDKCVNTEISALPYVVGK 420
421 MFVDYFQEDKEMMELEVEGKMAFIDMLEKENEMWAGTRKRAKARAVLAKVGYPE 480
421 MFVDYFQEDKEMMELEVEGKMAFIDMLEKENEMWAGTRKRAKARAVLAKVGYPE 480
481 FIMNDTHVNEEDLKAIFSEADYFGNVLTQRTKLAOSDFEMLRKAVPKEMWNTPTYNAAF 540
481 FIMNDTHVNEEDLKAIFSEADYFGNVLTQRTKLAOSDFEMLRKAVPKEMWNTPTYNAAF 540
541 YSASTNQIIEFPAGELQKPFMGTEYPRSLISYGAIGVIGHFTGFDNNGKRYKNGNLD 600
541 YSASTNQIIEFPAGELQKPFMGTEYPRSLISYGAIGVIGHFTGFDNNGKRYKNGNLD 600
601 PMWSTSESEKFEKTKCMINOSNYWKKAGLANKGRTLGENTADNGLEAFRAVRKMY 660
601 PMWSTSESEKFEKTKCMINOSNYWKKAGLANKGRTLGENTADNGLEAFRAVRKMY 660

QY 661 INDRQGLIEEPLLGITFTNNQLEFLSYAHVRCNSYRPEARQVQIGASPPQVRVNGA 720
Db 661 INDRQGLIEEPLLGITFTNNQLEFLSYAHVRCNSYRPEARQVQIGASPPQVRVNGA 720
QY 721 ISNSEEFOKAFNCPPNSTNRGMDSCRLW 749
Db 721 ISNSEEFOKAFNCPPNSTNRGMDSCRLW 749

RESULT 2

AAY84627 standard; Protein; 749 AA.

AAV84627;

25-JUL-2000 (first entry)

Amino acid sequence of a human PEX protein.

Human; PEX gene; Xp22.1; X-linked hypophosphatemic rickets; osteoblast;

parathyroid hormone; PTH; osteoclast; bone; bone breakdown;

parathyroid hormone related peptide; PTHrP; metabolic bone disease;

osteomalacia; osteoporosis; osteopetrosis; Paget's disease.

Homo sapiens.

Key Location/Qualifiers

Modified-site 71 /note= "potential N-glycosylation site"

Modified-site 238 /note= "potential N-glycosylation site"

Modified-site 263 /note= "potential N-glycosylation site"

Modified-site 290 /note= "potential N-glycosylation site"

Modified-site 301 /note= "potential N-glycosylation site"

Modified-site 377 /note= "potential N-glycosylation site"

Modified-site 484 /note= "potential N-glycosylation site"

Modified-site 726 /note= "potential N-glycosylation site"

Modified-site 736 /note= "putative prenylation site"

Modified-site /note= "potential N-glycosylation site"

W0200018954-A2.

06-APR-2000.

27-SEP-1999; 99WO-CA00895.

28-SEP-1998; 98CA-2245903.

(UYMC-) UNTV MCGILL.

Karaplis AC, Goltzman D, Lipman ML, Henderson JE;

WPI; 2000-293177/25.

N-PSDB; AAA12670.

Diagnosis and treatment of metabolic bone diseases e.g. osteomalacia

and osteoporosis comprises determining the level of parathyroid hormone

related peptide in a patient -

Disclosure: Fig 2A; 52pp; English.

The present sequence is encoded by the human PEX gene. The PEX gene spans

the deleted region Xp22.1 in X-linked hypophosphatemic rickets. The gene

is mutated in non-deletion patients with the disorder. PEX is a cell

membrane-associated protein with its active site in the extracellular

compartment. The cells with the highest level of PEX expression are the

compartments.


```

Db 241 EAKSTRDLYKEMDTAVLLGANSRAEHDKSVLRLEIKLAELMIEHENTSEANYNKA 300
Oy 301 NISELSAMIPOFDMIGYIKKVIDIRIPLHLKDISENNVYVVPQFCKDLFRLLGSEKK 360
Db 301 NISELSAMIPOFDMIGYIKKVIDIRIPLHLKDISENNVYVVPQFCKDLFRLLGSEKK 360
Oy 361 TIANTLVWRMYSTRIPMLSRFRFWMLEFSRVIOGTTTLTPQMDKCVNFESALPYVVK 420
Db 361 TIANTLVWRMYSTRIPMLSRFRFWMLEFSRVIOGTTTLTPQMDKCVNFESALPYVVK 420
Oy 421 MFVDFVFOEDKKEEMELVGVWRAPFDMLEKENEMMDGTRKAKARAVLAKGYPE 480
Db 421 MFVDFVFOEDKKEEMELVGVWRAPFDMLEKENEMMDGTRKAKARAVLAKGYPE 480
Oy 481 FIMNDTVNEDLKAIFSEADYGVNLQTRKYLAQSDPFMLRAVYKTEMTFNPTVNAF 540
Db 481 FIMNDTVNEDLKAIFSEADYGVNLQTRKYLAQSDPFMLRAVYKTEMTFNPTVNAF 540
Oy 541 YSASTNOIRPAGELOKPFMGTEPRSLSYGALGYVGEHTHGFDDNNGRRYKNGMD 600
Db 541 YSASTNOIRPAGELOKPFMGTEPRSLSYGALGYVGEHTHGFDDNNGRRYKNGMD 600
Oy 601 PMWSTSESEKFKETKCMINQYSNTYWKAGLVNKGKRTIGENINADNGLEAPRAYKK 660
Db 601 PMWSTSESEKFKETKCMINQYSNTYWKAGLVNKGKRTIGENINADNGLEAPRAYKK 660
Oy 661 INDRROGLEEPILPGITTFNNOLFSLAHVACNSYRDEARBOVOIGASHPPQFVNGA 720
Db 661 INDRROGLEEPILPGITTFNNOLFSLAHVACNSYRDEARBOVOIGASHPPQFVNGA 720
Oy 721 INSEFEOKAFNCPPNSTNNRGMDSCLRM 749
Db 721 INSEFEOKAFNCPPNSTNNRGMDSCLRM 749

RESULT 4
AAB08130
ID AAB08130 standard; Protein: 765 AA.
XX
AC AAB08130:
XX
DT 04-DEC-2000 (first entry)
XX
DE A murine neutral endopeptidase metalloproteinase-like enzyme NL-1.
XX
KW NEPRILysin; neutral endopeptidase metalloproteinase-like enzyme;
KW neurotrophic enzyme; protein production; protein secretion;
KW fertility; bone disease; abnormal phosphate metabolism.
XX
OS Mus sp.
XX
PN W0200047750-A2.
XX
PD 17-AUG-2000.
XX
PE 11-FEB-2000; 2000MO-CA00147.
XX
PR 11-FEB-1999; 99CA-2260376.
XX
PA (UYMO-) UNIV MONTREAL.
XX
PI Desrosiers L, Bolleau G;
XX
DR WPI: 2000-549148/50.
XX
DR N-PSDB: AAA63763.
XX
PT Novel neutral endopeptidase-like metalloproteinase polypeptides and
PT polynucleotides, used to screen for related sequences and enzyme
XX inhibitors, used for the treatment of NL-3 related bone disorders -
XX
PS Claim 2; Fig 3; 59pp; English.

```

```

XX
CC The present sequence represents a murine neutral endopeptidase
CC metalloproteinase-like enzyme, designated NL-1. The specification
CC also describes NL-2 and NL-3. The NL enzymes are used to test for
CC specific inhibitors. The N-terminal region of the enzymes can be used
CC to promote production and secretion of foreign proteins and active
CC bioproteins, using chimeric constructs containing the foreign protein
CC downstream from and in phase with the N-terminal region. The NL enzymes
CC have been localized to the brain, and may be useful in the
CC treatment of neurological diseases such as Alzheimer's disease, pain,
CC and psychiatric disorders. NL enzymes have also been localized to the
CC testis and ovaries, and may be used to control fertility. They have
CC also been localized to bones, and may be used to treat bone diseases,
CC and abnormal phosphate metabolism related to improper peptide
CC processing by the NL-3 enzyme.
XX
SQ Sequence 765 AA.
Query Match 34.8%; Score 1375.5; DB 21; Length 765;
Best Local Similarity 38.8%; Pred. No. 4.7e-109;
Matches 295; Conservative 147; Mismatches 267; Indels 51; Gaps 18;
Oy 18 GTRIALVVE--VGGTIVLTILF-----LYSGILSLQAKOBYCLKEPCIEAAAIL 67
Db 29 GAIVTLGVYSIGKQPLITSLHESWDEKTVYKRALDSSLKSDICTTSPCVIAARIL 88
Oy 68 SKVNSVDPDQNFRRPACDWTISNPIDPMSYGVYPMLRHNVDTLKELEKSTISRR 127
Db 89 ENMDSDRNCEYFYAGGWLRRHVIPETNSRVFDILRDELVELIKVLEDSTISQR 148
Oy 128 DTEALAKKILYSSCMNEKAEKADAPLHLIHSFRRPVLESINQPGVSWER--K 184
Db 149 --PAVEKAKTLRSCMNSVIEKRDSEPLSVLK--MVGMPVAMDK-----WNETMGLK 199
Oy 185 FSLIOTLATFRGQYSNSYFIRLYVSPDKASNEHILKIDQATSLAVREDYLDNSTEAKS 244
Db 200 WELERQIALVNLNSQFNRRVLIDLFIMNDQNSRHVYIDPGLTGMNSRETYFOEDNNHK- 258
Oy 245 YRDALYKEMVDVAVL-----LGANSRAEHDKSVLRLEIKLAELMIEHENTSEANYN 297
Db 259 VRKAVLEFMTSVATMLKKDONLSKESAMVEAEVLETHLANVPOEKRRHVTALY 318
Oy 298 NKNINISELSAM--IPQDMIGYIKKY--IDTRILYPLHLKDISENNVYVVPQFCKDL 352
Db 319 HRMDLMELOERFGLKGFNMTLFIQNLISVEYELF-----PDERVYVYGYPILENLE 371
Oy 353 ILGSEKRTIANTLVWRMYSTRIPMLSRFRFWMLEFSRVIOGTTTLTPQMDKCVNFES 412
Db 372 IIDSYSARTMONTLVWRMYSTRIPMLSRFRFWMLEFSRVIOGTTTLTPQMDKCVNFES 431
Oy 413 ALPYYVGMFVDVYFOEDKKEEMELVGVWRAPFDMLEKENEMMDGTRKAKARAV 472
Db 432 NMEASVAGSLYIKRAFSDKSTYRELIEKIRSVFONDDELN--WDESKKRAQKAKANI 490
Oy 473 LAKVGYPEFIM--NDFVNEEDLKAIFSEADYGVNLQTRKYLAQSDPFMLRAVYKTEW 530
Db 491 RQIGIDPYIILEDNKHLEDEYSLSLTFEEDYFENGLOLNKNAQRSLKRLKREVDNLM 550
Oy 531 FTNPTVNAFYASTNOIRPAGELOKPFMGTEPRSLSYGALGYVGEHTHGFDDNNG 590
Db 551 ITGAAYVNAFYSPNRNOIYFAGILOPFF--SKQOPOSINFGIGVIGHIHTHDDNG 609
Oy 591 RRYDKNGNLDPMWSTSESEKFKETKCMINQYSNTYWKAGLVNKGKRTIGENINADNG 649
Db 610 RNFDRKNGNLDPMWSTSESEKFKETKCMINQYSNTYWKAGLVNKGKRTIGENINADNG 669
Oy 650 LREAFRAYRWYINDROGLEEPILPGITTFNNOLFSLAHVACNSYRDEARBOVOIGA 709
Db 670 VQOAVKAVLWMLAD--GKQDRPLGILNLYAQLFFNTYQVCGSYRBEFAVQSIKTIV 726
Oy 710 HSPQFRYNGAISNSEFOKAFNCPPNSTNNRGMDSCLRM 749
Db 727 HSPKRYVLSLQNTLPGFSEAFHCPRGSPMH--PMKRCRLM 765

```

RESULT 5
 AAB60562 standard; Protein: 753 AA.
 XX
 AC AAB60562;
 XX
 DT 27-APR-2001 (first entry)
 XX
 DE Human neprilysin-like membrane metalloproteinase SNEPB.
 XX
 KW Human; SNEPB; neprilysin-like membrane metalloproteinase;
 KW splice variant; alternative splicing; zinc endopeptidase family;
 KW neuropeptide; peptide hormone; processing; metabolism; vaccine;
 KW drug screening; renal insufficiency; hepatic disease; ischemia; pain;
 KW hypertension; cancer; inflammation; cardiovascular disease;
 KW neuronal disease; pancreatic disease; prostatic disease;
 KW cerebroprotective; hypotensive; cytosolic; antiinflammatory;
 KW cardiovascular; hepatotropic.
 XX
 OS Homo sapiens.
 XX
 PN EP1069188-A1.
 XX
 PD 17-JAN-2001.
 XX
 PF 15-JUL-1999; 99EP-0401767.
 XX
 PR 15-JUL-1999; 99EP-0401767.
 XX
 PA (SNFT) SANOFI-SYNTHELABO.
 XX
 PI Jagerschmidt A, Agnel M, Culouscou J;
 DR WPT: 2001-212582/22.
 DR N-PSDB: AAF59660.
 XX
 PT New membrane-associated metalloproteinase SNEPB, SNEPB and SNEPC
 PT polypeptides and polynucleotides, useful for treating e.g. acute and
 PT chronic renal insufficiency, pain, stroke, cancer, inflammation, renal
 PT and hepatic ischemia -
 XX
 PS Claim 11; Page 33-35; 72pp; English.
 XX
 CC The invention relates to the human SNEPB, SNEPB and SNEPC proteins, and
 CC the cDNAs encoding them. SNEPB, SNEPB and SNEPC are neprilysin-like
 CC membrane metalloproteinases and are the products of alternative splicing.
 CC The substrate(s) for the SNEPB proteins are not as yet known, although
 CC the neprilysin family of zinc endopeptidases play key roles in the
 CC processing and/or metabolism of neuropeptides and peptide hormones. SNEPB
 CC nucleotides may be used as hybridisation probes for cDNA and genomic
 CC DNA; to isolate full-length cDNAs and genomic clones encoding SNEPB,
 CC SNEPB or SNEPC; to isolate cDNA and genomic clones of SNEPB homologues;
 CC as research reagents and material for the discovery of treatments and
 CC diagnostics for animal and human diseases; and for chromosome
 CC identification. The SNEPB proteins may be used as immunogens to
 CC produce antibodies immunospecific for SNEPB, SNEPB or SNEPC. Such
 CC antibodies are used to isolate or identify clones expressing the
 CC protein, or to purify the proteins by affinity chromatography.
 CC SNEPB proteins may also be used in screening for compounds which modulate
 CC SNEPB endopeptidase activity, and to assess enzymatic cleavage of small
 CC molecule substrates in cells, cell-free preparations, chemical libraries
 CC and product mixtures. The SNEPB proteins (as vaccine compositions),
 CC SNEPB nucleotides, and SNEPB activators or inhibitors may be used
 CC to treat acute and chronic renal insufficiency, renal and hepatic
 CC ischemia, pain, stroke, hypertensive disease, cancer, inflammation, as
 CC well as cardiovascular, neuronal, pancreatic, prostatic, renal,
 CC respiratory or hepatic diseases. They may also be used in modulating
 CC peptide activation and/or degradation in the brain or kidney or in
 CC another organ, or to diagnose or treat any disorder related to abnormal
 CC expression of SNEPB, SNEPB or SNEPC. The present sequence represents

CC SNEPB.
 XX
 SQ Sequence 753 AA;
 XX
 Query Match 34.4%; Score 1362; DB 22; Length 753;
 Best Local Similarity 38.6%; Pred. No. 6,6e-108;
 Matches 295; Conservative 152; Mismatches 273; Indels 44; Gaps 18;
 QY 9 VETGKKANR-----GTRIALVYFVGTVLGLTLLFLVLSGSLISQAKQECYCKPCIE 61
 DB 11 VESAGRAGQKRPGLEGGILLLLTALVALGVLADNRGLPEADQSEVCTTCRCVI 70
 QY 62 AAAAILSKVNLSPDCNFFERACDGIISNPIPEDMPSYGVYFMLRHNDLKLLEK 121
 DB 71 AAARLQMDPTTEPCDDFYFACGMLRRVPEIETSRISIFVLDLEVLILKAVLEN 130
 QY 122 SISRRDTEALQAKILYSSCMNEKAIKADAKLLILKRSPPRWVLSNIGPEBWS 161
 DB 131 STA--KDRPAVEKAKATILRSCMNOSYIEKRSQPLDIL--EVGGMVAMDR-----WN 181
 QY 182 ER---KESLQTLAFRGQYSNYSFIRLYSPDDKASNEHILKIDQATLSLAVREDYLDN 238
 DB 182 ETVGLEWELERQALMNSQFNRRVILDFINDDQNSRHIIYIDQPLGMPSEYFENG 241
 QY 239 STEAKSYRDALYKFWDTAVIL--GANSR---AEHDKSVLRLEIKIETIMPHENRT 292
 DB 242 GSNRK-VREAYLQFMVSVATLLREDANLPDSCLVQEDMVQVLETLQAKATVPOEERH 300
 QY 293 SE-AMYNKNISLSAM--IIOFDWLGIRKVIDTRLPKHK-DISPEENVVVRVPOYFK 348
 DB 301 DVIALYHRMGLEELQSGELGFDWTLFIQVLS----VKILPDEEVVYVIGPIQLQ 355
 QY 349 DLFRIISERKKTIANLYWVMVYSRIPLNSRFQYRWLEFSRVLTGTTLLPQDKCVN 408
 DB 356 NLENITDIYSARTIONLYWRLVLDRLGSLQRFQDTRVNYRKALFGTMVEEVRRECVC 415
 QY 409 FTESALPYVVGKQFVDYFQEDKEMEMELVGVYMAFLIDKEKEMEMAGTKKAKK 468
 DB 416 YVNSNMENAVGSLYVREAPPGDSKSNVRELIDKVTIVVEETLD--ELGMWDESKKAKQEK 474
 QY 469 ARAVLAKVGYPEFIMNDT--VNEIDKAIKFEADYFGNVLTQRYKLAQSPDFMLRKAPV 526
 DB 475 AMSIRQIGHPDYILETRIRRLDEEYSNLFSEDLTFENSLNKLKVGQSRJLRKREKVD 534
 QY 527 KTEMFTNPTTVNAFVYASASTNQIRPAGELQKPFEMGTEYPRSLSGALGVYGHFTGE 586
 DB 535 PNMIIIGAIVNAFYSFNRNQIYFPAIILQPPFF--SKEOPQALNFGIGMTVGHETIGE 593
 QY 587 DNNGRYDKNGNIDPMWSTSEBEKEFEKTKMIMNOVSNTYMKAG--LNYGKRTIGENIA 645
 DB 594 DDNGRNFEDKNGNMDWMSNFSTQHFRESECMYIQTGNTSWDLADBNQVNGFNTIGENIA 653
 QY 646 DNGLEAFAYRWKWINDRQGLEBPLPGITFTNNQLEFSLYAHVRCNSYRPEARQOV 705
 DB 654 DNGGVQAYKAYLKW---AEQKQDQLGDLTDHQLDFINVAQWCSYRPEFAIOSI 710
 QY 706 QIASHSPQDFRVNCAISNEEPQAKNCPNPSNMGMSCRIM 749
 DB 711 KTVHSPDKRYVLGSLQNLAAFDTHCARGTGM--PKERCWV 753
 RESULT 6
 AAB83842 standard; Protein: 753 AA.
 XX
 AC AAB83842;
 XX
 DT 23-JUL-2001 (first entry)
 XX
 DE Amino acid sequence of a human metalloproteinase enzyme IG5.
 XX
 KW Metalloproteinase; IG5; infection; pain; cancer; diabetes; obesity;
 KW anorexia; bulimia; asthma; Parkinson's disease; acute heart failure;

hypertension; hypertension; urinary retention; osteoporosis;
 KW angina pectoris; myocardial infarction; stroke; ulcer; allergy;
 KW benign prostatic hypertrophy; migraine; psychotic disorder;
 KW neurological disorder; autism; multiple sclerosis; Alzheimer's disease;
 KW neurodegenerative disease; sleep disorder; epilepsy; kidney disease;
 KW cardiovascular disease; arteriosclerosis; cerebrovasospasm;
 KW subarachnoid hemorrhage; cerebral ischemia; cerebral infarction;
 KW peripheral vascular disease; Raynaud's disease; motility disorder;
 KW gastrointestinal disorder; gastric emptying; gastroparesis; diarrhea;
 KW inflammation; chemotherapy induced injury; tumor invasion;
 KW immune disorder; arthritis; endotoxin shock; sepsis; diabetes mellitus;
 KW severe mental retardation; dyskinesia; Huntington's disease;
 KW Gilles de la Tourette's syndrome.
 OS Homo sapiens.
 XX
 XX
 PN W0200136610-A1.
 PD 25-MAY-2001.
 PF 17-NOV-2000; 2000WC-EP11532.
 PR 19-NOV-1999; 99EP-0203862.
 PR 19-NOV-1999; 99NL-1013616.
 PR 31-MAY-2000; 2000EP-0201937.
 PR 31-MAY-2000; 2000NL-1015356.
 XX
 XX
 PA (SOLV) SOLVAY PHARM BV.
 PI Deleersnijder W, Wieggers R, Weske M;
 DR MPI: 2001-343815/36.
 DR N-PSDB: AAF89739.
 XX
 PT New IGSS polypeptides useful for treating infections, pain, cancer,
 PT diabetes, obesity, anorexia, bulimia, asthma, schizophrenia,
 PT hypertension, urinary retention and Parkinson's disease -
 PT
 XX
 XX
 PS Claim 3; Page 9-10; 115pp; English.
 CC The present sequence represents a human metalloprotease enzyme designated
 CC IGSS. IGSS polynucleotides and polypeptides are useful for treating
 CC infections, pain, cancer, diabetes, obesity, anorexia, bulimia, asthma,
 CC Parkinson's disease, acute heart failure, hypotension, hypertension,
 CC urinary retention, osteoporosis, angina pectoris, myocardial infarction,
 CC stroke, ulcers, allergies, benign prostatic hypertrophy, migraine,
 CC psychotic and neurological disorders, autism, multiple sclerosis,
 CC Alzheimer's disease, and other neurodegenerative diseases, sleep
 CC cerebrovasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral
 CC infarction, peripheral vascular disease, Raynaud's disease, kidney
 CC diseases, gastrointestinal disorders, motility disorders and conditions
 CC of delayed gastric emptying, post-operative or diabetic gastroparesis,
 CC diarrhoea, inflammations, chemotherapy induced injury, tumor invasion,
 CC immune disorders, arthritis, endotoxin shock, sepsis, complications of
 CC diabetes mellitus, and severe mental retardation and dyskinesias, such
 CC as Huntington's disease or Gilles de la Tourette's syndrome.
 CC
 CC
 SO Sequence 753 AA;
 Query Match 34.2%; Score 1352; DB 22; Length 753;
 Best Local Similarity 38.4%; Pred. No. 4.8e-107;
 Matches 293; Conservative 153; Mismatches 274; Indels 44; Gaps 18;
 QY 9 VETGKKANR-----STRIALVYFVGTLVLTIIIVISOGILSLQAQOEICARPECIE 61
 DB 11 VESAGRRGQKRGFLBGLLILLYALVALGVLADRRGIPERAEVSEVCTTPGCYI 70
 QY 62 AAAAILSKVLSVDCNFRFACDGNISNPIEDMPSGYVPMLRHNVADLKLELEK 121
 DB 71 AAARILONMPTPEPCDDDFYACAGGWLRRHVIPETNSRIFDVLRLDELEVLKAVLEN 130
 QY 122 SISRRTEALIQAKILYSSCNEKALIKADAKPLHLIIRHSFRRPVLIESNIGPGWVS 181

DB 131 STA--KRRPAVERKARTILYRCAMQSYTERKGSPLDLIT-EVVGMPAMDR-----WN 181
 QY 182 ER--KSSLQTLATREGQYSNVEFRLVYSPDCKASNEHILKDLQATLSLAVREDYLDN 238
 DB 182 ETVGLEWELEROLALMNSQFNRRVILDLFTWMDQSSHHIYIDQPLTGMPSRRYING 241
 QY 239 STEAKSYDALYFQVDTAVL--GANSR-----AEHDKSVLRKEITAIEMIPHENRT 292
 DB 242 GSNRK-VREAYLOPMVSATLREDNLPDSCLOVEDMMOVLLETQLAATVPOEERH 300
 QY 293 SE-AMTKNMSLSAM--IPQDWLGYIKYIDRLYPLHK-DISPEENVVVRPOYFK 348
 DB 301 DVIALYRMGLELQSQFOLKGFNMNTLFIQYVLS--VKIKLPEEVEVYVGIPLQ 355
 QY 349 DLFRIIGSEKKTIANYLVWRVYNSIPNLSSRFQYRMLERSRYAQGTTLTLPQWCKVN 408
 DB 356 NLENITDYSARKIQNTLVWRVLVDRIGLSQRFQDTRVYNRKALFTVMEVWRRCVG 415
 QY 409 FIESALPYVGMFVDVYFQEDKKEMELVGVAFIDMLEKENMDAGTRKRAEK 468
 DB 416 YVNSNMENAVSLYREAPGDSKSNVRELIDKRVTEVELD-ELGMDEESKKRAQEK 474
 QY 469 ARAYLAKVGYPEFIMNDH--VNEDLKAIKSEADYFGNVLQTRKYLAQSDFEWLKRAVP 526
 DB 475 AMSIREQIGHPIYILEENMRRLDEEYSNLFSEDLYFENSQNLKVGASRLKRLREKVD 534
 QY 527 KTEWFTNPTTVAFYSASTNQIRFAGELQKPFEGTGPYSLSYAGIYVGHETGTF 586
 DB 535 PNLMTIGAAVVAFYSPRNQIVFPAGILOPPF-SKEQPOLNFGGIGVIGHEITHGP 593
 QY 587 DNNGRKYDKNGLDWSTSEBEKKEKTKCMINQYSNYWYKRAK-DNVGKRTLGENTIA 645
 DB 594 DNGRNPFKNGMDMWSNFSIOHRESECMIIQYQNSYWDLADQENVGFNTLGENIA 653
 QY 646 DNGGLREAFRAVKWINDRQGLEPILPGITFNNOLFTLSAIVHCNSYREARREOV 705
 DB 654 DNGVGRQYKAYLKKM--AEGKDQOLPGILDTHEDLFTINTAQWCGSYRPEFAIQSI 710
 QY 706 QIGASPPQFRVNGAISNSEFOKAFNCPNSTNMRGMSCRIM 749
 DB 711 KIDVHSPKRYRLVSLQMLAFAFTFCARGTPMH-PKRCRW 753
 RESULT 7
 ID AAY44177 standard; Protein; 774 AA.
 AC AAY44177;
 DT 01-FEB-2000 (first entry)
 DE Rat membrane metalloprotease NEPII protein.
 XX
 XX
 KW Rat; membrane metalloprotease; neprilysine II; NEPII; inactivation;
 KW neuron; hormone; peptide messenger; inhibitor; detection; disorder;
 KW cardiovascular disease; neurodegenerative disease; growth disorder;
 KW hypothalamic-hypophyseal axis; endocrine disorder.
 XX
 OS Rattus rattus.
 XX
 PN FR2777291-A1.
 PD 15-OCT-1999.
 PF 08-APR-1998; 98FR-0004389.
 PR 08-APR-1998; 98FR-0004389.
 PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.
 PI Ouimet T, Gros C, Haret C, Bonhomme MC, Facchinetti P,
 Schwartz JC;

XX WPI: 1999-593429/51.
 DR N-PSDB: AAZ28810.
 XX New membrane metalloprotease NEP II, involved in proteolysis of
 PT neuronal and hormonal peptides, used to screen for inhibitors,
 PT potentially useful for treating e.g. cardiovascular disease
 XX
 PS Claim 1: Page 12-16; 29pp; French.
 XX
 CC This sequence represents the rat membrane metalloprotease designated
 CC neprilysin II (NEPII), which is involved in (in)activation of neuronal
 CC and hormonal peptide messengers. NEPII is used to screen for specific
 CC substrates (used to detect NEPII in cells and tissues) or inhibitors,
 CC which can also be used to detect NEPII or for treatment of disorders
 CC related to peptidergic signalling in which NEPII is involved, e.g.
 CC cardiovascular or neurodegenerative diseases; growth disorders of
 CC endocrine origin; disturbances of the hypothalamic-hypophyseal axis
 CC or endocrine disorders.
 CC
 XX Sequence 774 AA:
 SQ
 Query Match 34.1%; Score 1351; DB 20; Length 774;
 Best Local Similarity 38.2%; Pred. No. 6.1e-107; Indels 46; Gaps 18;
 Matches 289; Conservative 156; Mismatches 266;
 QY 18 GTRIALVVF--VGGTL-VLGTILF-----LVSGGLLSIAQKQCYCLKECTEAAAIL 67
 DB 39 GAITLVGVYSIGKQLPLNSLHVSHERTVKRVLRDSSQSKDICTPSCVIAAARLL 98
 QY 68 SKVNLSDPCDNFERRACDGNISNPIEDMPSGYPMRHRVADLKLEKLSRRR 127
 DB 99 QNMDSKPCDNFQYACGWLRRHVIPENSRYSVFILDELYELKVLVDSSVQHR 158
 QY 128 DTEAQRKILYSSCMNEKAEKADAKPLHLIRSPFRWPVLESNIGPEGVMSER--K 184
 DB 159 --PAVERKAKTLYRSCMNSVLEKRDSEPLNLVL--DMIGMPVAMDK-----WNETGMPK 209
 QY 185 FSLQTLATFRGOYSNSVFIIRLYVSPDKASNEHILKIDQATLSLAVREDYLDNSTPAKS 244
 DB 210 WELERQLAVLNSQFRRVRLIDFLIMNDQNSRHVIYIDOPTLMPREYTF--KEDSHR 267
 QY 245 YRDALYKENVDAVL-----IGANSRAEDMKSVLEKLEIKELMIPHENRYS--BMY 297
 DB 268 VREAYLQFMTSVATMLRDLNPGETDLVQEMAOVLLEHIANATVPQKRRIDVATLY 327
 QY 298 NKNMISELSAM--IPOFDMLGYIKKVIDTRYPLKDISPSENVVVRVPYQKFLRLIG 355
 DB 328 HRMGLELDERGIKGFNTLFTQNLVLSVQV---ELLPMEEVVYVGIPILEMLEIID 383
 QY 356 SEERKTIANTLVWRMYSKIPNLSRFQYRMLEFRRVIOGTTTLPPQDKCVNFIESALP 415
 DB 384 VEPAQTLQNLVWRLVLDIGLSIQFQKARVDYRKALGITMEVRRRECVSYNSME 443
 QY 416 YVVGKLVDPVDFQEDKKEEMELVEGVRAWFIDMLEKENEMWDAGTKRKAKARAVLYAK 475
 DB 444 SAVGSLIKRAFSKDSKISYSELIEKIRSVFVNDDELN--WMDDESKKKAQKALNIREQ 502
 QY 476 VGYPEFTM--NDTHVNEDLKATFSEADYFGNVLQTRKTLASDFELKAPKTEMTFN 533
 DB 503 IGYDYLIEDNNRHLDEYSLSLTFENQLMKNNNAORSKLKLEKVDQNMILIG 562
 QY 534 PTYNAYFASSTNOIRFPAGELQKPFWGTETPRSLSYAGIYVGHFTFGDNGGRKY 593
 DB 563 AAVNAYFSPRRNLIVPACILQPPF--SKDQOALNFGIGVIGHETTHGDDGRNF 621
 QY 594 DKNGLDPMWSTSESEKFEKTKCMINQYNSYWKKA--GLNYSKGTLETINDNGGLRE 652
 DB 622 DKNGMLDMWSNFARHFRQOSQCMQIYNSFWELADNONVNGSTLGENIDNGGVQ 681
 QY 653 AFRAARKVINDRQGLEPILPGITFTNNQLFELSYAHVNCNSYRPAAREQVOIGAHSP 712
 DB 682 AYKATLQWL---ABSGRQRLPGILNTYADLFFINVAQWCGSVRPFALQSIKTIVHSP 738

QY 713 POFVNGAISNSEFQKAFNCPSNTMNGMDSCLRW 749
 DB 739 LKRYVIGSLQNLPGFSEAFHCPGSPMH--PAMRGRIRW 774
 RESULT 8
 ID AAB60561
 XX AAB60561 standard; Protein: 779 AA.
 AC
 XX
 XX
 DE 27-APR-2001 (first entry)
 DE Human neprilysin-like membrane metalloprotease SNEPa.
 XX
 XX Human: SNEPa; neprilysin-like membrane metalloprotease;
 KW splice variant; alternative splicing; zinc endopeptidase family;
 KW neuropeptide; peptide hormone; processing; metabolism; vaccine;
 KW drug screening; renal insufficiency; hepatic disease; jaundice; pain;
 KW hypertension; cancer; inflammation; cardiovascular disease;
 KW neuronal disease; pancreatic disease; prostatic disease;
 KW respiratory disease; gene therapy; nephrotropic; vasotropic; analgesic;
 KW cerebroprotective; hypotensive; cytostatic; antiinflammatory;
 KW cardiovascular; hepatotropic.
 OS Homo sapiens.
 XX
 XX EPI069188-A1.
 XX
 PD 17-JAN-2001.
 PD 15-JUL-1999; 99EP-0401767.
 PF 15-JUL-1999; 99EP-0401767.
 PR 15-JUL-1999; 99EP-0401767.
 PA (SNFI) SANOFI-SYNTHELABO.
 PI Jagerschmidt A, Agnel M, Culouscou J;
 DR WPI: 2001-212582/22.
 DR N-PSDB: AAF59659.
 XX
 PT New membrane-associated metalloprotease SNEPa, SNEPb and SNEPc
 PT polypeptides and polynucleotides, useful for treating e.g. acute and
 PT chronic renal insufficiency, pain, stroke, cancer, inflammation, renal
 PT and hepatic ischemia
 PS Claim 11; Page 28-30; 72pp; English.
 XX
 XX The invention relates to the human SNEPa, SNEPb and SNEPc proteins, and
 CC the cDNAs encoding them. SNEPa, SNEPb and SNEPc are neprilysin-like
 CC membrane metalloproteases and are the products of alternative splicing.
 CC The substrate(s) for the SNEP proteins are not as yet known, although
 CC the neprilysin family of zinc endopeptidases play key roles in the
 CC processing and/or metabolism of neuropeptides and peptide hormones. SNEP
 CC nucleotides may be used as hybridisation probes for cDNA and genomic
 CC DNA; to isolate full-length cDNAs and genomic clones of SNEP homologues;
 CC SNEPb or SNEPc; to isolate cDNA and genomic clones of SNEP homologues;
 CC as research reagents and material for the discovery of treatments and
 CC diagnostics for animal and human diseases; and for chromosome
 CC identification. The SNEP proteins may be used as immunogens to
 CC produce antibodies immunospecific for SNEPa, SNEPb or SNEPc. Such
 CC antibodies are used to isolate or identify clones expressing the
 CC protein, or to purify the proteins by affinity chromatography.
 CC SNEP proteins may also be used in screening for compounds which modulate
 CC SNEP endopeptidase activity, and to assess enzymatic cleavage of small
 CC molecule substrates in cells, cell-free preparations, chemical libraries
 CC and product mixtures. The SNEP proteins (as vaccine compositions),
 CC SNEP nucleotides, and SNEP activators or inhibitors may be used
 CC to treat acute and chronic renal insufficiency, renal and hepatic
 CC ischaemia, pain, stroke, hypertensive disease, cancer, inflammation, as
 CC well as cardiovascular, neuronal, pancreatic, prostatic, renal,

CC respiratory or hepatic diseases, they may also be used in modulating
CC peptide activation and/or degradation in the brain or kidney or in
CC another organ, or to diagnose or treat any disorder related to abnormal
CC expression of SNEPA, SNEP or SNEPC. The present sequence represents
CC SNEPA.
XX

SO Sequence 779 AA:

Query Match 33.9%; Score 1343.5; DB 22; Length 779;
Best Local Similarity 39.5%; Pred. No. 2.7e-106;
Matches 286; Conservative 144; Mismatches 257; Indels 37; Gaps 17;

42 OGILSLQAKOEYCLKPECIAAAILSKVNLSDPCDNFFRACDGMISNNPIPDMSY 101
DB 77 RGIPAEQSEVCTTGCYIAAARIQNDPTEPCDDYQACGWLRRHVIPTNSRY 136
QY 102 GYVPMLRHNVDLKLELEKESISRDRDEAIQAKILYSSCNEKAIEKADAKPLHLIR 161
DB 137 SIFDVLREDEVLKAKVLENSTRA--KDRPAVEKANTLYRSCMNOGVIEKRSQPLDIL- 193
QY 162 HSPFRNPVLESNIGPEGVSR--KFSLLQPLATFRQYSNSVYFRLYSPDQKASNEH 218
DB 194 EYVGVPVAMDR-----WNETVGLFEMLEERQLALMSQFRRVILDLFINDDQNSRH 247
QY 219 ILLKIDQATSLAVREDYLDNSFEAKSYDALKYKAVDTAVLL--GANSR--AEHDMK 272
DB 248 IYIDOPTIGMSREYFRNGSNNK--VREAVLQFVSVATLLRDANLPRDSCVQEDMV 306
QY 273 SVLRLEIKAIETIMPHENTSE--AMYNKMNISELSAM--IPQPMYIKYKVIDTRLYPH 329
DB 307 QVLELETOLAKATVPOEERHVIYALYHRMGLEIQQSGFKGFPMTLFIQTVLSS----- 361
QY 330 LR-DISPENNVVVRVPOEFKDLFRIGSEKKTANTLYRMYVSRIPNLSRRROYRWLE 388
DB 362 VKIKLLPDEEVVYVCIPLQWLENIIDYSAKRTQNTLYRVLVLDRIQSLSQRFKTRVY 421
QY 389 ESRVIOGTTTLLPOMDKCVNFIESALPYVVGKMEVDYVFOEDKKEMMEELVEGVRAFLD 448
DB 422 YRKALFTVMEVEMRRECVGVNSNMENAVGSLYREAFPGDCKSNARELIDVRYVEYE 481
QY 449 MLEKENEMDAGTRKAKERAKRAVLAIVGPEPLMDTH--VEDDKAIKFEADYFGNV 506
DB 482 TLD-ELGWMDESEKKAKQEKAMSRDQIGHPDYLTLETNRRLDEEYSNLFSEDLTFENS 540
QY 507 LOTKKYLAOSDFEWLRAVAKTEFTNPTVNAFASASTQIFRPAQELQKPFEGTEP 566
DB 541 LQNLKVAQSRSLRKLRKREKVDPMIIGAAVNAFYSPNNQIVFAGILQPPF--SKEDP 599
QY 567 RSLSYGAIGYVGHFEGFDNNGRKYDKNGNLDPMWSTSESEKREKTKCMINQSYNY 626
DB 600 QALNFGSIGVIGHETTFGDDNGRFDDNGNMNMWMSNFSTQHFREDOSECMIYQGNYS 659
QY 627 WKKAG--LVNKGKRTTGENTLADNGGLREAFRAKVIINDRQGLREPLLGITFTNNOLEF 685
DB 660 WDLADQONVGFNTLTGENTLADNGVQAVKALKM--AEGGKQOQPLGDLTTHEQDLEF 716
QY 686 LSYAHRCNSYRREARVOVGASPPQFRVNGAISNSEEFQAKFNCPPNSTNRGMD 745
DB 717 INAQWCSSTYRERAIOSIKTIDVSPKRYVLSGLQMLAFLDTHCARCTPMH--EKR 775
QY 746 CRIM 749
DB 776 CRVM 779

RESULT 9
AAB83841
ID AAB83841 standard; Protein: 779 AA.

XX AAB83841;
XX
XX 23-JUL-2001 (first entry)
XX

DE Amino acid sequence of a human metalloprotease enzyme IG55.
XX
XX Metalloprotease; IG55; infection; pain; cancer; diabetes; obesity;
KW anorexia; bulimia; asthma; Parkinson's disease; acute heart failure;
KW hypotension; hypertension; urinary retention; osteoporosis;
KW benign prostatic hypertrophy; stroke; ulcer; allergy;
KW neurological disorder; autism; multiple sclerosis; Alzheimer's disease;
KW neurodegenerative disease; sleep disorder; epilepsy; kidney disease;
KW cardiovascular disease; arteriosclerosis; cerebrovasospasm;
KW subarachnoid hemorrhage; cerebral ischemia; cerebral infarction;
KW peripheral vascular disease; Raynaud's disease; motility disorder;
KW gastrointestinal disorder; gastric emptying; gastroparesis; diarrhoea;
KW inflammation; chemotherapy induced injury; tumour invasion;
KW immune disorder; arthritis; endotoxin shock; sepsis; diabetes mellitus;
KW Gilles de la Tourette's syndrome.

Homo sapiens.

WO200136610-A1.

25-MAY-2001.

17-NOV-2000; 2000WO-EP11532.

19-NOV-1999; 99EP-0203862.

19-NOV-1999; 99NL-1013616.

31-MAY-2000; 2000EP-0201937.

31-MAY-2000; 2000NL-1015356.

(SOLV) SOLVAY PHARM BV.

DeJersnijder W, Wieggers R, Weske M;

WPI; 2001-343815/36.

N-PSDB; AAF89738.

New IG55 polypeptides useful for treating infections, pain, cancer,

diabetes, obesity, anorexia, bulimia, asthma, schizophrenia,

hypertension, urinary retention and Parkinson's disease

Claim 3; Page 8; 115pp; English.

The present sequence represents a human metalloprotease enzyme designated

IG55. IG55 polynucleotides and polypeptides are useful for treating

infections, pain, cancer, diabetes, obesity, anorexia, bulimia, asthma,

Parkinson's disease, acute heart failure, hypotension, hypertension,

urinary retention, osteoporosis, angina pectoris, myocardial infarction,

stroke, ulcers, allergies, benign prostatic hypertrophy, migraine,

psychotic and neurological disorders, autism, multiple sclerosis,

Alzheimer's disease, and other neurodegenerative diseases, sleep

disorder, epilepsy, cardiovascular diseases, arteriosclerosis,

cerebrovasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral

infarction, peripheral vascular disease, Raynaud's disease, kidney

diseases, gastrointestinal disorders, motility disorders and conditions

of delayed gastric emptying, post-operative or diabetic gastroparesis,

diarrhoea, inflammation, chemotherapy induced injury, tumour invasion,

immune disorders, arthritis, endotoxin shock, sepsis, complications of

diabetes mellitus, and severe mental retardation and dyskinesias, such

as Huntington's disease or Gilles de la Tourette's syndrome.

SO Sequence 779 AA:

Query Match 33.7%; Score 1333.5; DB 22; Length 779;
Best Local Similarity 39.2%; Pred. No. 2e-105;
Matches 284; Conservative 145; Mismatches 258; Indels 37; Gaps 17;

QY 42 OGILSLQAKOEYCLKPECIAAAILSKVNLSDPCDNFFRACDGMISNNPIPDMSY 101
DB 77 RGIPAEQSEVCTTGCYIAAARIQNDPTEPCDDYQACGWLRRHVIPTNSRY 136
QY 102 GYVPMLRHNVDLKLELEKESISRDRDEAIQAKILYSSCNEKAIEKADAKPLHLIR 161

```

DB      137 SIFDVLRLDELVLKAVLENSTA--KDRPAVEKARTLVKSCNMQSVIEKRGQPLDLTL- 193
      :: || :::: || || | : : | :::: || || || : || ::|| ||
QY      162 HSPFRMPVLESNIGPEGVMSER---KESLLQTLAFRGQYSVPIRLVSPDDKASNEH 218
      || | | | | | | | | | | | | | | | | | | | | | | | |
DB      194 EYVGGPVPVAMDR-----WNETVGLMELEERLALMNSQFNKRVLLDLFIWMDONSSRH 247
      || | | | | | | | | | | | | | | | | | | | | | | | |
QY      219 ILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFWDAVAVLL--GANSR---AEDMK 272
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      248 IYIDQPTLGMPRSREYFNGSNRK-VREAYLQFMVSVATLLREDANLPDSCLOVEDMK 306
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      273 SVLRLEIKIAEIMIPHENRTS-AMTKNNISELSM--IPQDMLGYIKKYIDRLYPH 329
      | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      307 OVLELETOAKATVPQEEHHDYALYHRMGLLELSQFGKGFNMWTLFTQYVLS----- 361
      | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      330 LK-DISEPENVVVRVPQYKDFRLIGSERKRTIANYLVWRMYSTRIPULSRFOYRWLE 388
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      362 VKIKLPDEEVVYGYIPYQNLNENIIDYASARTIQNYLVWRVLDRLIGSLQRFKDTRYN 421
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      389 FSRVIGTFTTLFPQMDKCVNFIESALPIYVGMKFDVYFQEDKKEEMEEVGVRAFTD 448
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      422 YRRALFTGWEEYVRMECVGYVNSNMENAVGSLYVREAFPGDSKSVRELIDKRTVYE 481
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      449 MEKEMEMDAGTKRRAKARAVLAKVGPPEFIMDTH--VVEDLKAIKFSADYFGV 506
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      482 TLD-ELGMDDESKKRAQEKAMSIRQDIGHPTDILEEMNRRLDEYSNLNFSDDLXENS 540
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      507 LQTRKYLAQSDFPWLKRAVAKTEMTPTTNNAFYASASTNQIRPAGLOKPEFWGTEYP 566
      | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      541 LQNLKVGAGRSLSKRLKREKVPNMIIGAAYVNAFSPNRQIYFPAGILOPPFF-SKEOP 599
      | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      567 RSLSYGAIGYVGHFTHGPDNNGRKDYKNGNLDPMWSTSEKFEKTKCMINOYSNY 626
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      600 QALNFGIGIYVGHFTHGPDNNGRKDYKNGNLDPMWSTSEKFEKTKCMINOYSNY 659
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      627 WKKAG-LNVGKRTIGENINDGRLREAFRAYRKWINDRQGLEEPLLPITFTNNQLEF 685
      | | | | | | | | | | | | | | | | | | | | | | | | | |
DB      660 WDLADEQNVGFNTLGININDNGVRQAYKAYLKKM--AEGGKDQQLPGLDLTHQLEF 716
      | | | | | | | | | | | | | | | | | | | | | | | | | |
QY      686 LSYAHVRCNSYRPEAREQOIGAHSPPOFRVNGAISNSEPQAFKPCPNSTIMNGMS 745
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      717 INYQWVGSGYRPEFAIQSIKIDVHSPLKYRVLGSLQNLAAFDTFHCARGTPEH-PKER 775
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      746 CRM 749
      || | |
DB      776 CRM 779
      || | |

```

RESULT 10

AA08131
 AAB08131 standard; Protein; 770 AA.

AA08131;

04-DEC-2000 (first entry)

A human neutral endopeptidase metalloproteinase-like enzyme NL-2.

Nepilysin; neutral endopeptidase metalloproteinase-like enzyme;

NEP-like enzyme; protein production; protein secretion;

neurological disease; Alzheimer's disease; pain; psychiatric disorder;

fertility; bone disease; abnormal phosphate metabolism.

Homo sapiens.

W0200047750-A2.

17-AUG-2000.

11-FEB-2000; 2000MO-CA00147.

11-FEB-1999; 99CA-2260376.

```

PA      (UNMO-) UNIV MONTREAL.
XX      Desgroselliers L, Boileau G;
PI      WPI: 2000-549148/50.
DR      N-PSDB; AAA63764.
XX      Novel neutral endopeptidase-like metalloproteinase polypeptides and
PT      polynucleotides, used to screen for related sequences and enzyme
P7      inhibitors, used for the treatment of NL-3 related bone disorders -
XX      Claim 3; Fig 4; 59pp; English.
CC      The present sequence represents a human neutral endopeptidase
CC      metalloproteinase-like enzyme, designated NL-2. The specification
CC      also describes NL-1 and NL-3. The NL enzymes are used to test for
CC      specific inhibitors. The N-terminal region of the enzymes can be used
CC      to promote production and secretion of foreign proteins and active
CC      bioproteins, using chimeric constructs containing the foreign protein
CC      downstream from and in phase with the N-terminal region. The NL enzymes
CC      are have been localised to the brain, and may be useful in the
CC      treatment of neurological diseases such as Alzheimer's disease, pain,
CC      and psychiatric disorders. NL enzymes have also been localised to the
CC      testis and ovaries, and may be used to control fertility. They have
CC      also been localised to bones, and may be used to treat bone diseases,
CC      and abnormal phosphate metabolism related to improper peptide
CC      processing by the NL-3 enzyme.
SQ      Sequence 770 AA:
Query Match 33.7%; Score 1332.5; DB 21; Length 770;
Best Local Similarity 39.2%; Pred. No. 2,4e-105;
Matches 284; Conservative 145; Mismatches 258; Indels 37; Gaps 17;
QY      42 QGILSLQAEKQECIAPECEIAAALISKYNSVDCDDNFRPAGCWGINSNPIDPMPSY 101
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      68 RIPEAQEVSEVCTPGVIAARLQNDPTECDQDIPGACGWLRRHVIFPTNSRY 127
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      102 GYPMRLRHVNDLKLKELKESISRRTDTEALOKALYKSCNNEKAIEKADAKPLHLIR 161
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      128 SIFDVLRLDELVLKAVLENSTA--KDRPAVEKARTLVKSCNMQSVIEKRGQPLDLTL- 184
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      162 HSPFRMPVLESNIGPEGVMSER---KESLLQTLAFRGQYSVPIRLVSPDDKASNEH 218
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      185 EYVGGPVPVAMDR-----WNETVGLMELEERLALMNSQFNKRVLLDLFIWMDONSSRH 238
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      219 ILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFWDAVAVLL--GANSR---AEDMK 272
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      239 IYIDQPTLGMPRSREYFNGSNRK-VREAYLQFMVSVATLLREDANLPDSCLOVEDMK 297
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      273 SVLRLEIKIAEIMIPHENRTS-AMTKNNISELSM--IPQDMLGYIKKYIDRLYPH 329
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      298 OVLELETOAKATVPQEEHHDYALYHRMGLLELSQFGKGFNMWTLFTQYVLS----- 352
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      330 LK-DISEPENVVVRVPQYKDFRLIGSERKRTIANYLVWRMYSTRIPULSRFOYRWLE 388
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      353 VKIKLPDEEVVYGYIPYQNLNENIIDYASARTIQNYLVWRVLDRLIGSLQRFKDTRYN 412
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      389 FSRVIGTFTTLFPQMDKCVNFIESALPIYVGMKFDVYFQEDKKEEMEEVGVRAFTD 448
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      413 YRRALFTGWEEYVRMECVGYVNSNMENAVGSLYVREAFPGDSKSVRELIDKRTVYE 472
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      449 MEKEMEMDAGTKRRAKARAVLAKVGPPEFIMDTH--VVEDLKAIKFSADYFGV 506
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      473 TLD-ELGMDDESKKRAQEKAMSIRQDIGHPTDILEEMNRRLDEYSNLNFSDDLXENS 531
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      507 LQTRKYLAQSDFPWLKRAVAKTEMTPTTNNAFYASASTNQIRPAGLOKPEFWGTEYP 566
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      532 LQNLKVGAGRSLSKRLKREKVPNMIIGAAYVNAFSPNRQIYFPAGILOPPFF-SKEOP 590
      | : | | | | | | | | | | | | | | | | | | | | | | | |
QY      567 RSLSYGAIGYVGHFTHGPDNNGRKDYKNGNLDPMWSTSEKFEKTKCMINOYSNY 626
      | : | | | | | | | | | | | | | | | | | | | | | | | |
DB      591 QALNFGIGIYVGHFTHGPDNNGRKDYKNGNLDPMWSTSEKFEKTKCMINOYSNY 650
      | : | | | | | | | | | | | | | | | | | | | | | | | |

```

QY 627 WKAG-LNVKGRITLGINADNGLRAPAFRAKWKINDROGLEPILPITITNNQLFF 685
 Db 651 WDLADEQVNGFNTLGINADNGSVRAKAYILKWM--AEGKDOQLPGDLTHQLEFF 707
 QY 686 LSTAHVRCNSYRPPAREQVQIGAHSPPOFRVNGAISNSEEFQAFNCPPNSTNRGMD 745
 Db 708 INVAQVWCGSYRPEFAIOSIKTDVHSPDKYVLSLQNLAAFDTHCANGTPIH--PKER 766
 QY 746 CRLW 749
 Db 767 CRW 770

RESULT 11
 ABB79521 standard; protein; 779 AA.
 ID ABB79521 standard; protein; 779 AA.
 AC ABB79521;
 XX 23-SEP-2002 (first entry)
 DE Human SEP endopeptidase.
 XX SEP: endopeptidase; enzyme; human; neuropeptide Y1 receptor;
 KM male sexual dysfunction; male erectile dysfunction; obesity;
 KW anorexia; bulimia; vasotropic; anorectic; therapy; inhibitor.
 OS Homo sapiens.
 XX MO200247670-A1.
 PN 20-JUN-2002.
 PD 10-DEC-2001; 2001WO-1B02399.
 XX 15-DEC-2000; 2000GB-0030647.
 PR 06-APR-2001; 2001GB-0008730.
 PR 23-APR-2001; 2001GB-0009910.
 PR 04-MAY-2001; 2001GB-0011037.
 PR 29-JUN-2001; 2001US-0895367.
 PR 13-JUL-2001; 2001US-0905846.
 PR 24-AUG-2001; 2001GB-0020679.
 XX (PFIZ) PFIZER LTD.
 PA (PFIZ) PFIZER INC.
 PI Naylor AM, Van Der Graaf PH, Wayman CP;
 DR WPI: 2002-547828/58.
 DR N-PSDB; ABB84279, ABB84280.
 XX Use of an inhibitor of neuropeptide Y in the preparation of medicament
 PT for the treatment or prevention of male erectile dysfunction
 XX Disclosure; Fig 9; 17pp; English.
 PS The present sequence is the protein sequence of human SEP, a
 CC soluble secreted endopeptidase. The invention relates to the use
 CC of an inhibitor of NPY, or an inhibitor of NPY Y1 receptor,
 CC especially an inhibitor selective for an NPY or NPY Y1 receptor
 CC associated with male genitalia, in the preparation of a medicament
 CC for the treatment or prevention of male sexual dysfunction,
 CC especially male erectile dysfunction (MED). The NPY inhibitor
 CC may be used with an auxiliary active agent such as an SEP
 CC inhibitor. The invention provides an assay that can be used to
 CC detect candidate inhibitors of SEP. In addition to treatment of
 CC MED, NPY inhibitors can also be used to treat abnormal drink and
 CC food intake disorders, such as obesity, bulimia, anorexia and
 CC metabolic disorders.
 XX Sequence 779 AA;

Query Match 33.7%; Score 1332.5; DB 23; Length 779;
 Best Local Similarity 39.2%; Pred. No. 2.4e-105;
 Matches 284; Conservative 145; Mismatches 258; Indels 37; Gaps 17;

QY 42 OGLSLQAKQECCLKECEIAAATILSKVNSVDCDNDFRACGMSIINNPIEDMPSY 101
 Db 77 KGIPEAQEVESECTTGGVIAAARILQNDPTTECDDEYFACGGMRRVPIETNSRY 136
 QY 102 GYVPMLRHNVDLKLEKLEKSISRRODEALOKAKILVSSCNEKAIEKADAKPLHLTR 161
 Db 137 SIFDVLDELVEYLKAVLENSTA--KDRPAVEKARTILVSCMNSVIEKRSQPLDIL- 193
 QY 162 HSPFRPVLSENIQPEGVWSE--KESILQTLATFRQYNSVFIRLYVSPDKASNEH 218
 Db 194 EYVGGPVPAMD--WNETVGLMELEQLQALMNSQFNRRLVIDFIMNDQNSRH 247
 QY 219 ILKLDQATLSLAVREDYLDNSTEAKSYDALYKFWADPAVL--GANSR--AEIDMK 272
 Db 248 IYIDQPTLGMPSREIYNGSNRK-VREAYLQFVAVATLREDANLPSCVLQEDMV 306
 QY 273 SVLRLEIKIATIMIPHENRTSE-AMYNKNMISELSAM--IPQDWLYKKVIDTRLYPH 329
 Db 307 QVLELEQLAKATVQOEERHVDVIALYHRMGLLELOSGLGKGFNWTLFIQTVLSS----- 361
 QY 330 LK-DISPSENVVVRPOYFKDLFRIGSERKKTANTLYMAMYSRIPNSRRQYMLE 388
 Db 362 VKIKLPEEYVYVGIPLQMLENIDITYSARTQNLVWLVLVDRIGLSLQREKDRVN 421
 QY 389 FSRVIQGTITLLPQMDKCNFIESALPYVVGKMFVDYFQEDKEMAEELVEGVRAFTD 448
 Db 422 YRKALFTVVEEVRWRECVGYVNSMENAVALSYVREAFPEDSKSMVRELIDKRYVFE 481
 QY 449 MLEKENEMWDAGTRKRAKRAKARAVLAVGYREFIMANTH--VNEDLAKIFSEADYFGNV 506
 Db 482 TLID-ELGMDESKKKAQEKASIREQIGHDPYILEEMNRRLDEEYVSNLNFSEDLFEYS 540
 QY 507 LQTRKYLAQSDFEWLKRAVPKTEWFTNPTVNAFYSASTNOIRPAGELQKPFWGEYV 566
 Db 541 LQNLKVGQBSLRKLRKREKVPNMLIIGAAYVNAFYSNRQIYFPACILQPPF-SKEOP 599
 QY 567 RSLSTGALGVYGHFTHGDDNGRKDKYKDNIDPMWSTSESEKFEKTKCMATQYSNYY 626
 Db 600 QALNFGGIGMVTGHEITHGDDNGRNFEDKNGNMADWMSNFSTQHFREQSCMITYGUNS 659
 QY 627 WKAG-LNVKGRITLGINADNGLRAPAFRAKWKINDROGLEPILPITITNNQLFF 685
 Db 660 WDLADEQVNGFNTLGINADNGSVRAKAYILKWM--AEGKDOQLPGDLTHQLEFF 716
 QY 686 LSTAHVRCNSYRPPAREQVQIGAHSPPOFRVNGAISNSEEFQAFNCPPNSTNRGMD 745
 Db 717 INVAQVWCGSYRPEFAIOSIKTDVHSPDKYVLSLQNLAAFDTHCANGTPIH--PKER 775
 QY 746 CRLW 749
 Db 776 CRW 779

RESULT 12
 AAU78850 standard; protein; 779 AA.
 ID AAU78850;
 XX 18-JUN-2002 (first entry)
 DE Novel neprilysin family protein, 56638.
 XX Neprilysin family; human; gene therapy; protein therapy; vaccine;
 KW neprilysin protease; pain; pain associated disorder; tissue injury;
 KW chest pain; complex regional pain syndrome; CRPS; headache; migraine;
 KW reflex sympathetic dystrophy; RSD; tooth pain; musculoskeletal disorder;
 KW joint pain; surgery; inflammation; irritable bowel syndrome; anaemia;
 KW aberrant spermatid cell activity; infertility; cancer; brain disorder;

FT	Region
----	--------

Best Local Similarity 39.26; Pred. NO. 2.4e-105;
Matches 284: Conservative 145: Mismatches 258: Indels 37: Gaps 17.

```

QY 42 OGLSLQAKOEYCLKPECIEAAAILSKVNLSDPCDNFFRACDGIWISNPIPEDMPSY 101
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 77 RGIPEAGVSEVCTTGPCVIAAARILQNMDDPTTEPCDDYQFACGGWLRHHVPEITSRY 136
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 102 GYVFWLRHNVDLKLELEKSISSRRDTEAIOKAKIYSSCMNEKAEKADAKPLHLR 161
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 137 SIFVLRDELEVLKAVLENSTA--KDRPAVEKARTLYRSCMNSQVIEKRSQPLDIL- 193
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 162 HSPFRWPLESNIPEGVWSR---KFSLOTLATFRGQYSNSVFILYSPDOKASNEH 218
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 194 EVVGGWPVAMDR-----WNETVGLWELEERQALMNSQFNRRVLDLFINDDQNSRH 247
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 219 ILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFWVDVAVL--GANSR---AEHDMK 272
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 248 IYIDQPTLGMPRSREYFNGSNRK--VREAYLQPMVSVATLLREDANLPDSCLYQEDMY 306
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 273 SVLRLEIKIAEIMIPHENTSE--AMYNKNISLSAM--IPQFDWLGYYIKKYIDTRLYPH 329
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 307 QVLELETLQAKATVPOEERHDVIALYHRMGLLEEQSOFGLKGFMTLFIQTVLSS----- 361
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 330 LK-DISEPENVVAVRPOYFKDLFRILGSEKKTIANLYVMWYSRIPNLSRPFQYRWLE 388
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 362 VKIKLPDEEVVYVGIPIQLNLENTIDYSAKTIONTLVWRVLVDRIGSLSQRFKQTRVN 421
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 389 FSRVIOGTTTLLPQMDKCVNFIESALPYVVGKMFVDVYFOEDKEMMEELVEGVMAFID 448
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 422 YRKALFGTMEVVRMRECVGVVNSMENAAGSLYVREAFPDSDKSMVRELIDKRYTFVE 481
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 449 MLEKENEMDAGTRKRAKERAVALAVGYEPIFMDNTH--VNDDLAIKFSEADYGVN 506
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 482 TLD-ELGWMDESKKKAQEKMSIREQIGHDYLLEENNRRLDEYSNLFNSEDLYFENS 540
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 507 LQTRKYLAQSDPFMLRKAVPTEWFTNPTVNAFYASASTNOIRPAGELQKPFMGTEYP 566
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 541 LQNLKVGQBSRLKREKRVDPNMLIIGAAYVNAFYSRNRNDIYVPAIILQPF--SKEP 599
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 567 RSLSTGAIVTIGHEFTGPDNNGRYDKNGNLDPMWSTSESEKFKKTKCMINQYSNY 626
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 600 QALNFGGIGAVTIGHEITGFDNGRNDKNGMDMWSNFSQJHFRQSECMIOYQNGYS 659
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 627 WKKAG-LNVKGRITLGENIADNGLRFAFRAYRKWINDRQGLDEEPLPGLTFTNNGLF 685
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 660 WDLDEQWVNGFNLTGENIADNGVROAYKAYLKWM--AEGKDDQLPGDLTHQGL 716
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 686 LSYAHVRCSYRPEAAROVQIGAHSPPOFRNGAISNSEFOKAFKCPKSTNRMGMS 745
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 717 INVAQWVGSTRPEFAISIKTDVHSPKRYVLSGLQNLAAFDTRHCARCTPMH-PKER 775
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 746 CRLW 749
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 776 CRWV 779
   : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

RESULT 13
AAEI7779
ID AAEI7779 standard; Protein: 779 AA.

AAEI7779;

07-MAY-2002 (first entry)

Human soluble secreted endopeptidase (SEP) protein.

Human; secreted endopeptidase; SEP; endocrine; vasotropic; analgesic;

KW enzyme; gynaecological; antisense-therapy; male erectile dysfunction;

KW MED; female sexual dysfunction; FSD; female sexual arousal disorder;

KW FSD; premature ejaculation; anorgasmia; vaginismus.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Domain 570..779

/label= Catalytic_domain

XX Homo sapiens.

XX WO200206492-A1.

XX 24-JAN-2002.

XX 16-JUL-2001; 2001WO-1B01263.

XX 14-JUL-2000; 2000GB-0017387.

XX (PF12) PFIZER LTD.

XX (PF12) PFIZER INC.

XX Harrow ID, Stacey P, Walsh RT, Wayman CP, Wayman CP, Phillips SC;

XX WPI; 2002-155042/20.

XX N-PSDB; AAD28544.

XX An isolated and/or purified nucleic acid encoding a human soluble

XX secreted endopeptidase which is useful for treating sexual dysfunction,

XX for e.g. male erectile dysfunction or female sexual dysfunction such as

XX female sexual arousal disorder.

XX Claim 4; Page 162; 167p; English.

XX The invention relates to an isolated and/or purified nucleic acid

XX encoding a human soluble secreted endopeptidase (SEP). The anti-SEP

XX antibody and the compound which inhibits or selectively inhibits the

XX human SEP protein are useful in the manufacture of a medicament for

XX the prophylaxis and/or treatment of sexual dysfunction, in particular

XX male erectile dysfunction (MED) or female sexual dysfunction (FSD)

XX (e.g. female sexual arousal disorder (FSD)). The SEP polypeptides are

XX also useful for treating the above disorders and other disorders such

XX as premature ejaculation, anorgasmia, sexual pain (e.g. vaginismus) and

XX hypactive sexual desire disorder. The present sequence is human SEP

XX protein.

XX Sequence 779 AA;

XX Query Match 33.7%; Score 1332.5; DB 23; Length 779;

XX Best local Similarity 39.2%; Pred. No. 2,4e-105;

XX Matches 284; Conservative 145; Mismatches 258; Indels 37; Gaps 17;

QY 42 OGLSLQAKOEYCLKPECIEAAAILSKVNLSDPCDNFFRACDGIWISNPIPEDMPSY 101

Db 77 RGIPEAGVSEVCTTGPCVIAAARILQNMDDPTTEPCDDYQFACGGWLRHHVPEITSRY 136

QY 102 GYVFWLRHNVDLKLELEKSISSRRDTEAIOKAKIYSSCMNEKAEKADAKPLHLR 161

Db 137 SIFVLRDELEVLKAVLENSTA--KDRPAVEKARTLYRSCMNSQVIEKRSQPLDIL- 193

QY 162 HSPFRWPLESNIPEGVWSR---KFSLOTLATFRGQYSNSVFILYSPDOKASNEH 218

Db 194 EVVGGWPVAMDR-----WNETVGLWELEERQALMNSQFNRRVLDLFINDDQNSRH 247

QY 219 ILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFWVDVAVL--GANSR---AEHDMK 272

Db 248 IYIDQPTLGMPRSREYFNGSNRK--VREAYLQPMVSVATLLREDANLPDSCLYQEDMY 306

QY 273 SVLRLEIKIAEIMIPHENTSE--AMYNKNISLSAM--IPQFDWLGYYIKKYIDTRLYPH 329

Db 307 QVLELETLQAKATVPOEERHDVIALYHRMGLLEEQSOFGLKGFMTLFIQTVLSS----- 361

QY 330 LK-DISEPENVVAVRPOYFKDLFRILGSEKKTIANLYVMWYSRIPNLSRPFQYRWLE 388

Db 362 VKIKLPDEEVVYVGIPIQLNLENTIDYSAKTIONTLVWRVLVDRIGSLSQRFKQTRVN 421

QY 389 FSRVIOGTTTLLPQMDKCVNFIESALPYVVGKMFVDVYFOEDKEMMEELVEGVMAFID 448

Db 422 YRKALFGTMEVVRMRECVGVVNSMENAAGSLYVREAFPDSDKSMVRELIDKRYTFVE 481

QY 459 AGTKRAREKARAVLAKVGYPEFIMNDH--VNEDLAKIKSEADYFGNVLQTRKLAOS 516
 Db 414 ESKKKAQEKAMSIREQDGHDIYLEEMNRIDEYSNLNFSDDLFEENSLQMLKYGAGR 473
 QY 517 DEFMLRKAVPTETFTNPTNAFYASTNOIRPAGLELOKPFMGTEYPRSLSYGAIYV 576
 Db 474 SLRKLRKVDPMILITIGAAVNAFYSPNRNOIYFPGIILPPF-SKEQOLNFGSIGIM 532
 QY 577 IVGHEFTGPDNNKRYDKNGNDLPMWSTSESEKFEKTKCMINQYSNTYWKAG-LNVK 635
 Db 533 VIGHEITHGDDNCRNFDKNGNMWMSNFTQHFRQSECMITQYQYNGNSMDLADQONV 592
 QY 636 GKRTLGENDNGGLREAFRAKRWINDRROGLEEPLLPITFTNNQLEFSLYAHNRCS 695
 Db 593 GFNTLGENIADNGCVROAYKAYLKKM--AEGKDQDLPGDLDITHQLEFTINAYQWCS 649
 QY 696 YRPEARQVOIGAHSPPOFRVNGAISNSEFOAKNCPNPNSTNNRMDSCRLM 749
 Db 650 YRPEAFQSIKTIVHSPDKRYVLSLQNLAAFDTFHCARGTPTH-PKECRHVM 702

RESULT 15
 AAB83840

ID AAB83840 standard; Protein; 691 AA.

XX AAB83840;

XX 23-JUL-2001 (first entry)

DE Amino acid sequence of a human metalloprotease enzyme IGSS.

XX Metalloprotease; IGSS; infection; pain; cancer; diabetes; obesity;
 KW anorexia; bulimia; asthma; Parkinson's disease; acute heart failure;
 KW hypertension; hypertension; urinary retention; osteoporosis;
 KW angina pectoris; myocardial infarction; stroke; ulcer; allergy;
 KW benign prostatic hyperplasia; migraine; psychotic disorder;
 KW neurological disorder; autism; multiple sclerosis; Alzheimer's disease;
 KW neurodegenerative disease; sleep disorder; epilepsy; kidney disease;
 KW cardiovascular disease; arteriosclerosis; cerebrovasospasm;
 KW subarachnoid hemorrhage; cerebral ischemia; cerebral infarction;
 KW peripheral vascular disease; Raynaud's disease; motility disorder;
 KW gastrointestinal disorder; gastric emptying; gastroparesis; diarrhoea;
 KW inflammation; chemotherapy induced injury; tumor invasion;
 KW immune disorder; arthritis; endotoxin shock; sepsis; diabetes mellitus;
 KW severe mental retardation; dyskinesia; Huntington's disease;
 KW Gilles de la Tourette's syndrome.

OS Homo sapiens.

XX WO200136610-A1.

XX 25-MAY-2001.

XX 17-NOV-2000; 2000WO-EPI1532.

XX 19-NOV-1999; 99EP-0203862.

XX 19-NOV-1999; 99NL-1013616.

XX 31-MAY-2000; 2000EP-0201937.

XX 31-MAY-2000; 2000NL-1015356.

XX (SOLV) SOLVAY PHARM BV.

XX Deleersnijder W, Wieggers R, Weske M;

XX WPI, 2001-343815/36.

XX N-PSDB; AAF89737.

XX New IGSS polypeptides useful for treating infections, pain, cancer,
 PT diabetes, obesity, anorexia, bulimia, asthma, schizophrenia,
 PT hypertension, urinary retention and Parkinson's disease
 XX Claim 3; Page 6; 115pp; English.

CC The present sequence represents a human metalloprotease enzyme designated
 CC IGSS. IGSS polynucleotides and polypeptides are useful for treating
 CC infections, pain, cancer, diabetes, Obesity, anorexia, bulimia, asthma,
 CC Parkinson's disease, acute heart failure, hypotension, hypertension,
 CC urinary retention, osteoporosis, angina pectoris, myocardial infarction,
 CC stroke, ulcers, allergies, benign prostatic hyperplasia, migraine,
 CC psychotic and neurological disorders, autism, multiple sclerosis,
 CC Alzheimer's disease, and other neurodegenerative diseases, sleep
 CC disorder, epilepsy, cardiovascular diseases, arteriosclerosis,
 CC cerebrovasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral
 CC infarction, peripheral vascular disease, Raynaud's disease, kidney
 CC diseases, gastrointestinal disorders, motility disorders and conditions
 CC of delayed gastric emptying, post-operative or diabetic gastroparesis,
 CC diarrhoea, inflammation, chemotherapy induced injury, tumor invasion,
 CC immune disorders, arthritis, endotoxin shock, sepsis, complications of
 CC diabetes mellitus, and severe mental retardation and dyskinesias, such
 CC as Huntington's disease or Gilles de la Tourette's syndrome.

SO Sequence 691 AA;

Query Match 33.4%; Score 1322.5; DB 22; Length 691;
 Best Local Similarity 39.5%; Pred. No. 1.4e-104;

Matches 281; Conservative 143; Mismatches 251; Indels 37; Gaps 17;

QY 54 CLKPECIEAAMALISVNI:SVPCDNFFRACDGMISNPIPEDMPSYGYVWLRHNVLD 113
 Db 1 CTPPGCVIAAARLQNMDDPTTECDPFYFACGGLRRHVIPETNSRYSIPVLRDELAV 60
 QY 114 KKELEKSISSRRPTEAIOKAKILYSSCMNEKIAEKDAPKLIHLIRHSFRRPVLESN 173
 Db 61 IKAVALENSTA-KDRAVEKARILYRSCMNQSYTERKGSPLLDIL-EVVGPGVAMDR 117
 QY 174 IPEBGWMSR---KSLQTLATERGQYSNVFRLYVSPDDKASNHILKDOATLSLA 230
 Db 118 -----WNTVGLLEWELEROLANMSQFRRLVLDLTMNDQSSRHIIYDQPLGMP 171
 QY 231 VREDYLDNSTEAKSYDALYKENVDTAVIL--GANSR---AEHDKSVLRLEIKIAEL 284
 Db 172 SREYFENGSGNRK-VREYLDPMVSVATILREDNLPDRDCLVQEDMVOULETETGLAA 230
 QY 285 MLEPHNRPS-AMTKNANISLSAM-IPODWLGYIKRYIDRLYPLK-DISPENYV 340
 Db 231 TVPOERHDVYALYHRMGLLELOQFGLKGFNMTLFIQYVLS-----YKIKLPDEYV 285
 QY 341 VRVPQFQDLFRILGSEKRTIANYLVWRVYSGIRPLSRPQYRLDESRYVQGTITLL 400
 Db 286 YGIPYQNLNLENIIDTYSARTIONYLVRKLVLDRIQSLQRFQDTRVNRKALFGTMVE 345
 QY 401 PWDKCVNFISALPYVVGKAFVDVYQEDKKEEMELVEGVAFIDMLEKENEMDAG 460
 Db 346 VRMECVGYVNSNMENAVGSLYVEAFPGDSKMWVRELIDKVTVEVLELD-ELGMDEE 404
 QY 461 TKRAKAREKARAVLAKVGYPEFIMNDH--VNEDLAKIKSEADYFGNVLQTRKLAOS 516
 Db 405 SKKAQEKAMSIREQDGHDIYLEEMNRIDEYSNLNFSDDLFEENSLQMLKYGAGR 473
 QY 519 FWLRAVPTETFTNPTNAFYASTNOIRPAGLELOKPFMGTEYPRSLSYGAIYV 576
 Db 465 RKLREKVDPMILITIGAAVNAFYSPNRNOIYFPGIILPPF-SKEQOLNFGSIGIM 532
 QY 579 IVGHEFTGPDNNKRYDKNGNDLPMWSTSESEKFEKTKCMINQYSNTYWKAG-LNVK 635
 Db 524 GHEITHGDDNCRNFDKNGNMWMSNFTQHFRQSECMITQYQYNGNSMDLADQONV 592
 QY 636 GKRTLGENDNGGLREAFRAKRWINDRROGLEEPLLPITFTNNQLEFSLYAHNRCS 695
 Db 584 NTLGENIADNGCVROAYKAYLKKM--AEGKDQDLPGDLDITHQLEFTINAYQWCS 649
 QY 696 YRPEARQVOIGAHSPPOFRVNGAISNSEFOAKNCPNPNSTNNRMDSCRLM 749
 Db 641 YRPEAFQSIKTIVHSPDKRYVLSLQNLAAFDTFHCARGTPTH-PKECRHVM 702

Thu May 22 07:48:40 2003

us-09-913-955a-1.rag

Page 15

Search completed: May 21, 2003, 18:47:44
Job time : 84 secs

GenCore version 5.1.4.p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 21, 2003, 18:46:24 : Search time 30 seconds
(without alignments)
734.592 Million cell updates/sec

Title: US-09-913-955a-1

Perfect score: 3958

Sequence: 1 MEATGSSVETGKANKRGR.....AFNCPNSTMNGMDSCRLM 749

Scoring table: BLOSUM62

Gapop 10.0, Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database:

Issued Patents_AA:*
1: /cgn2_6/ptodata/1/1aa/5A.COMB.pep.*
2: /cgn2_6/ptodata/1/1aa/5B.COMB.pep.*
3: /cgn2_6/ptodata/1/1aa/6A.COMB.pep.*
4: /cgn2_6/ptodata/1/1aa/6B.COMB.pep.*
5: /cgn2_6/ptodata/1/1aa/PCITUS.COMB.pep.*
6: /cgn2_6/ptodata/1/1aa/backfile1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1257	31.8	703	US-08-646-273-25	Sequence 25, Appl
2	1257	31.8	753	US-08-646-273-36	Sequence 36, Appl
3	1248.5	31.5	758	US-08-289-112-2	Sequence 2, Appl
4	1241.5	31.4	708	US-08-646-273-23	Sequence 23, Appl
5	1241.5	31.4	754	US-08-646-273-30	Sequence 30, Appl
6	1184	29.9	787	US-08-574-763-2	Sequence 2, Appl
7	983.5	24.8	775	US-09-305-640-2	Sequence 2, Appl
8	963.5	24.3	567	US-08-646-273-19	Sequence 19, Appl
9	527.5	13.3	189	US-08-646-273-14	Sequence 14, Appl
10	246	6.2	181	US-09-305-640-4	Sequence 4, Appl
11	116	2.9	725	US-08-813-940-25	Sequence 25, Appl
12	114.5	2.9	990	US-08-393-625-20	Sequence 20, Appl
13	114.5	2.9	990	US-08-466-961A-20	Sequence 20, Appl
14	114.5	2.9	990	US-08-645-193B-15	Sequence 15, Appl
15	108	2.7	681	US-08-655-345-4	Sequence 4, Appl
16	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
17	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
18	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
19	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
20	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
21	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
22	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
23	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
24	108	2.7	681	US-09-183-275-4	Sequence 4, Appl
25	106.5	2.7	803	US-08-062-368-2	Sequence 2, Appl
26	105.5	2.7	548	US-09-601-091-2	Sequence 2, Appl
27	105	2.7	479	US-08-484-106-10	Sequence 10, Appl

28	105	2.7	479	US-08-484-106-10	Sequence 10, Appl
29	103.5	2.6	548	US-09-601-091-4	Sequence 4, Appl
30	103.5	2.6	548	US-09-398-395A-52	Sequence 52, Appl
31	103.5	2.6	878	US-09-255-829-12	Sequence 12, Appl
32	103.5	2.6	907	US-09-255-829-16	Sequence 16, Appl
33	103.5	2.6	953	US-09-255-829-14	Sequence 14, Appl
34	103.5	2.6	1013	US-09-255-829-18	Sequence 18, Appl
35	103	2.6	871	US-09-255-829-2	Sequence 2, Appl
36	103	2.6	871	US-09-255-829-8	Sequence 8, Appl
37	103	2.6	871	US-09-255-829-26	Sequence 26, Appl
38	103	2.6	873	US-09-255-829-6	Sequence 6, Appl
39	103	2.6	894	US-09-255-829-4	Sequence 4, Appl
40	103	2.6	1296	US-08-480-604A-28	Sequence 28, Appl
41	103	2.6	1296	US-08-405-496A-28	Sequence 28, Appl
42	103	2.6	1296	US-08-915-136-28	Sequence 28, Appl
43	103	2.6	1296	US-08-286-819A-29	Sequence 29, Appl
44	103	2.6	2291	US-08-980-357-29	Sequence 29, Appl
45	101.5	2.6	607	US-09-134-001C-2994	Sequence 2994, Ap

ALIGNMENTS

RESULT 1
US-08-646-273-25

Sequence 25, Application US/08646273

Patent No. 606502

GENERAL INFORMATION:

APPLICANT: Krieger, Burkhard, Seuburger, Harald, Meyer, Thomas, Schmidt,

APPLICANT: Martin, Jacob, Elard, Olier, Rainier, Subkowski, Thomas, Hellen, Heln

TITLE OF INVENTION: Endothelin Converting Enzyme (ECE).

NUMBER OF SEQUENCES: 36

CORRESPONDENCE ADDRESS:

ADDRESSER: Kell & Weinlauf

STREET: 1101 Connecticut Avenue

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20036

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage

COMPUTER: IBM AT-compatible, 80486 processor

OPERATING SYSTEM: MS-DOS version 6.0

SOFTWARE: WordPerfect version 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/646,273

FILING DATE: 16-NOV-1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/EP94/03706

FILING DATE: 11-NOV-1994

INFORMATION FOR SEQ ID NO: 25:

SEQUENCE CHARACTERISTICS:

LENGTH: 703 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: protein

US-08-646-273-25

Query Match 31.8%; Score 1257; DB 3; Length 703;
Best Local Similarity 37.6%; Pred. No 5.6e-115;
Matches 281; Conservative 126; Mismatches 276; Indels 64; Gaps 21;

OY 21 IALVFVGGTIVLTITFLVSGQLSLQAKQCEIKPECEIAAAAILSKYNLSYPCDNF 80
DB 3 VIVIVL-----LAAGIVACIALAGIOYCRSPSLSACVSVSSIISSMDPTVDPCHDF 58
OY 81 FRPACDGSISNNPPEDEMPISGVYFWLEHNDLTKELKESISRRDTEAIOKAKIYS 140
DB 59 FSYAGGKIKANPPVDPGSHRWGFTSNLMEHQALIKHLENSTA--SYSEKRAQYYIR 116
OY 141 SCMNEKAIEKADAKRLILRLHSPFRMPVLESNIGPEGVSEKRSILQTLATFRGOYSN 200

```

;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 753 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-646-273-36

Query Match      31.8%; Score 1257; DB 3; Length 753;
Best Local Similarity 37.6%; Pred. No. 6,3e-115;
Matches 281; Conservative 126; Mismatches 276; Indels 64; Gaps 21;

Db      117 ACNMTETRIEELRAKPLMELIERLG-GWNI-----TGPAKDNFQ--DILQVYTAHYRT 166
Qy      201 SVFIRLYVSPDDKASNEHILKLDQATSLAVREDYLDNSTEAKSYRAALKKEMVDATVLL 260
;      167 SPFSVYVYASADSKNSNSVIVDQSGIGLPSRDYLL-NKTENENYVLTGYLNYVQJLKL 225
Qy      261 GANSRA-EHDMKSVLRLEIKIAIMIPHENRTSEAM-YKMNISELSAMIPOFDMGYI 318
Db      226 GGGDEEAIROPQOQILFETALANITIPQEKRRDEELIYKVTAAELQTLAPAINLPLF- 284
Qy      319 KKVIDTLRYPLKDISPENNVVRVPOYKDLFRILGSEKTKITANTLVARMYYSRIPL 378
Db      285 ---LNTIFYP--VEINSEPIVVDKEYLEQISTLTINTDRCILNNMIMNLVTKTSSEFL 339
Qy      379 SRRQYRMLESRYIOGT-TTLTPQWDKCVNFESALPYVVGKMFVDVYPOEDKKEEMEE 437
Db      340 DQRFQDADEKFMEMYGTGKTKCLPRMKFCVSDPENNLGALGPMFKATFAEDSKSIAT 399
Qy      438 LVEGVRAFTDMLKEKEMMDAGTKRKAKEAVALAKVYPEFIM-----NDTHV 488
Db      400 ILEIKAFESL-STLKMDEETRSKAKADAIYIMIGYPNFINDPKELDKVENDYTA 458
Qy      489 NEDLKAIFSEADYFGNVLOTFRKYLAOSDFW-----LRKAVPTKEMFTNPTVAFYS 542
Db      459 VPDL-----YFENAMRF-----FNFSMVTADQLRKANRQMSMTPTPMVAAYIS 503
Qy      543 ASTNOIRFPAGELQKPPFWGTEYPRSLSTYGALGIVYGHFTGFDNNGRKYDKNGNLDPW 602
Db      504 PTNKEIVFPAGILOAPFYTRSS-PKALNFGGIGVVGHELTAFADQGREYDKDGLRPM 562
Qy      603 WSESEKFEKTKCMINQYSNYVMKAGLANKGRTIGENTADNGLEAREATRKWTN 662
Db      563 WKNSVYEAFRQTECEVQYSNT--SYNGEPVNGRTTLENTADNGLEAARAVQNW- 619
Qy      663 DRQGLLEPLPGITFTNNQLEFLSYAHVRCNSYREARQVOIGAHSPPOFRVNGAIS 722
Db      620 -KNGAEHS-LPTLGLTNQLEFLGFAQWCSVRTPESHGELIDPHSPSFRVIGSIS 677
Qy      723 NSEEFQAFNCPPNSTMNGMDSCLRM 749
Db      678 NSKEFSEHRCPPGSPMN-PRHKEVW 703

RESULT 2
; US-08-646-273-36
; Sequence 36, Application US/08646273
; Patent No. 6065502
; GENERAL INFORMATION:
; APPLICANT: Kroege, Burkhard, Seuburger, Harald, Meyer, Thomas, Schmidt,
; APPLICANT: Martin, Jacob, Elard, Oter, Rainer, Subkowski, Thomas, Hellen, Heinz.
; TITLE OF INVENTION: Endothelin Converting Enzyme (ECE).
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kell & Weinkauff
; STREET: 1101 Connecticut Avenue
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.4 MB storage
; OPERATING SYSTEM: MS-DOS version 6.0
; SOFTWARE: WordPerfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/646, 273
; FILING DATE: 16-NOV-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP94/03706
; FILING DATE: 11-NOV-1994
; INFORMATION FOR SEQ ID NO: 36:

```

```

;
; SEQUENCE CHARACTERISTICS:
; LENGTH: 753 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; US-08-646-273-36

Query Match      31.8%; Score 1257; DB 3; Length 753;
Best Local Similarity 37.6%; Pred. No. 6,3e-115;
Matches 281; Conservative 126; Mismatches 276; Indels 64; Gaps 21;

Qy      21 IALVYFGGTLVGLITFLVSGILSLQAKQECIAKPCICIAAAIISKVLSPDCDF 80
Db      53 VLVVL-----LAAGLVACLAAGIQYRRSPVCSLSEACVSTSLISSMDPTVPCDF 108
Qy      81 FEPACDGIWNNIPEDMPSYGVYPMVLRNVDLKLKELLEISISRRDTEAIGAKIYS 140
Db      109 FSYACGGWIKANPVDPGHSRWGTFENLWEHNOAIKHLLENSTA--SYSEAKRAQYYR 166
Qy      141 SCMNKAIEKADAPLILHNSPPRPVLENSIGPEVSEKRFSLQTLAFRGQYSN 200
Db      167 ACNMTETRIEELRAKPLMELIERLG-GWNI-----TGPAKDNFQ--DILQVYTAHYRT 216
Qy      201 SVFIRLYVSPDDKASNEHILKLDQATSLAVREDYLDNSTEAKSYRAALKKEMVDATVLL 260
Db      217 SPFSVYVYASADSKNSNSVIVDQSGIGLPSRDYLL-NKTENENYVLTGYLNYVQJLKL 275
Qy      261 GANSRA-EHDMKSVLRLEIKIAIMIPHENRTSEAM-YKMNISELSAMIPOFDMGYI 318
Db      276 GGGDEEAIROPQOQILFETALANITIPQEKRRDEELIYKVTAAELQTLAPAINLPLF- 334
Qy      319 KKVIDTLRYPLKDISPENNVVRVPOYKDLFRILGSEKTKITANTLVARMYYSRIPL 378
Db      335 ---LNTIFYP--VEINSEPIVVDKEYLEQISTLTINTDRCILNNMIMNLVTKTSSEFL 389
Qy      379 SRRQYRMLESRYIOGT-TTLTPQWDKCVNFESALPYVVGKMFVDVYPOEDKKEEMEE 437
Db      390 DQRFQDADEKFMEMYGTGKTKCLPRMKFCVSDPENNLGALGPMFKATFAEDSKSIAT 449
Qy      438 LVEGVRAFTDMLKEKEMMDAGTKRKAKEAVALAKVYPEFIM-----NDTHV 488
Db      450 ILEIKAFESL-STLKMDEETRSKAKADAIYIMIGYPNFINDPKELDKVENDYTA 508
Qy      489 NEDLKAIFSEADYFGNVLOTFRKYLAOSDFW-----LRKAVPTKEMFTNPTVAFYS 542
Db      509 VPDL-----YFENAMRF-----FNFSMVTADQLRKANRQMSMTPTPMVAAYIS 553
Qy      543 ASTNOIRFPAGELQKPPFWGTEYPRSLSTYGALGIVYGHFTGFDNNGRKYDKNGNLDPW 602
Db      554 PTNKEIVFPAGILOAPFYTRSS-PKALNFGGIGVVGHELTAFADQGREYDKDGLRPM 612
Qy      603 WSESEKFEKTKCMINQYSNYVMKAGLANKGRTIGENTADNGLEAREATRKWTN 662
Db      613 WKNSVYEAFRQTECEVQYSNT--SYNGEPVNGRTTLENTADNGLEAARAVQNW- 669
Qy      663 DRQGLLEPLPGITFTNNQLEFLSYAHVRCNSYREARQVOIGAHSPPOFRVNGAIS 722
Db      670 -KNGAEHS-LPTLGLTNQLEFLGFAQWCSVRTPESHGELIDPHSPSFRVIGSIS 727
Qy      723 NSEEFQAFNCPPNSTMNGMDSCLRM 749
Db      728 NSKEFSEHRCPPGSPMN-PRHKEVW 753

RESULT 3
; US-08-289-112-2
; Sequence 2, Application US/08289112
; Patent No. 5688640
; GENERAL INFORMATION:
; APPLICANT: Tanigisawa, Masashi
; TITLE OF INVENTION: Endothelin Converting Enzyme-1: A
; TITLE OF INVENTION: Membrane-Bound Metalloprotease That Catalyzes The
; TITLE OF INVENTION: Proteolytic Activation of Big Endothelin-1

```

```

: NUMBER OF SEQUENCES: 5
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Arnold, White & Durkee
: STREET: P. O. Box 4433
: CITY: Houston
: STATE: TX
: COUNTRY: USA
: ZIP: 77210-4433
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/289,112
: FILING DATE: 10-APR-1994
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Parker, David L.
: REGISTRATION NUMBER: 32,165
: REFERENCE/DOCKET NUMBER: US/08/414/PAR
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 713-787-1400
: TELEFAX: 713-789-2679
: TELEX: 79-0924
: INFORMATION FOR SEQ ID NO: 2:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 758 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
: US-08-289-112-2

```

```

Query Match      31.5%; Score 1248.5; DB 1; Length 758;
Best Local Similarity 37.9%; Pred. No. 4.4e-114;
Matches 282; Conservative 121; Mismatches 281; Indels 61; Gaps 21;

```

```

QY 23 LVVVGGLTILVLTILVSGLLSLQAKQCYCLKEPCIEAAALISKYNLSVPCDNFRR 82
DB 57 LVVVL-ALLAAALVACLAIVLGIOYQTRPVSCLSEGCISVTSILSSMDPTVPQDFF 115
QY 83 PACDGMISNPIDEDMPCSYGVFWLRHNVDLKLLEKISRRTDPAIOKAKILYSSC 142
DB 116 YACGGMKINPDPGHSRGTSPNLMENQALIKHLENSTA--SVSEAKRAQAYYRAC 173
QY 143 MNEKAIKADAKPLHLILHSPFPMVLESNIGPEGVSEKRESLQTLATFRGYSNSV 202
DB 174 MNEIRIELKAKPLMELIELKLG-GWNT-----TGPMDKDNFQ--DTLQVYTSHTSP 223
QY 203 FTRLYVSPDDKASNEHILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFWDAVLLGA 262
DB 224 FFSYVVSADSKNSNSNVIOVDQSGLGPSRDYTL-NKTENEKVLGYLNYMVQLKLLGG 282
QY 263 NS-SRAEDHAKSVLKEIKIAEIMIPHENRTSEAM-YNNKMSISELSAMIPQDWLGYTK 320
DB 283 GAEDTIRPQMOOILDFETALANITTPQEKRRDEELIYHKVPAAELOTLAPAINMLPF--- 339
QY 321 VDTFRYLPLKDISPENNVAVVPQYFKDLPRILGSEKRTIANTLVWRMYRSRPNLSR 380
DB 340 -LNTLFYF--VEINSEPTVIYDKETLSKVSLLINSTKCLNNMIMNVLKRTSSFLDQ 396
QY 381 RFQYRWLEFSRYLQGT-TTLLPQMDKCVNFTESALPYVVGKAFVDVYQEDKEKMEELV 439
DB 397 RFQDADEKFEWYGTCTKICLPFRMKFCVSDENTLGFALGPWFVAKATPAEDSKNIASTII 456
QY 440 EGVRAAFIDMLEKENMDAGTKRKAKEKARAVLAKVGYPEETM-----NDTHVNE 490
DB 457 IEIKAFEEEST-STLKWDEDETRKSAKEKADAIYNNMIGYPNFIMDKELDKVFNVTYAVP 515
QY 491 DTKATKFSADYFGNVLTQRTKYLQSDFFW-----LKRVPKTPWFNTPTVNAFVAS 544
DB 516 DL-----YFENAMF-----FNFSWRYTADQLKAPKRDQMSKTPPVNNAIYSP 560

```

```

QY 545 TNQIRPAGELQKPFWGTERTSLSYGAIGVIGHEFTGPDNGRKRYDNGNLDPMWS 604
DB 561 KNEIYFAGILQAPFYTRSS-PNALNFGGIGVYGHLLTAFPDQGEYKDNLRPMWK 619
QY 605 TESEKREKTKMINOISNYWKRAJLNYKGRKTIGENIADNGGLEAFRAYRKWINDR 664
DB 620 NSSVEAFKQOTACWEQYGN--SVNGEPVNGRHTLTGENIADNGLEKAAVRAVQNVW--K 675
QY 665 RQGLEPPLRGITITNNQPLFLSAHYRCHNSYRREARQVOIGAHSPQPRNGAISNS 724
DB 676 KNGAEQ-TLPTPLGLTNQPLFLSFGYQVCSVRPESSHEGLITDPHSRFRVIGSISNS 734
QY 725 EEFQAFNCPPNSYNNRGMDSCLRM 749
DB 735 KEFSEHHCPPGSPMN-PHEKCEVW 758

```

```

RESULT 4
US-08-646-273-23
: Sequence 23, Application US/08646273
: Patent No. 6065502
: GENERAL INFORMATION:
: APPLICANT: Kroeger, Burkhard, Seubberger, Harald, Meyer, Thomas, Schmidt,
: APPLICANT: Martin, Jacob, Elard, Otter, Rainer, Subkowski, Thomas, Hille, Hein
: TITLE OF INVENTION: Endothelin Converting Enzyme (ECE).
: NUMBER OF SEQUENCES: 36
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Keil & Weinkeuf
: STREET: 1101 Connecticut Avenue
: CITY: Washington
: STATE: D.C.
: COUNTRY: USA
: ZIP: 20036
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
: COMPUTER: IBM AT-compatible, 80486 processor
: OPERATING SYSTEM: MS-DOS version 6.0
: SOFTWARE: WordPerfect version 5.1
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/646,273
: FILING DATE: 16-NOV-1994
: CLASSIFICATION: 435
: PRIOR APPLICATION NUMBER:
: APPLICATION NUMBER: PCT/EP94/03706
: FILING DATE: 11-NOV-1994
: INFORMATION FOR SEQ ID NO: 23:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 708 amino acids
: TYPE: amino acid
: TOPOLOGY: linear
: MOLECULE TYPE: protein
: US-08-646-273-23

```

```

Query Match      31.4%; Score 1241.5; DB 3; Length 708;
Best Local Similarity 37.9%; Pred. No. 1.9e-113;
Matches 282; Conservative 120; Mismatches 282; Indels 61; Gaps 21;

```

```

QY 23 LVVVGGLTILVLTILVSGLLSLQAKQCYCLKEPCIEAAALISKYNLSVPCDNFRR 82
DB 7 LVVVL-ALLAAALVACLAIVLGIOYQTRPVSCLSEGCISVTSILSSMDPTVPQDFF 65
QY 83 PACDGMISNPIDEDMPCSYGVFWLRHNVDLKLLEKISRRTDPAIOKAKILYSSC 142
DB 66 YACGGMKINPDPGHSRGTSPNLMENQALIKHLENSTA--SVSEAKRAQAYYRAC 123
QY 143 MNEKAIKADAKPLHLILHSPFPMVLESNIGPEGVSEKRESLQTLATFRGYSNSV 202
DB 124 MNEIRIELKAKPLMELIELKLG-GWNT-----TGPMDKDNFQ--DTLQVYTSHTSP 173
QY 203 FTRLYVSPDDKASNEHILKLDQATLSLAVREDYLDNSTEAKSYRDALYKFWDAVLLGA 262
DB 174 FFSYVVSADSKNSNSNVIOVDQSGLGPSRDYTL-NKTENEKVLGYLNYMVQLKLLGG 232

```


QY 658 RKNWINDROGLELEPLIGITFTNNOLFSLYAHVRCNSYRPARARQVIGAHSPQRY 717
Db 688 KQWV--REHGPBHP-LPRLKTYTHDQLEFIAFQNMCKIKRSOSIYLQVLTDKHADEHYR 744
QY 718 NGAISNEEFQKAPNCPNPNSTNRGMDSCRLW 749
Db 745 LGSVSOFEERGFACHPKDSPMNPA-HKCSVW 775

RESULT 8

US-08-646-273-19
; Sequence 19, Application US/08646273
; Patent No. 606502
; GENERAL INFORMATION:
; APPLICANT: Kroeger, Burkhard, Seubberger, Harald, Meyer, Thomas, Schmidt,
; TITLE OF INVENTION: Martin, Jacob, Elard, Otter, Rainer, Subkowski, Thomas, Hillen,
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Kell & Weinlauf
; STREET: 1101 Connecticut Avenue
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
; COMPUTER: IBM AT-compatible, 80486 processor
; OPERATING SYSTEM: MS-DOS version 6.0
; SOFTWARE: WordPerfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/646,273
; FILING DATE: 16-NOV-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP94/03706
; FILING DATE: 11-NOV-1994
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 567 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-646-273-19

Query Match 24.3%; Score 963.5; DB 3; Length 567;
Best Local Similarity 37.7%; Fred. No. 3.8e-86;

Matches 226; Conservative 96; Mismatches 216; Indels 61; Gaps 21;

QY 106 WLRHNVDTKLEKLEKISRRRDTFAQAKIYSSCMNKAIEKADAPLHLHSHPF 165
Db 12 W-EHNOAI-IKHLNSTA--SVSEARNDQDEYRACMETRIEELKAKPMELIEKLG- 66
QY 166 RWPVLESNIGPEGYSRKSLSIQTATFRGQYNSVFIRLYVSPDKASNEHILKDA 225
Db 67 GWNV-----TGPWMDNFQ--DTLOVYSHYHTSPFSYVSADKSNNSNVIGQDS 117
QY 226 TLSIAVEDYLDNSTEAKSYRDALYKEMVDTAVILGANS-SRAEHMKVYVLEKIAEI 284
Db 118 GLGPSNDYLL-NKTEHEKVLGYLYNMQGLKLGGAEDTIRPQMOOILDEFETALNI 176
QY 285 MIPHEINTSEAM-YKNMINSLSAMIPQFMDLYIKVYDTRLYPHLKDISSENVVRY 343
Db 177 TTPQEKREDELLYHKYTAELQTLAPAINMLPE---LNTIFYP--VEINSSEPIAYD 230
QY 344 POFENDFRILGSEKRTIANYLVMMVYSRIPNLSRRQYMWLESPRYIOGT-TLLPQ 402
Db 231 KEILSVSTILNSTKCLNNYIMVNLVKTSSPFDORQDADEKFMVMTGKTKCLPR 290
QY 403 WDCVNFISALPYVVGKMFVDYVQEDKKEKMEELVEGVRAFLDMLKEMEMDAGTK 462
Db 291 WKFCVSDTEMTLGFALGPRFVFKATFREDSKNIASELILEIKAFESL-STLKWMEDETR 349

QY 463 RKAKEKARAVLAKVGYEFTIM-----NDTHVNEDLKATKSEADYFGNVLOTIRYL 513
Db 350 KSAKEKADAIYNNIGYFNPINIMDKELDKFNYTAVPDL-----YFENAKF----- 396
QY 514 AQSDFW-----LRKAVKTEMTFTNPTVNAFYSASTNOIRFPAGELQKPFPGTEYPR 567
Db 397 --FNFMSRYTADQLRRKAPNRDQMSMTPPVNAVYSPTKNEIVFPAGILQAFYTRSS-PN 453
QY 568 SLISYGAIVYVGHFTHGFDNNGRKRYDKNGNDLPWMTSESEKREKTKMINYSYTW 627
Db 454 ALNFGSIGVYVGHFTHGFDNNGRKRYDKNGNDLPWMTSESEKREKTKMINYSYTW 627
QY 628 KKAAGLVKGRKRLGENIADNGGLREAFRAYRKWINDROGLELEPLIGITFTNNOLF 686
Db 512 SVNGEVPVNGRHTLGENIADNGGLKAAVAYQNMV--KKNAGQ-TLPITGLTNNQLEFL 567

RESULT 9

US-08-646-273-14
; Sequence 14, Application US/08646273
; Patent No. 606502
; GENERAL INFORMATION:
; APPLICANT: Kroeger, Burkhard, Seubberger, Harald, Meyer, Thomas, Schmidt, Hein
; TITLE OF INVENTION: Martin, Jacob, Elard, Otter, Rainer, Subkowski, Thomas, Hillen,
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Kell & Weinlauf
; STREET: 1101 Connecticut Avenue
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
; COMPUTER: IBM AT-compatible, 80486 processor
; OPERATING SYSTEM: MS-DOS version 6.0
; SOFTWARE: WordPerfect version 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/646,273
; FILING DATE: 16-NOV-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP94/03706
; FILING DATE: 11-NOV-1994
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 189 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-646-273-14

Query Match 13.3%; Score 527.5; DB 3; Length 189;
Best Local Similarity 51.8%; Fred. No. 6.6e-44;

Matches 101; Conservative 32; Mismatches 55; Indels 7; Gaps 5;

QY 555 LQKPFWEGETEYPRSLSYGAIVYVGHFTHGFDNNGRKRYDKNGNDLPWMTSESEKREK 614
Db 2 LQAPFYTRSS-PAALNFGGIGVYVGHFTHGFDNNGRKRYDKNGNDLPWMTSESEKREK 60
QY 615 TKCMINQYSYTWKKAAGLVKGRKRLGENIADNGGLREAFRAYRKWINDROGLELEPL 674
Db 61 TACMVQDQYNY-SVNGEVPVNGRHTLGENIADNGGLKAAVAYQNMV--KKNAGQ-TLP 115
QY 675 GITEFTNNOLFSLYAHVRCNSYRPARARQVIGAHSPQRYVNGAISNEEFQKAPNCP 734
Db 116 TLTGLTNNOLFSLYAHVRCNSYRPARARQVIGAHSPQRYVNGAISNEEFQKAPNCP 175
QY 735 PNSTANRGMDSCRLW 749
Db 176 PGSPMN-PHMKCEVW 189

RESULT 10
US-09-305-640-4
Sequence 4, Application US/09305640B
Patent No. 6255468
GENERAL INFORMATION:
APPLICANT: SmithKline Beecham plc
TITLE OF INVENTION: No. 6255468el Compounds
FILE REFERENCE: GP30124
CURRENT APPLICATION NUMBER: US/09/305,640B
CURRENT FILING DATE: 1999-05-05
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 4
LENGTH: 181
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: UNSURE
LOCATION: (134)(145)(162)
US-09-305-640-4

Query Match 6.2%; Score 246; DB 4; Length 181;
Best Local Similarity 32.6%; Pred. No. 3.9e-16;
Matches 62; Conservative 36; Mismatches 76; Indels 16; Gaps 5;

QY 476 VGPETIMNDHYNEDLKAKFSEADYFGNVIQTRKIYLAQSPFMRKAVPTKEMFTNPT 535
DB 1 VGPEDILKPDVADKEYE-FEVHEKTYFKNNIINSIFSLQSVKKIROBVDKSTWLLPQ 59
QY 536 TVNAFASASTNOIRPAGELQKPFWGTETPRSLSYGAIGVIGHEFTGFPNNNG----- 590
DB 60 ALNAYILPKNNQWVFAAGLQ-PTLYDPDFPOSINAGGIGITIIHGLTHGIGLGGPVVL 118
QY 591 RKYKNGNDPWWSTSEKFEKTKCMINQYSNYYWKRAGLNVKGR--TLGENTADNG 648
DB 119 REPACTGGEFASLQPSCEKLSASFPXLMTTFN-----VLQPGRETYWENIAVWG 171
QY 649 GLEAFRAFR 658
DB 172 GLKLAYHAIR 181

RESULT 11
US-08-813-940-25
Sequence 25, Application US/08813940
Patent No. 5834279
GENERAL INFORMATION:
APPLICANT: Rubin, Harvey
APPLICANT: Yang, Jude
APPLICANT: Avaribock, David
APPLICANT: Curran, Sean
TITLE OF INVENTION: Methods of Identifying Compounds that
TITLE OF INVENTION: Inhibit DNA Synthesis in Mycobacterium Tuberculosis and
TITLE OF INVENTION: Composition, Reagents and Kits for Performing the Same
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5834279rls
STREET: One Liberty Place, 46th Floor
CITY: Philadelphia
STATE: Pennsylvania
COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: Windows
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/813,940
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/612,271
FILING DATE: 07-MAR-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Deluca, Mark
REGISTRATION NUMBER: 33,229
REFERENCE/DOCKET NUMBER: UPAP-0220
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 725 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-813-940-25

Query Match 2.9%; Score 116; DB 2; Length 725;
Best Local Similarity 19.5%; Pred. No. 0.029;
Matches 139; Conservative 113; Mismatches 242; Indels 218; Gaps 37;

QY 109 HNDIKELLESISRRDTEAIQAKILYSSCMEKALEKADKLLHLRSPRMP 168
DB 68 HNDKELLYLIRENYER---EVLDO---YSRNFVTLDDRAVAK-----KFRFP 111
QY 169 VLESNIGEGVMSKESKSLQTLATPFGQ-----YNSVYIRLYSPDDKASNEHLKL 222
DB 112 TFLGAF-----KITYSTLTKTFDCKRIKLEFEDRVVWVALLTAGDALLAEV-- 160
QY 223 DQATLSLAVRDYLDNSTEAKSYNDALYKFWVDYAVLLGA-NSSRAEDMKSVLRLEIKI 281
DB 161 -----DEIIDG-----RFQPAITPFLNSGKRGEPVSCFLLRVDNM 198
QY 282 AEIMPHENRISSEAMYNKMINSELAMTPQPDWLGVIKVIDTLYLH--LKDISESN 338
DB 199 ESI-----GRSINSALQSKRGGV-----ALLTPIREGAIKNIEMOSS 240
QY 339 VVVRVPOYFKDLER--LGESEKKTIANYL-----VWRVYRIPNLSRRPOYRWLEF 389
DB 241 GYIPIMKLEDAFSTANOLGA-RQAGAVYLHAHPDIYRFLDKREADEKIRIKTLSTL 299
QY 390 SRVIGTTTLLPQWDKCVNFIESALPYVVGKMFVDVYFOEDKKEMELVGVMAPIDM 449
DB 300 GVVIDITFELAKRNDWYLF--PYDY-----ERYVGVPADISV 338
QY 450 LEKENMDAGTKRKKAR--AVLAKY-----GYPEFINMD-----TH-- 487
DB 339 TEKYYEMVDARIRKTKIKAREFQTLAELOPESGYPIIMFEDVYVNRANPDGKITHSNL 398
QY 488 -----VNEDLKAKFSEADYFGNV--LQTRKIYLAQSPF-----FMR----- 522
DB 399 CSEILQVSTPLFNDLSYAKVK-DISCNLSLNIATMSPDAQTEIVAIRLFAVR 457
QY 523 -----KAVPKTEWTFNPTVNAFYASSTNOIRPAGELQKPFWGT-----YPSL 569
DB 458 HQTHIKSVSIRQGNDS-----HAIGQOMLHGYLARERIFYSDGIDETNIYETV 512
QY 570 SYGALGV---YGHFETH--GFDNNGRYDKKNGNDPWWSTSEKFEKTKCMINQYSN 624
DB 513 LYHALPASNRILIEGTHKGFERS--KYASEEFDKY---TDIWEPRKQKVAQLFAD 566
QY 625 YYWKRAGLNVKGRRLGENIADNGILREAFRAYRWINDRQGLEPILPGITFTNNOLF 684
DB 567 -----AGIRIPQ-----DWRRLKESVQH-----GIYNOMLQAVPPG-- 602
QY 685 FLSYAHVRCNSYRPEARQV---QIG-AHPPQPRVNGAISNEEOKAF 731
DB 603 -ISYINHTSISHPYISKVYKREKIGRYVPADYMN---DNLEYEDAI 650

RESULT 12
US-08-392-625-20

RESULT 13
 US-08-466-961A-20
 : Sequence 20, Application US/08466961A
 : Patent No. 5843709
 :
 : GENERAL INFORMATION:
 : APPLICANT: Entlian, Karl-Dieter
 : APPLICANT: G tz, Friedrich
 : APPLICANT: Schnell, No. 5843709bert
 : APPLICANT: Augustin, Johannes
 : APPLICANT: Engelke, Gernar
 : APPLICANT: Rosenstein, Ralf
 : APPLICANT: Kaletta, Cortina
 : APPLICANT: Klein, Cora
 : APPLICANT: Wieland, Bernd
 : APPLICANT: Kupke, Thomas
 : APPLICANT: Jung, G nther
 : APPLICANT: Kellner, Roland
 : TITLE OF INVENTION: Biosynthetic Process for the Preparation of
 : TITLE OF INVENTION: Chemical Compounds
 : NUMBER OF SEQUENCES: 42
 : CORRESPONDENCE ADDRESS:
 : ADDRESSEE: Sterne, Kessler, Goldstein & Fox
 : STREET: 1100 New York Avenue, NW
 : CITY: Washington
 : STATE: D.C.
 : COUNTRY: U.S.A.
 : ZIP: 20005
 :
 : COMPUTER READABLE FORM:
 : MEDIUM TYPE: Floppy disk
 : COMPUTER: IBM PC compatible
 : OPERATING SYSTEM: PC-DOS/MS-DOS
 : SOFTWARE: PatentIn Release #1.0, Version #1.25
 : CURRENT APPLICATION DATA:
 : APPLICATION NUMBER: US/08/466,961A
 : FILING DATE: 06-JUN-1995
 : CLASSIFICATION: 435
 :
 : PRIOR APPLICATION DATA:
 : APPLICATION NUMBER: US 08/392,625
 : FILING DATE: 22-FEB-1995
 : PRIOR APPLICATION NUMBER:
 : APPLICATION NUMBER: US 07/876,791
 : FILING DATE: 30-APR-1992
 :
 : PRIOR APPLICATION DATA:
 : APPLICATION NUMBER: US 07/784,234
 : FILING DATE: 31-OCT-1991
 : ATTORNEY/AGENT INFORMATION:
 : NAME: Esmond, Robert W.
 : REGISTRATION NUMBER: 32,893
 : REFERENCE/DOCKET NUMBER: 0652, 0980004
 : TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 371-2600
 TELEFAX: (202) 371-2540
 INFORMATION FOR SEQ ID NO: 20:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 990 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 US-08-466-961A-20

Query Match 2.9% Score 114.5; DB 2; Length 990;
 Best Local Similarity 19.6% Pred. No. 0.07; Indels 149; Gaps 30;

Matches 107; Conservative 92; Mismatches 199; Indels 149; Gaps 30;

QY 196 GQYSNSVFIRLYSPDDKASNEHIILKDAQATLSLAVREYLDNSTEAKSYRDAL-----Y 250
 DB 104 GFSENNNIKI-----KDSFHKDKVKGQMWIKLVH--YLE--SDYTYKDSFVIMNQ 155
 QY 251 KFMVDVAVLLGANSRAEDKMSVRLKIAEIMIPHENRTSEAMYNK-----300
 DB 156 NYIYNRRLYLDNNSSTTEKRNVDLSVKYNSILVFI--HNSKKNITYEELVOLISSKYSI 214
 QY 301 -NISELSAMIPQDMLGYIKKYIDRLYPHLKDISENVVAVVPQYKDFRILGSEK 359
 DB 215 ENKEEVAVVOEL-----INKEIIFSDLRPTLENKNP-----IDYIINSLNP 256
 QY 360 KTIANYLVWAV-----YSRIPNLSRRFOYRWLEFSRVIGTTLTPQWDKCVNFI 411
 DB 257 K--NSLVGTLINISNEITKYSKMP--LGKGEYKLDI-----VNLMSQLFVSKNYIQ 304
 QY 412 SALPYVVGKMFVYVYQEDKKEAMELYEGV--RWAFIDMLEKENMDAGTKRAKAKAR 470
 DB 305 -----IDYIIDSRLNELKOSLADNISEAVYIIMLSPNHF---GTRTIR----- 345
 QY 471 AVLAQVGYPEFIMNDTHVNDLKAIR--FSEADYFGNVLOTREKYLAOSDFEMLRK---A 524
 DB 346 -----NYHEFEF--DKYGFQQLVNLKOLSLDINGFG--YPKKDSYSFSNNIAFLKRYLLA 397
 QY 525 VKPTW--FTNPTVNAFYSASTNOIRPAG--ELQKPFWGTEYPRSLSYGAIGVVGHE 581
 DB 398 IONNSHIEITENDVKNLEKNTVSKINAPVSTIYSEIYFNGSIKGYEDFAVISPLIGS- 456
 QY 582 FTGFGDNGGKRYK--NGNLDPMWSTSESEKREKTKCMINOYSN-----YMKAG 631
 DB 457 -----FNAGATFGRTGNF-----NIRKKNOLOKEIYVHHYNNVNNENDELSIQLENP 504
 QY 632 LNVGKRTIGENIADNGGLREAFRAYRKWINDRQGLEP-----LLPGITFTNNOL 683
 DB 505 LNSRNVNILLNN-----RIYNTCLN-----LNPKSDIDINDIFIGATF--NKL 546
 QY 684 FFLSYAH 690
 DB 547 YLYSEKH 553

RESULT 14
 US-08-645-193B-15
 Sequence 15, Application US/08645193B
 Patent No. 5962253
 GENERAL INFORMATION:
 APPLICANT: Kupke, Thomas
 APPLICANT: Goltz, Friedrich
 APPLICANT: Kempfer, Christoph
 APPLICANT: Jung, Gunther
 TITLE OF INVENTION: Oxidative Decarboxylation of Peptides
 TITLE OF INVENTION: Catalyzed by Flavoprotein EpiD
 NUMBER OF SEQUENCES: 70
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
 STREET: 1100 New York Avenue, Suite 600
 CITY: Washington
 STATE: D.C.
 COUNTRY: U.S.A.
 ZIP: 20005

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/645,193B
 FILING DATE: 13-MAY-1996
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Esmond, Robert W.
 REGISTRATION NUMBER: 32,893
 REFERENCE/DOCKET NUMBER: 0652.1540000
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 371-2600
 TELEFAX: (202) 371-2540
 INFORMATION FOR SEQ ID NO: 15:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 990 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: not relevant
 MOLECULE TYPE: protein
 US-08-645-193B-15

Query Match 2.9% Score 114.5; DB 2; Length 990;
 Best Local Similarity 19.6% Pred. No. 0.07; Indels 149; Gaps 30;

Matches 107; Conservative 91; Mismatches 200; Indels 149; Gaps 30;

QY 196 GQYSNSVFIRLYSPDDKASNEHIILKDAQATLSLAVREYLDNSTEAKSYRDAL-----Y 250
 DB 104 GFSENNNIKI-----KDSFHKDKVKGQMWIKLVH--YLE--SDYTYKDSFVIMNQ 155
 QY 251 KFMVDVAVLLGANSRAEDKMSVRLKIAEIMIPHENRTSEAMYNK-----300
 DB 156 NYIYNRRLYLDNNSSTTEKRNVDLSVKYNSILVFI--HNSKKNITYEELVOLISSKYSI 214
 QY 301 -NISELSAMIPQDMLGYIKKYIDRLYPHLKDISENVVAVVPQYKDFRILGSEK 359
 DB 215 ENKEEVAVVOEL-----INKEIIFSDLRPTLENKNP-----IDYIINSLNP 256
 QY 360 KTIANYLVWAV-----YSRIPNLSRRFOYRWLEFSRVIGTTLTPQWDKCVNFI 411
 DB 257 K--NSLVGTLINISNEITKYSKMP--LGKGEYKLDI-----VNLMSQLFVSKNYIQ 304
 QY 412 SALPYVVGKMFVYVYQEDKKEAMELYEGV--RWAFIDMLEKENMDAGTKRAKAKAR 470
 DB 305 -----IDYIIDSRLNELKOSLADNISEAVYIIMLSPNHF---GTRTIR----- 345
 QY 471 AVLAQVGYPEFIMNDTHVNDLKAIR--FSEADYFGNVLOTREKYLAOSDFEMLRK---A 524
 DB 346 -----NYHEFEF--DKYGFQQLVNLKOLSLDINGFG--YPKKDSYSFSNNIAFLKRYLLA 397
 QY 525 VKPTW--FTNPTVNAFYSASTNOIRPAG--ELQKPFWGTEYPRSLSYGAIGVVGHE 581
 DB 398 IONNSHIEITENDVKNLEKNTVSKINAPVSTIYSEIYFNGSIKGYEDFAVISPLIGS- 456
 QY 582 FTGFGDNGGKRYK--NGNLDPMWSTSESEKREKTKCMINOYSN-----YMKAG 631
 DB 457 -----FNAGATFGRTGNF-----NIRKKNOLOKEIYVHHYNNVNNENDELSIQLENP 504
 QY 632 LNVGKRTIGENIADNGGLREAFRAYRKWINDRQGLEP-----LLPGITFTNNOL 683
 DB 505 LNSRNVNILLNN-----RIYNTCLN-----LNPKSDIDINDIFIGATF--NKL 546
 QY 684 FFLSYAH 690
 DB 547 YLYSEKH 553

RESULT 15
 US-08-655-345-4
 Sequence 4, Application US/08655345

Patent No. 5830742
 GENERAL INFORMATION:
 APPLICANT: Black, Roy A.
 APPLICANT: Rauch, Charles
 APPLICANT: March, Carl J.
 APPLICANT: Cerretti, Douglas P.
 TITLE OF INVENTION: TNF- α CONVERTING ENZYME
 NUMBER OF SEQUENCES: 9
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Immunex Corporation
 STREET: 51 University Street
 CITY: Seattle
 STATE: WA
 COUNTRY: USA
 ZIP: 98101
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: Apple Macintosh
 OPERATING SYSTEM: Apple Operating System 7.5.2
 SOFTWARE: Microsoft Word for Apple, Version 6.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/655,345
 FILING DATE:
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/504,614
 FILING DATE: 20-JUL-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/428,458
 FILING DATE: 8-JUN-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Malaska, Stephen L.
 REGISTRATION NUMBER: 32,655
 REFERENCE/DOCKET NUMBER: 2507-B
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 587-0430
 TELEFAX: (206) 233-0644
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 681 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-655-345-4

Query Match 2.7% Score 108; DB 2; Length 681;

Best Local Similarity 18.98; Pred. No. 0.16; Indels 266; Gaps 38;

Matches 140; Conservative 96; Mismatches 237; Indels 266; Gaps 38;

QY 93 PIPEMPGVYVWLRHNVDLKLEKLEKSSRRRDEALQAKILYSSCMNEKAIEKAD 152
 DB 1 PRPPDPGFGH-----QRLKLDLSLDYD-----ILSLNIOGHSVRKRD 42
 QY 153 AKPLIHT--LRHSEFRMPVLESNIGPGVSEKRFSLQTLATFRGOYSNVFIRLYVS 209
 DB 43 LQTSFHVETLLTFSAK-----RHFKLYLTSSTERFSQNFV-----VV 81
 QY 210 PDDKASNHILKLDQATISLAVREDYLDNSTEAKSYRDALKKFWADAVILGANSRAEH 269
 DB 82 VDGKNESEYTKWODFTGHVGEF--DSRYLA-----HIRDDVITIRINTDGAHY 130
 QY 270 DMKSVLRLEIKIAELIMPHENTSE--AMYNKNISLSAM-IPQDFMLGIYKRIKVIDTR 325
 DB 131 NIEPLMR-----VNDTKDKRMLLYKSEDIKNVSRLOSPKV--CGYLKVDNEEL 177
 QY 326 LYPHLKDISPSENVVYRV-----POYFD-----LFRILGSEKRTIANYLYVR 369
 DB 178 LPKGLVDEPPELHVRRADPDMKNTCKLLVADHREYRYMGREGSESTTNLYL-- 235
 QY 370 MYSTRIPNLSRRFOYRW-----LEFSRVIOGTTTLTPQWDKCVNFIESALPYV 418
 DB 236 ELIDRVDDIYNTS--WDNAGFKGYGIGIQLIIRIKSPQEVKP-GEKHYNMAKS----- 286

QY 419 GKMFVYVQEDK-----KEMEEELVEGVRAFIIDMLEKENEMWDAGTRRKKAKARAVL 473
 DB 287 -----YNEEKDAMDYKMLLEQSFDI-----AEEASRYCL 317
 QY 474 ARV-GYEFIMNDTHVNEDLKAIFSEADYRGVNLQTKRYLAQSDFFWLKRAVREKTEFT 532
 DB 318 AHLEFYODPDMGTL-----GLAVYGSPPRANSHGV-----CFR----- 350
 QY 533 NPTVNAFYSASTNQLRPPAGELKPPFMGTPEPSLSYG-----AIGVIHGEFTHGF 586
 DB 351 -----ATYS-----PVG--KKNITLNSGLITKRYGKTIILKEADLYTTHLGHNF 394
 QY 587 DNNGRKYDKNGNIDPWWSTSESEKREKTKCMINOYSNYMKRAGLVNG----- 636
 DB 395 ---GAHDPDG-----LAECAPNEDQGKGYWYPIAVSGDHENKMFEN 435
 QY 637 --KRITGENIADNGILREAFR-AYRKMINDRQGLEPFLRGITFTNNQLEFLSAHARC 693
 DB 436 CSKOSIYKTIIESKA--QECFOERSNRCVCGNSVHDEGECDPGIMYLNND-----TCC 485
 QY 694 NSYRPEAREYOYIGAHSP-----QFRVNGAISNSEEFOKAFN-----C 733
 DB 486 NS--DCTLEKGYQCSDRNSPCKNCOFE-----TAQKQGEALINATCKGVSCTGNSSEC 538
 QY 734 PP-----NSTMNRGMDSCR 747
 DB 539 PPGNAEDDTVCLDLGCK 557

Search completed: May 21, 2003, 18:50:38
 Job time : 34 secs

Db 248 IIVIDPFLGMPREXYENGNSNRK-VREAYLOFMVSVATILREBDANLPDSCLOVEDMY 306
Qy 273 SVLRLEIKIAEIMPHNNTSE-AMYNKNISELSAM--IPQDMLGYYIKVDTRLYPH 329
Db 307 QVLELEIQLAKAYPOEERHDVATLHMRGLEEQSGFLKGNWFLIQTIVLSS----- 361
Qy 330 LK-DISESENVYVPOYFDLFRILGSEKRTIANYLVWAMYSRIPNLSRFOYRWLE 388
Db 362 VKILPDEEVYVYGIYILQNLNITIDTYSARTIONLWRLVLDRIGLSQCFKOTRYN 421
Qy 389 FSRVIOQTILLPQMDKCVFISALPYVYGMFVDYFOEDKEMMEELVESVRAFLD 448
Db 422 YRRLFTETVEEVRMRCVGVYVSNMENAVALSVLEAEFGDSKSMVRELIDKRVFEVE 481
Qy 449 MLEKENMDAGTRKRAKRAVLAQVYEPFINMDTH--VVEDKAIKESADYFGVY 506
Db 482 TLDP-ELGMDDESKKRAQEAAMIREQIHPDITLBMNRDEEYSNLFSIDLTFEVS 540
Qy 507 LQTRKYLQSDFFWLKRAVKTMTPTVNAFYASASTNOLFRPAGELQKPFPGTEYR 566
Db 541 LQNLKVAQASLRKRLREKVDPLMIIIGAAYVNAFYSPNNQIYFPAIGILQPPFF-SKEQ 599
Qy 567 RSLSYGAGIYVHEFTHGDNNGRYDKNGLDPWWSSTESEKREKTKMINTSYNTY 626
Db 600 QALNFGIGVIGHEITHGDDGNFDRKNGNMDWMSNSTOHPREOSECMYIYGANS 659
Qy 627 WKRAQ-LNVGKRTLGENIADNGLEAREAFAYRWINDRROGLEBLLGITFTNNQLFE 685
Db 660 WDLADQNVNGFNTLGENIADNGVQAAYKAYIKM---AEGKDDQLGDLITHTQLEFF 716
Qy 686 LSAHRCNSYRREARBOYOGAHSPPOFRVNGAISNSEEFOKAFNCPNSTMNGMS 745
Db 717 INTAQWCSYRREAFIOQIKTDVHSLPKRYVLGSLQNLAAAFDFHCARGPMMH-PKER 775
Qy 746 CRLM 749
Db 776 CRYW 779

RESULT 2
US-09-978-295A-526
Sequence 526, Application US/09978295A
Patent No. US20020156006A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gertsen, Mary E.
APPLICANT: Godowski, Audrey
APPLICANT: Grimaldi, Paul J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paonli, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same

FILE REFERENCE: P2630P1C11
CURRENT APPLICATION NUMBER: US/09/978, 295A
CURRENT FILING DATE: 2001-10-15
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08

Db 642 KAAVNAVAMT - RKHG-EEQOLPAVGLTNHOLFVFGAQCWCVRPRESSHEGLVDPH 698
Oy 711 SPOFRVNGAISNSEEFOKAFNCPNSTMNGMDSCLRM 749
Db 699 SPARRVLTJLSNRSDFLRHFCGCVGSPMNG-OLCEVM 736

RESULT 3
US-09-978-697-526
Sequence 526, Application US/09978697
Patent No. US20020169284A1
GENERAL INFORMATION:
APPLICANT: Ashkenazi, Avi
APPLICANT: Baker Kevin P.
APPLICANT: Botstein, David
APPLICANT: Deenoyers, Luc
APPLICANT: Eaton, Dan
APPLICANT: Ferrara, Napoleon
APPLICANT: Filvaroff, Ellen
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Gerber, Hanspeter
APPLICANT: Gerritsen, Mary E.
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, J. Christopher
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Kijavlin, Ivar J.
APPLICANT: Kuo, Sophia S.
APPLICANT: Napier, Mary A.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
APPLICANT: Wood, William I.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630P1C27
CURRENT APPLICATION NUMBER: US/09/978,697
CURRENT FILING DATE: 2001-10-16
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/07450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077991
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939

PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27

PRIOR APPLICATION NUMBER: 60/083322
 PRIOR FILING DATE: 1998-04-28
 PRIOR APPLICATION NUMBER: 60/083392
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083495
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083496
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083499
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083545
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083554
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083558
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083559
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083500
 PRIOR FILING DATE: 1998-04-29
 PRIOR APPLICATION NUMBER: 60/083742
 PRIOR FILING DATE: 1998-04-30
 PRIOR APPLICATION NUMBER: 60/084366
 PRIOR FILING DATE: 1998-05-05
 PRIOR APPLICATION NUMBER: 60/084414
 PRIOR FILING DATE: 1998-05-06
 PRIOR APPLICATION NUMBER: 60/084441
 PRIOR FILING DATE: 1998-05-06
 PRIOR APPLICATION NUMBER: 60/084637
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084639
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084640
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084598
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084600
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084627
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/084643
 PRIOR FILING DATE: 1998-05-07
 PRIOR APPLICATION NUMBER: 60/085339
 PRIOR FILING DATE: 1998-05-13
 PRIOR APPLICATION NUMBER: 60/085338
 PRIOR FILING DATE: 1998-05-13
 PRIOR APPLICATION NUMBER: 60/085323
 PRIOR FILING DATE: 1998-05-13
 PRIOR APPLICATION NUMBER: 60/085582
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085700
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085689
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085579
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085580
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085573
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085704
 PRIOR FILING DATE: 1998-05-15
 PRIOR APPLICATION NUMBER: 60/085697

Query Match 30.9%; Score 1223; DB 9; Length 736;
 Best Local Similarity 35.2%; Pred. No. 3e-91; Indels 40; Gaps 18;
 Matches 267; Conservative 145; Mismatches 307;

QY 2 EATGSSV--ETGKANRGTRIAL-VFVGGLVLGTILF--LVSGGL-LSLOAKOEXCL 55
 DB 7 ELGAGSNVGRKQTRQLLSRQLLEVLAVGASILLALLGLGCLVAVGVYHNDPSHSTL 66
 QY 56 KPCIEAALATSKVNLSPDCDNFRFRAACDGNISNPIEDMPSYGVYVWLRHNVDLKL 115

DB 67 TEACINVACKILESIDRGVSPCEDFYQSCGGMIRNPNLPDGRSRWNTFNLSMDONAIL 126
 QY 116 KELLEKSISRDRDTFAIOAKILYSCMNEKAIERKADAPLHILRHSPRPVLESNG 175
 DB 127 KILLENT--FNSSSEAEQTOREYFISCLOVERIEELGAPLPLD-----EKIG 174
 QY 176 P--EGWSESRKPSILQATFATFGQYSNVFIRLYVSPDCKASNEHILKLDQATLSLA 232
 DB 175 GMAITGPWQDNF--MEVKAAGVIRATPFTVYISADSKSNSNVIGVDQSGFLPBR 232
 QY 233 EDYLDNSTEAKSYRDLVYFMDTAVLQANSRAEHDKSVLRLEIKAEIMIH--EKR 291
 DB 233 DYLL-NRTANEKVLTAIYLLDMEELGMLGGRPTSTREQOQVLELEIQLANTVPODQR 291
 QY 292 TSEMANKNMISLISAMIGOFDMLGKIKYIDRLVPHLKDISPSNVVVRPOYKDFP 351
 DB 292 DEEKIYHKMISLISLQALAPSDWLEFLSLSP-----LELSDSEPVVYVGMIDYQVS 345
 QY 352 RIIGSERKTIANYIVRWYVSRIPMLSRFOYRWLEFSRVIOGT--TLLPQWDCVNF 410
 DB 346 ELINRTEPSILNNVLLIMNLVQKTTSSLDRFEESAQKLETLTYGTRKSCVPRWQTCISNT 405
 QY 411 ESALPIYVGKMEYDVYFOEDKKEMEELVEGVNATIDMEKENEMMDAGTRKAKEKAR 470
 DB 406 DDALGEMIGSLFVKATPDRQSKETIAGMISEITAEEL--GOLVWMDERTQAAEKAD 464
 QY 471 AVLAKVGPPEFINNDPHEVNDLKAIFSEADYFGVLYQTRKYLAQSDPFWLKAAPKTEM 530
 DB 465 AIYDMIGEPDIFLEPKELDYDGYEISESFQOMNLNFKAKMAQOLKRPBRDQM 524
 QY 531 FTNPTVNAVYSATNOIRPAGELQPFPGTEPRSLSYAGIYVGHETHTGDNNG 590
 DB 525 SMPQGTNAVAYLLPTKNEIVPAGILOAPFY--ARNHPKALNFGIGVVMGHEITHARDQ 583
 QY 591 KRYDKGNLDPWSTSESEKFEKTKMIOYNSYVKKRGLVWVKRRTIGENIADNGI 650
 DB 584 REYDKGNLDPWSTSESEKFEKTKMIOYNSYVKKRGLVWVKRRTIGENIADNGI 641
 QY 651 REAFRAVKNVINDROGILEPILPGITFNNQLEFLSYAHVRCNSYREPAARQOYIGAH 710
 DB 642 KAAYNAIKAML--RKHG-EEQQLPAVGLTNHOLFVFGFAVWCVSRPESHSGLVTDPH 698
 QY 711 SPPOFRVNGAISNEEFQKAFNCPNSTMNGMDSCRW 749
 DB 699 SPARFRVIGTILSNRDLRHFGCPVGSPPNPG--QLCEVW 736

RESULT 4
 US-09-978-192A-526
 Sequence 526, Application US/09978192A
 Patent No. US2002017753A1
 GENERAL INFORMATION:
 APPLICANT: Ashkenazi, Avi
 APPLICANT: Baker Kevin P.
 APPLICANT: Botstein, David
 APPLICANT: Desnoyers, Luc
 APPLICANT: Eaton, Dan
 APPLICANT: Ferrara, Napoleon
 APPLICANT: Filvaroff, Ellen
 APPLICANT: Fong, Sherman
 APPLICANT: Gao, Wei-Qiang
 APPLICANT: Gerber, Hanspeter
 APPLICANT: Gerritsen, Mary E.
 APPLICANT: Goddard, Audrey
 APPLICANT: Grimaldi, Paul J.
 APPLICANT: Gurney, Austin L.
 APPLICANT: Hillan, Kenneth J.
 APPLICANT: Kijavlin, Ivar J.
 APPLICANT: Kuo, Sophia S.
 APPLICANT: Napier, Mary A.
 APPLICANT: Pan, James;

APPLICANT: Paoni, Nicholas F.
APPLICANT: Roy, Margaret Ann
APPLICANT: Shelton, David L.
APPLICANT: Stewart, Timothy A.
APPLICANT: Tumas, Daniel
APPLICANT: Williams, P. Mickey
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2630PIC9
CURRENT APPLICATION NUMBER: US/09/978,192A
PRIOR FILING DATE: 2001-10-15
PRIOR APPLICATION NUMBER: 09/918585
PRIOR FILING DATE: 2001-07-30
PRIOR APPLICATION NUMBER: 60/062250
PRIOR FILING DATE: 1997-10-17
PRIOR APPLICATION NUMBER: 60/064249
PRIOR FILING DATE: 1997-11-03
PRIOR APPLICATION NUMBER: 60/065311
PRIOR FILING DATE: 1997-11-13
PRIOR APPLICATION NUMBER: 60/066364
PRIOR FILING DATE: 1997-11-21
PRIOR APPLICATION NUMBER: 60/077450
PRIOR FILING DATE: 1998-03-10
PRIOR APPLICATION NUMBER: 60/077632
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077641
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077649
PRIOR FILING DATE: 1998-03-11
PRIOR APPLICATION NUMBER: 60/077791
PRIOR FILING DATE: 1998-03-12
PRIOR APPLICATION NUMBER: 60/078004
PRIOR FILING DATE: 1998-03-13
PRIOR APPLICATION NUMBER: 60/078886
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078936
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078910
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/078939
PRIOR FILING DATE: 1998-03-20
PRIOR APPLICATION NUMBER: 60/079294
PRIOR FILING DATE: 1998-03-25
PRIOR APPLICATION NUMBER: 60/079656
PRIOR FILING DATE: 1998-03-26
PRIOR APPLICATION NUMBER: 60/079664
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079689
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079663
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079728
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079786
PRIOR FILING DATE: 1998-03-27
PRIOR APPLICATION NUMBER: 60/079920
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/079923
PRIOR FILING DATE: 1998-03-30
PRIOR APPLICATION NUMBER: 60/080105
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080107
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333

PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366
PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07

```

; PRIOR APPLICATION NUMBER: 60/084640
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084598
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084600
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084627
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/084643
; PRIOR FILING DATE: 1998-05-07
; PRIOR APPLICATION NUMBER: 60/085339
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085338
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085323
; PRIOR FILING DATE: 1998-05-13
; PRIOR APPLICATION NUMBER: 60/085582
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085700
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085689
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085579
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085580
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085573
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085704
; PRIOR FILING DATE: 1998-05-15
; PRIOR APPLICATION NUMBER: 60/085697

```

Query Match 30.2%; Score 1223; DB 9; Length 736;
 Best Local Similarity 35.2%; Pred. No. 3e-91;

Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

```

QY 2 EATGSSV--ETGKANKRGTAL-VVVGGLVLTIF--LVSGGL-LSIAKQCYCL 55
DB 7 ELGAGSNVGFQKGTQLLSRTQLLEVLGASILLALGLGLVAGVYHNDPSHSTCL 66
QY 56 KPCICIAAAILSKVNLSDPCDNFRRFCQDMISNNPIEDMPSGVYPMLRHNVDLKL 115
DB 67 TEACIVAVAKILSLDRGSPCEDFYQFCGCGIRRNPLPDGSRNNTNSLMDONAIL 126
QY 116 KELLESIARRDTEAIOAKILLYSCMNEKAIEKADAKPLHLIHSFPFVLESNIG 175
DB 127 KHLLENT-TFNSSSEAEKTOREFYLSCLQVERIEELGAPLNDL-----EKIG 174
QY 176 P--EGVSEKRFSLQTLATFRGOYSNVFRLYVSPDKASNEHILKLDATLSLAVR 232
DB 175 GKNITGPMQDNF--MEVLKAVAGYTRATPFYIYISADSKSSNSNVIOVDQSGFLPSR 232
QY 233 EDYLDNSTEAKSYRDALYKFNVDYAVLLGANSRAEHDMKSVLRLEIKIAEIMIPH-ENR 291
DB 233 DYLL-NRTANEKVLTAIYDYMELGMLLGRPTSTREMOQVLELEIQTALNTYVQDDR 291
QY 292 TSEAMYNKNINISLAMPDPDWLCYIKKVIDTRLYPHLKDISPSENVVVRVQYKDLF 351
DB 292 DEEKIYHKMSISELQALAPSMQMLEFLSLSP-----LELSDPEPVVYGMVDLQVYS 345
QY 352 RILGSEKRTIANYLWVRVYSRIPNLSRRROYRWLEFSRYIQCQ-TLLIQMDKCVMT 410
DB 346 ELINTEESIILNLYIMLVQKTTSSLDRRRESAQEKLETLTYGTRKSCVPRWQICISNT 405
QY 411 ESALPYVVGKMFVDYFOEDKKEKMELEVEGRNAFIDMLEKENEMDAGTKRKAKEKAR 470
DB 406 DDALEFALGSLFVKATFPDRQSEIKAEIGMISEIRAFEEAL--GQLVWMDKEROAKERAD 464
QY 471 AVIAKVGPEPIMNDTHNEDLKAKESEADYFGVAVLOTTRYLAQSDFFWLRKAVPKTEW 530
DB 465 AITYDMIGPDPILPEKEDDYDGYEISDSFQNMNLNLYNFSAKVAMDQLRKPPSRDOW 524
QY 531 FTNPITVNAFYSASTNQIRFPAGELQKPFVWGTEVPRSLSYGALGVYIGHFHTGFQNG 590

```

```

DB 525 SMTPQIVNAYVLEPTKNEIYFPAGILLQAPFY-ARNHFKALNFGSIGVYMGHETLHAFDDQG 583
QY 591 RKYDKGNLDDPMWSTSESEKFEKTCMNOYSNTYWKAGLNVGKRTLGENDGCL 650
DB 584 REYDKGNLRPMWQNESLAFNRHTACMEQYNY--QVNGERLNGRQTIGENDGCL 641
QY 651 REAFRAYRKWINDRQGLEEPLPGITFTNNOLFSLYAHVRCNSYRPAAREQOIGAH 710
DB 642 KAAVNAVYKAML--RKHG-DEQQLPAGVLNHLQFLFYGPAQVWCYRTPESSHEGLVTPDH 698
QY 711 SPQFVYVNAISNSEFOAFENCNPSTNMRGMSCRIM 749
DB 699 SPARFVILQTLNSRDLRHFRCQPVGSPWMPNG-QLCEVW 736

RESULT 5
US-09-999-832A-526
; Sequence 526, Application US/0999832A
; Publication No. US20020192706a1
; GENERAL INFORMATION:
; APPLICANT: Ashkenazi, Avi
; APPLICANT: Baker Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan
; APPLICANT: Ferrara, Napoleon
; APPLICANT: Filvaroff, Ellen
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Gerber, Hanspeter
; APPLICANT: Gerritsen, Mary E.
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, J. Christopher
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Kijavlin, Ivar J.
; APPLICANT: Kuo, Sophia S.
; APPLICANT: Napier, Mary A.
; APPLICANT: Pan, James;
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Shelton, David L.
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2630P1C63
; CURRENT APPLICATION NUMBER: US/09/999, 832A
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: 09/918585
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: 60/062250
; PRIOR FILING DATE: 1997-10-17
; PRIOR APPLICATION NUMBER: 60/064249
; PRIOR FILING DATE: 1997-11-03
; PRIOR APPLICATION NUMBER: 60/065311
; PRIOR FILING DATE: 1997-11-13
; PRIOR APPLICATION NUMBER: 60/066364
; PRIOR FILING DATE: 1997-11-21
; PRIOR APPLICATION NUMBER: 60/077450
; PRIOR FILING DATE: 1998-03-10
; PRIOR APPLICATION NUMBER: 60/077632
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077641
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077649
; PRIOR FILING DATE: 1998-03-11
; PRIOR APPLICATION NUMBER: 60/077791
; PRIOR FILING DATE: 1998-03-12

```

Thu May 22 07:48:41 2003

US-09-913-955a-1.rapb

Page 8

1	PRIOR APPLICATION NUMBER: 60/078004
2	PRIOR FILING DATE: 1998-03-13
3	PRIOR APPLICATION NUMBER: 60/078886
4	PRIOR FILING DATE: 1998-03-20
5	PRIOR APPLICATION NUMBER: 60/078936
6	PRIOR FILING DATE: 1998-03-20
7	PRIOR APPLICATION NUMBER: 60/078910
8	PRIOR FILING DATE: 1998-03-20
9	PRIOR APPLICATION NUMBER: 60/078939
10	PRIOR FILING DATE: 1998-03-20
11	PRIOR APPLICATION NUMBER: 60/079294
12	PRIOR FILING DATE: 1998-03-25
13	PRIOR APPLICATION NUMBER: 60/079656
14	PRIOR FILING DATE: 1998-03-26
15	PRIOR APPLICATION NUMBER: 60/079664
16	PRIOR FILING DATE: 1998-03-27
17	PRIOR APPLICATION NUMBER: 60/079689
18	PRIOR FILING DATE: 1998-03-27
19	PRIOR APPLICATION NUMBER: 60/079663
20	PRIOR FILING DATE: 1998-03-27
21	PRIOR APPLICATION NUMBER: 60/079728
22	PRIOR FILING DATE: 1998-03-27
23	PRIOR APPLICATION NUMBER: 60/079786
24	PRIOR FILING DATE: 1998-03-27
25	PRIOR APPLICATION NUMBER: 60/079920
26	PRIOR FILING DATE: 1998-03-30
27	PRIOR APPLICATION NUMBER: 60/079923
28	PRIOR FILING DATE: 1998-03-30
29	PRIOR APPLICATION NUMBER: 60/080105
30	PRIOR FILING DATE: 1998-03-31
31	PRIOR APPLICATION NUMBER: 60/080107
32	PRIOR FILING DATE: 1998-03-31
33	PRIOR APPLICATION NUMBER: 60/080165
34	PRIOR FILING DATE: 1998-03-31
35	PRIOR APPLICATION NUMBER: 60/080194
36	PRIOR FILING DATE: 1998-03-31
37	PRIOR APPLICATION NUMBER: 60/080327
38	PRIOR FILING DATE: 1998-04-01
39	PRIOR APPLICATION NUMBER: 60/080328
40	PRIOR FILING DATE: 1998-04-01
41	PRIOR APPLICATION NUMBER: 60/080333
42	PRIOR FILING DATE: 1998-04-01
43	PRIOR APPLICATION NUMBER: 60/080334
44	PRIOR FILING DATE: 1998-04-01
45	PRIOR APPLICATION NUMBER: 60/081070
46	PRIOR FILING DATE: 1998-04-08
47	PRIOR APPLICATION NUMBER: 60/081049
48	PRIOR FILING DATE: 1998-04-08
49	PRIOR APPLICATION NUMBER: 60/081071
50	PRIOR FILING DATE: 1998-04-08
51	PRIOR APPLICATION NUMBER: 60/081195
52	PRIOR FILING DATE: 1998-04-08
53	PRIOR APPLICATION NUMBER: 60/081203
54	PRIOR FILING DATE: 1998-04-09
55	PRIOR APPLICATION NUMBER: 60/081229
56	PRIOR FILING DATE: 1998-04-09
57	PRIOR APPLICATION NUMBER: 60/081955
58	PRIOR FILING DATE: 1998-04-15
59	PRIOR APPLICATION NUMBER: 60/081917
60	PRIOR FILING DATE: 1998-04-15
61	PRIOR APPLICATION NUMBER: 60/081819
62	PRIOR FILING DATE: 1998-04-15
63	PRIOR APPLICATION NUMBER: 60/081952
64	PRIOR FILING DATE: 1998-04-15
65	PRIOR APPLICATION NUMBER: 60/081838
66	PRIOR FILING DATE: 1998-04-15
67	PRIOR APPLICATION NUMBER: 60/082568
68	PRIOR FILING DATE: 1998-04-21
69	PRIOR APPLICATION NUMBER: 60/082569
70	PRIOR FILING DATE: 1998-04-21
71	PRIOR APPLICATION NUMBER: 60/082704
72	PRIOR FILING DATE: 1998-04-22
73	PRIOR APPLICATION NUMBER: 60/082804

1	PRIOR FILING DATE: 1998-04-22
2	PRIOR APPLICATION NUMBER: 60/082700
3	PRIOR FILING DATE: 1998-04-22
4	PRIOR APPLICATION NUMBER: 60/082797
5	PRIOR FILING DATE: 1998-04-22
6	PRIOR APPLICATION NUMBER: 60/082796
7	PRIOR FILING DATE: 1998-04-23
8	PRIOR APPLICATION NUMBER: 60/083336
9	PRIOR FILING DATE: 1998-04-27
10	PRIOR APPLICATION NUMBER: 60/083322
11	PRIOR FILING DATE: 1998-04-28
12	PRIOR APPLICATION NUMBER: 60/083392
13	PRIOR FILING DATE: 1998-04-29
14	PRIOR APPLICATION NUMBER: 60/083495
15	PRIOR FILING DATE: 1998-04-29
16	PRIOR APPLICATION NUMBER: 60/083496
17	PRIOR FILING DATE: 1998-04-29
18	PRIOR APPLICATION NUMBER: 60/083499
19	PRIOR FILING DATE: 1998-04-29
20	PRIOR APPLICATION NUMBER: 60/083545
21	PRIOR FILING DATE: 1998-04-29
22	PRIOR APPLICATION NUMBER: 60/083554
23	PRIOR FILING DATE: 1998-04-29
24	PRIOR APPLICATION NUMBER: 60/083558
25	PRIOR FILING DATE: 1998-04-29
26	PRIOR APPLICATION NUMBER: 60/083559
27	PRIOR FILING DATE: 1998-04-29
28	PRIOR APPLICATION NUMBER: 60/083500
29	PRIOR FILING DATE: 1998-04-29
30	PRIOR APPLICATION NUMBER: 60/083742
31	PRIOR FILING DATE: 1998-04-30
32	PRIOR APPLICATION NUMBER: 60/084366
33	PRIOR FILING DATE: 1998-05-05
34	PRIOR APPLICATION NUMBER: 60/084414
35	PRIOR FILING DATE: 1998-05-06
36	PRIOR APPLICATION NUMBER: 60/084441
37	PRIOR FILING DATE: 1998-05-06
38	PRIOR APPLICATION NUMBER: 60/084637
39	PRIOR FILING DATE: 1998-05-07
40	PRIOR APPLICATION NUMBER: 60/084639
41	PRIOR FILING DATE: 1998-05-07
42	PRIOR APPLICATION NUMBER: 60/084640
43	PRIOR FILING DATE: 1998-05-07
44	PRIOR APPLICATION NUMBER: 60/084598
45	PRIOR FILING DATE: 1998-05-07
46	PRIOR APPLICATION NUMBER: 60/084600
47	PRIOR FILING DATE: 1998-05-07
48	PRIOR APPLICATION NUMBER: 60/084637
49	PRIOR FILING DATE: 1998-05-07
50	PRIOR APPLICATION NUMBER: 60/084639
51	PRIOR FILING DATE: 1998-05-07
52	PRIOR APPLICATION NUMBER: 60/084643
53	PRIOR FILING DATE: 1998-05-07
54	PRIOR APPLICATION NUMBER: 60/085339
55	PRIOR FILING DATE: 1998-05-13
56	PRIOR APPLICATION NUMBER: 60/085338
57	PRIOR FILING DATE: 1998-05-13
58	PRIOR APPLICATION NUMBER: 60/085323
59	PRIOR FILING DATE: 1998-05-13
60	PRIOR APPLICATION NUMBER: 60/085582
61	PRIOR FILING DATE: 1998-05-15
62	PRIOR APPLICATION NUMBER: 60/085700
63	PRIOR FILING DATE: 1998-05-15
64	PRIOR APPLICATION NUMBER: 60/085699
65	PRIOR FILING DATE: 1998-05-15
66	PRIOR APPLICATION NUMBER: 60/085799
67	PRIOR FILING DATE: 1998-05-15
68	PRIOR APPLICATION NUMBER: 60/085800
69	PRIOR FILING DATE: 1998-05-15
70	PRIOR APPLICATION NUMBER: 60/085737
71	PRIOR FILING DATE: 1998-05-15
72	PRIOR APPLICATION NUMBER: 60/085704
73	PRIOR FILING DATE: 1998-05-15
74	PRIOR APPLICATION NUMBER: 60/085697

PRIOR APPLICATION NUMBER: 60/080165
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080194
PRIOR FILING DATE: 1998-03-31
PRIOR APPLICATION NUMBER: 60/080327
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080328
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080333
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/080334
PRIOR FILING DATE: 1998-04-01
PRIOR APPLICATION NUMBER: 60/081070
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081049
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081071
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081195
PRIOR FILING DATE: 1998-04-08
PRIOR APPLICATION NUMBER: 60/081203
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081229
PRIOR FILING DATE: 1998-04-09
PRIOR APPLICATION NUMBER: 60/081955
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081817
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081819
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081952
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/081838
PRIOR FILING DATE: 1998-04-15
PRIOR APPLICATION NUMBER: 60/082568
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082569
PRIOR FILING DATE: 1998-04-21
PRIOR APPLICATION NUMBER: 60/082704
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082804
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082700
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082797
PRIOR FILING DATE: 1998-04-22
PRIOR APPLICATION NUMBER: 60/082796
PRIOR FILING DATE: 1998-04-23
PRIOR APPLICATION NUMBER: 60/083336
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/083322
PRIOR FILING DATE: 1998-04-28
PRIOR APPLICATION NUMBER: 60/083392
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083495
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083496
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083499
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083545
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083554
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083558
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083559
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083500
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: 60/083742
PRIOR FILING DATE: 1998-04-30
PRIOR APPLICATION NUMBER: 60/084366

PRIOR FILING DATE: 1998-05-05
PRIOR APPLICATION NUMBER: 60/084414
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084441
PRIOR FILING DATE: 1998-05-06
PRIOR APPLICATION NUMBER: 60/084637
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084639
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084640
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084598
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084600
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084627
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/084643
PRIOR FILING DATE: 1998-05-07
PRIOR APPLICATION NUMBER: 60/085339
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085338
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085323
PRIOR FILING DATE: 1998-05-13
PRIOR APPLICATION NUMBER: 60/085582
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085700
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085689
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085579
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085580
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085573
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085704
PRIOR FILING DATE: 1998-05-15
PRIOR APPLICATION NUMBER: 60/085697

Query Match 30.9%; Score 1223; DB 9; Length 736;
Best Local Similarly 35.2%; Pred. No. 3e-91;
Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

QY 2 EAETGSSV--ETGKANGFTIAL-VYFVGTVLGIITF--LYSGL-LSLQKDEYCL 55
DB 7 ELGAGSNVGFQKGTROLGSKTQLELVLAGASLLALLGCVALGVYHRDPSSHSTCL 66
QY 56 KPCIEAAMALISKVNLSDVPCDNFFRFACDGIWISNNPIEDMPSGVYPMLRHNVDLKL 115
DB 67 TEACIRAVAGKILSLDGVSPCEDFYOFSCGWTRRRNPDLGDSKRNFTFSLMDQAIL 126
QY 116 KELLEKSIRRDTEALQAKILYSSCMNEKAIEKADAKPLHLIRHSPRPWLESNIG 175
DB 127 KHLLENT-TENSSSEAAQKQRFYLSLOVERIEELGAQPLRLDI-----EKIG 174
QY 176 P---EGWSEKKEFSLQTLATFRGOYSNVETIRLYSPDDKASNEHLIKDQATLSLAVR 232
DB 175 GWNITGWDODNF--MEVLAIVAGTYATFTFTVYISADSKSSNSNVIOVDSGFLPSR 232
QY 233 EDYLDNSTEAKSYRDALYKEMVDJAVLLGANSRAEHDMKSVLRLEIKTAIEIPIH-ENR 291
DB 233 DYYL-NRTANEKYLTAVIDMEELGMLGGRPSTREQMOQVLELEIQANITVPQDDQRR 291
QY 292 TSEAMYNKKNISELSAMIPQDMIGYIKKYIDRLRPLHLKDIPSNSNVVVRVPPQFKDIF 351
DB 292 DEEETIHKMSISELQALAPMDMLELSP-----LELSDSEPPVYVYGMDYLOQVS 345
QY 352 RIIGSEKRTIANYLVWRMYSRIPNLISRFQVRWLEFSRVIGCT-TITLLPQMDCVNFI 410
DB 346 ELINRTEPSILNNYILNVLNVQKTTSSLDKRFESAOEKLLETLTGKCKSPRMQTCISNT 405


```

Db 7 ELGAGSNVGFQKTRQLGSRTOLEVLGASLLIALLLCLVLAQVYHRDPSHSTCL 66
OY KPECIEAAALISKVNLSVPCDNFFRACDGMISNNPDPEDMPSYGVYFWLRHNVDLKL 115
Db 67 TEACIRVAGKILIESLDGVSFCEDFYQSCGWMIRNPLPDGSRKWNFTNSLMDQNAL 126
OY KELLEKSISRRTDEATOKAKILYSSCMNEKAEKADAKPLHLIRHSPFRWPLESNI 175
Db 127 KHLLENT-TFNSSSEAEKQTRFYLSCLQVERIEELGAQPLRDL-----EKIG 174
OY 176 P---EGVWSEKESLLOTLATFRGOYSNVSFIRLYSPDDKASNEHLIKDOATLSLA 232
Db 175 GWNITGPMDQDNF--MEVLKAVAGTYRATPFYVYISADSKSSNSNVYQVDSGLFLPSR 232
OY 233 EDYLDNSTEAKSYDALKYKFWVDVAVLLGANSRAEHDMKSVYLEIKIAEIMIPH-ENR 291
Db 233 DYLL-NRTANEKVITAYLDYMEELGMLGGRPTSTREMOQVLELEIOLANTIVPQDQR 291
OY 292 TSEAMYNKMINISELSAMIPOFDMIGYIKKVIDTRLYPHLKDISPENYVVRPQYKDLF 351
Db 292 DEKTIYHKMSISELOALAPSMDWLEFLSLP-----LELSDEPVYVGYMDYLOQVS 345
OY 352 RIIGSERKKTITANYLVWRMYSRIPNLSRRFQYRWLEFSVIGOT--TLLPQMDKCVNFI 410
Db 346 ELINRTEPSILNNYLIMNLVOKTSSLDREFSAQEKLETLTYTKKSCVPRMOTCISNT 405
OY 411 ESALPYVVGKMFVDYVFOEDKKEMEELVEGVRAFIIDMLEKENEMDAGTKRKAKEAR 470
Db 406 DDLGALGSLFVKATFDRQSKIEAGMISEIRTAFEAL--GOLVWMDKTRQAAREKAD 464
OY 471 AVLAKEGPEFIMNDTHNEDLKAIFSEADYFVGNVLQTRKYLAOSDFEMLRKAVPTEW 530
Db 465 AITDMIGFDFLEKEDLDYDGEISDSFQNMNLNYSKAVMADOLKRPSPDQW 524
OY 531 FNNPTVNAFYASASTNQIRFPAGELQPFPGTEYPRSLSYAGIYVGHETHGEDNNG 590
Db 525 SMTPOTVNAAYLLPTKNEILVFPAGILQAPFY--ARNHPKALNFGIGVYMGHELTFAFDQ 583
OY 591 RKYDKGNLDPWMTSESEKFEKTKCMINQYSNYKFKAGLVNKGRTIGENTADNGL 650
Db 584 REYDKGNLDPWMTSESEKFEKTKCMINQYSNYKFKAGLVNKGRTIGENTADNGL 641
OY 651 REAFRAYRKWINDRQGLEPILGIFTNNQLEFSLYAHVRCNSYRPPAAREQVOIGAH 710
Db 642 KAAVNAAYKAWL--RKHG-EEQOLPAVGLTNHQLFFVGAQVWCVTRPSSHEGLVDPH 698
OY 711 SPPOFRVNGAISNSEFOKAFNCPNSTMNGMDSCRIM 749
Db 699 SPARFRVLGTLNSRDLRHFHGCVPVSPMANG-QLCEVW 736

RESULT 9
; Sequence 420, Application US/10175737
; Publication No. US20030013153A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C50
; CURRENT APPLICATION NUMBER: US/10/175,737
; CURRENT FILING DATE: 2002-06-19
; Prior Application removed - See File Wrapper or Palm

```

```

; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 420
; LENGTH: 736
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-175-737-420

Query Match      30.9%; Score 1223; DB 9; Length 736;
Best Local Similarity 35.2%; Pred. No. 36-91;
Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

OY 2 EAETGSV--ETGKANKRGTIAL-VVEVGGTLVLTILF--LVSGGL-LISLQAKOETCL 55
Db 7 ELGAGSNVGFQKTRQLGSRTOLEVLGASLLIALLLCLVLAQVYHRDPSHSTCL 66
OY KPECIEAAALISKVNLSVPCDNFFRACDGMISNNPDPEDMPSYGVYFWLRHNVDLKL 115
Db 67 TEACIRVAGKILIESLDGVSFCEDFYQSCGWMIRNPLPDGSRKWNFTNSLMDQNAL 126
OY 116 KELLEKSISRRTDEATOKAKILYSSCMNEKAEKADAKPLHLIRHSPFRWPLESNI 175
Db 127 KHLLENT-TFNSSSEAEKQTRFYLSCLQVERIEELGAQPLRDL-----EKIG 174
OY 176 P---EGVWSEKESLLOTLATFRGOYSNVSFIRLYSPDDKASNEHLIKDOATLSLA 232
Db 175 GWNITGPMDQDNF--MEVLKAVAGTYRATPFYVYISADSKSSNSNVYQVDSGLFLPSR 232
OY 233 EDYLDNSTEAKSYDALKYKFWVDVAVLLGANSRAEHDMKSVYLEIKIAEIMIPH-ENR 291
Db 233 DYLL-NRTANEKVITAYLDYMEELGMLGGRPTSTREMOQVLELEIOLANTIVPQDQR 291
OY 292 TSEAMYNKMINISELSAMIPOFDMIGYIKKVIDTRLYPHLKDISPENYVVRPQYKDLF 351
Db 292 DEKTIYHKMSISELOALAPSMDWLEFLSLP-----LELSDEPVYVGYMDYLOQVS 345
OY 352 RIIGSERKKTITANYLVWRMYSRIPNLSRRFQYRWLEFSVIGOT--TLLPQMDKCVNFI 410
Db 346 ELINRTEPSILNNYLIMNLVOKTSSLDREFSAQEKLETLTYTKKSCVPRMOTCISNT 405
OY 411 ESALPYVVGKMFVDYVFOEDKKEMEELVEGVRAFIIDMLEKENEMDAGTKRKAKEAR 470
Db 406 DDLGALGSLFVKATFDRQSKIEAGMISEIRTAFEAL--GOLVWMDKTRQAAREKAD 464
OY 471 AVLAKEGPEFIMNDTHNEDLKAIFSEADYFVGNVLQTRKYLAOSDFEMLRKAVPTEW 530
Db 465 AITDMIGFDFLEKEDLDYDGEISDSFQNMNLNYSKAVMADOLKRPSPDQW 524
OY 531 FNNPTVNAFYASASTNQIRFPAGELQPFPGTEYPRSLSYAGIYVGHETHGEDNNG 590
Db 525 SMTPOTVNAAYLLPTKNEILVFPAGILQAPFY--ARNHPKALNFGIGVYMGHELTFAFDQ 583
OY 591 RKYDKGNLDPWMTSESEKFEKTKCMINQYSNYKFKAGLVNKGRTIGENTADNGL 650
Db 584 REYDKGNLDPWMTSESEKFEKTKCMINQYSNYKFKAGLVNKGRTIGENTADNGL 641
OY 651 REAFRAYRKWINDRQGLEPILGIFTNNQLEFSLYAHVRCNSYRPPAAREQVOIGAH 710
Db 642 KAAVNAAYKAWL--RKHG-EEQOLPAVGLTNHQLFFVGAQVWCVTRPSSHEGLVDPH 698
OY 711 SPPOFRVNGAISNSEFOKAFNCPNSTMNGMDSCRIM 749
Db 699 SPARFRVLGTLNSRDLRHFHGCVPVSPMANG-QLCEVW 736

RESULT 10
; Sequence 420, Application US/10173706
; Publication No. US20030022293A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey

```



```

; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C7
; CURRENT APPLICATION NUMBER: US/10/173,706
; CURRENT FILING DATE: 2002-06-17
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 420
; LENGTH: 736
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-173-706-420

```

```

Query Match          30.9%; Score 1223; DB 9; Length 736;
Best Local Similarity 35.2%; Pred. No. 3e-91;
Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

```

```

2 EAETGSSV--ETGKANRGTAL-VVFGTGLVLTIF--LVSGGL-LSLQAKOEYL 55
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
7 ELGAGSNVGFQGTQRLGSLRQLELVLAGASLLAALLGCLVALGQYHRDPSHSTCL 66
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
56 KPECIEAAAILSKVNLSDPCDNFRCADGWNISNPIEDMPSGYVYRWLRHNVDLK 115
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
67 TEACIRVAGKILSLDRGVSPCEDFYQSCGWMIRRNPLDGRSHMNTFNSLMDQNAL 126
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
116 KELLEKSISRRTDTRALQAKILYSSCMNEKAEKADKPLHLIHRSPFRVLESNG 175
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
127 KHLLENT--TFNSSSEAEQKQRYLSCLQVERIEELGAQPLRLDI-----EKIG 174
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
176 P---EGWSEKRFSLQTLATFRGOYSNSVFIRLYVSPDDKASNEHILKLDQATLSLA 232
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
175 GKNITGPMQDNF--MEVLAAGVATRAFPFTYVISAQSSNSNVLYQVDSGLFLPSR 232
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
233 EDYLDNSTEAKSYDALYKEMVDVAVLGANSSRAEDHDKSVLRLEIKIAELMIPH--ENR 291
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
233 DYTL--NRTANEKYLTAFLDYMEELGMLGGRPTSTREQMOQVLELEIOLANTVPODQR 291
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
292 TSEAMTKANISELSAMIPQDMIGYIKKVIDTRILYPHLKDIPSENVVYRVQYKDF 351
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
292 DEEKIYHAKMSISELQALAPSMQMLEFLSLSP-----LEISDSEPVVYVYMDYLOQVS 345
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
352 RIIGSEKRTIANYLVWRVWYSRIPNLSRFRQYRWLEFSRVIOGT--TLLPQMDKCVNFI 410
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
346 ELINRTEPSILNNYLVNLYVQKTTSLDRFESAQEKLETLGYTKKSCVPRMOTCISNT 405
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
411 ESALPYVVGKMFVDYVFOEDKKEMEEVGYRAFIQMLEKENEMDAGTKRKAKEKAR 470
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
406 DDALGALGSLFVATFQDSQSEKIEAGMISEIRTAEEAL--GOLVWMDKTRQAAKAD 464
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
471 AYLAAGVGEFTINDHVNEDLKAIFSEADYFGVNLQRTKYLQASDFPWLKRAVPKTEM 530
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
465 AIYDMIGFDFILPEKELDQVYDGYEISDSFQNMNLNYSKAKYMAQDLKRPSPRDOM 524
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
531 FTNPNTVNAVYSASTNOIRPAGELQKPFMGTEYPRSLSYGAIGVIVGHEFTGPDNG 590
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
525 SMFGQYNAVAYLPTKNEILVPRAGILOAPF--ARNHPRKALNFGGIVGVGHEILHAFDDG 583
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
591 RKYKNGNDLPWSTSESEKFEKTKCMINOYSYVKKKAGLVKRRITGENIADNGCL 650
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
584 REYKKEGNLRPMWONESIAAFRNHTACMEBOYQY--QVNGERLNGRQTLGENTDNGCL 641
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
651 REAPRAVKYINDRQGLELPGITFTNNQJLEFLSYAHVRCGYSYREAPAREVOYGAH 710
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
642 KAAHNAIKRAML--RKHG--EEQQLPAVLINHQLEFVGFAQYWCYSVRIPSSHESGLVDPH 698
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
711 SPQFRVNGAISNSEFOKAFNCPPNSTNMGDSCLRM 749

```

```

DB 699 SPARERVLTLSNSHDLRHFRCVSPSPMNG-OLCEWV 736
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```

```

RESULT 11
US-10-175-738-420
; Sequence 420, Application US/10175738
; Publication No. US20030022294A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jilan
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C45
; CURRENT APPLICATION NUMBER: US/10/175,738
; CURRENT FILING DATE: 2002-06-19
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 420
; LENGTH: 736
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-175-738-420

```

```

Query Match          30.9%; Score 1223; DB 9; Length 736;
Best Local Similarity 35.2%; Pred. No. 3e-91;
Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

```

```

2 EAETGSSV--ETGKANRGTAL-VVFGTGLVLTIF--LVSGGL-LSLQAKOEYL 55
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
7 ELGAGSNVGFQGTQRLGSLRQLELVLAGASLLAALLGCLVALGQYHRDPSHSTCL 66
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
56 KPECIEAAAILSKVNLSDPCDNFRCADGWNISNPIEDMPSGYVYRWLRHNVDLK 115
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
67 TEACIRVAGKILSLDRGVSPCEDFYQSCGWMIRRNPLDGRSHMNTFNSLMDQNAL 126
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
116 KELLEKSISRRTDTRALQAKILYSSCMNEKAEKADKPLHLIHRSPFRVLESNG 175
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
127 KHLLENT--TFNSSSEAEQKQRYLSCLQVERIEELGAQPLRLDI-----EKIG 174
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
176 P---EGWSEKRFSLQTLATFRGOYSNSVFIRLYVSPDDKASNEHILKLDQATLSLA 232
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
175 GKNITGPMQDNF--MEVLAAGVATRAFPFTYVISAQSSNSNVLYQVDSGLFLPSR 232
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
233 EDYLDNSTEAKSYDALYKEMVDVAVLGANSSRAEDHDKSVLRLEIKIAELMIPH--ENR 291
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
233 DYTL--NRTANEKYLTAFLDYMEELGMLGGRPTSTREQMOQVLELEIOLANTVPODQR 291
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
292 TSEAMTKANISELSAMIPQDMIGYIKKVIDTRILYPHLKDIPSENVVYRVQYKDF 351
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
292 DEEKIYHAKMSISELQALAPSMQMLEFLSLSP-----LEISDSEPVVYVYMDYLOQVS 345
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
352 RIIGSEKRTIANYLVWRVWYSRIPNLSRFRQYRWLEFSRVIOGT--TLLPQMDKCVNFI 410
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
346 ELINRTEPSILNNYLVNLYVQKTTSLDRFESAQEKLETLGYTKKSCVPRMOTCISNT 405
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
411 ESALPYVVGKMFVDYVFOEDKKEMEEVGYRAFIQMLEKENEMDAGTKRKAKEKAR 470
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
406 DDALGALGSLFVATFQDSQSEKIEAGMISEIRTAEEAL--GOLVWMDKTRQAAKAD 464
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
471 AYLAAGVGEFTINDHVNEDLKAIFSEADYFGVNLQRTKYLQASDFPWLKRAVPKTEM 530
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :
465 AIYDMIGFDFILPEKELDQVYDGYEISDSFQNMNLNYSKAKYMAQDLKRPSPRDOM 524
| : : : : : : : : : : : : : : : : : : : : : : : : : : : :

```



```

Db 127 KHLLENT--TFNSSSEAEOKTOREYLSCLQVERIEELGAQPLRDLI-----EKIG 174
QY 176 P---EGWSEERKPSLLQTLATFRGOYSNVSFIRLYVSPDDKASNEHILKDAITLSAVR 232
Db 175 GWNITPMDQDNF--MEVTKAVAGTYRATPEFTYISADSXSNSNVIOYDQSGLEFLPSR 232
QY 233 EDYLDNSTEAKSYRDALYKENVDTAVLLGANSRAEDHDKSVLRLEIKIAEIMIPH--ENR 291
Db 233 DYTL--NRTANEKVLTAIYLDYMEELGMLGGRPTSTREQMOQVLELEIQLANTIVPODQR 291
QY 292 TTSAMNKNKNSISLSAMITQFMDLGYIKVYIDRLYPLHKDISPSENVVVRVPOYKDLF 351
Db 292 DEKRIYHKMSISELQALAPSMIDLEFLSFLSP-----LELSDSEPVVYGYMDYLOQVS 345
QY 352 RILGSEKRTKIANTLYVWRVYSRIPNLSRRFOYRWLEFSRYIGT--TLLPQMDKCVNFI 410
Db 346 ELINRPEPILNNYLTIMNLVOKTSSLDKRESAQEKLEITLYGKSKSCVPWQTCISNT 405
QY 411 ESALPYVVGKMFVDYVFOEDKEMMEELVEGVRAFDIMLEKENEMWDAGTKRKAERAR 470
Db 406 DDALGFALGSLFVKATFDROSKETAEAGMISEIRTAFEAL--GQLVWMDKTRQAKKAD 464
QY 471 AVLAKEYPEEIMNDHVNEDLKAIFSEADYFGNVLTQRTKILASDFEMLKRAVPKTEM 530
Db 465 AITDMIGFPEDEILPEKELDDYDGYEISDSFQNMNLNYSKAVMADOLKRPSPDQW 524
QY 531 FTNPVTYNAFYSTNQIRFPAGELQKPFPGTGYPRSLSYGAIGVYGHFTHGPDNG 590
Db 525 SMPQVNAVYLLPTKNEIYFPAGILQAPRY--ARNHPKALNFGIGVYGMHELTHAFDDG 583
QY 591 RYDKNGNLDPWWSDESEKEKTKCMINQYSNYWKAGLVNKGRTLGENTADGCL 650
Db 584 REYDKNGNLPRWQWONESLAFRNHTACMEQYNY--QVNGERLNGRQTLGENTIDNGCL 641
QY 651 REAFRAYRKWINDRQGLEEPLLPGITFTNNQLEFLSYAHVRCNSYRPEARQVOIGAH 710
Db 642 KAAVNAVYKWL--RKHG--EEQQLPAGVLJTNHQLFEVGFAGVWCVSVRTPESHGELVTDPH 698
QY 711 SPQGFVNGAISNSEEFQKAFNCPNNTNRMGMDSCRLM 749
Db 699 SPARFVLTGLTNSRDLRHFQCPVGPSPMNPQ--QLCEVW 736

RESULT 14
US-10-176-757-420
; Sequence 420, Application US/10176757
; Publication No. US20030022297A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC
; FILE REFERENCE: P3430R1C86
; CURRENT APPLICATION NUMBER: US/10/176,757
; PRIOR APPLICATION REMOVED - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 420
; LENGTH: 736
; TYPE: PRT
; ORGANISM: Homo Sapien
US-10-176-757-420
Query Match 30.9%, Score 1223, DB 9, Length 736;

```

```

Best Local Similarity 35.2%; Pred. No. 3e-91;
Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

QY 2 EAETGSSV--ETGKANRGTIRAL--VVFVGTLVLTILF--LVYSQGL--ISLQAKOEYCL 55
Db 7 ELGAGSNVGFQKGTQQLGSRFQLELVLAGASLLALLGICVALGQYHRDPSHSTCL 66
QY 56 KPECLEAAALILSKVNLSDPCDNFPRACGMSNNPIPEDMFSYGYVPLRINVDLKL 115
Db 67 TEACIRVAGKILTESLDRGVSPCEDFYOFCGCGWIRNDPLDGRSRWMTFNSLMQONAIL 126
QY 116 KELEKSISSRRDTEAIDAKILVSCMNKEAIKADAKPLHLIRSPFWPLYESNIG 175
Db 127 KHLLENT--TFNSSSEAEOKTOREYLSCLQVERIEELGAQPLRDLI-----EKIG 174
QY 176 P---EGWSEERKPSLLQTLATFRGOYSNVSFIRLYVSPDDKASNEHILKDAITLSAVR 232
Db 175 GWNITPMDQDNF--MEVTKAVAGTYRATPEFTYISADSXSNSNVIOYDQSGLEFLPSR 232
QY 233 EDYLDNSTEAKSYRDALYKENVDTAVLLGANSRAEDHDKSVLRLEIKIAEIMIPH--ENR 291
Db 233 DYTL--NRTANEKVLTAIYLDYMEELGMLGGRPTSTREQMOQVLELEIQLANTIVPODQR 291
QY 292 TTSAMNKNKNSISLSAMITQFMDLGYIKVYIDRLYPLHKDISPSENVVVRVPOYKDLF 351
Db 292 DEKRIYHKMSISELQALAPSMIDLEFLSFLSP-----LELSDSEPVVYGYMDYLOQVS 345
QY 352 RILGSEKRTKIANTLYVWRVYSRIPNLSRRFOYRWLEFSRYIGT--TLLPQMDKCVNFI 410
Db 346 ELINRPEPILNNYLTIMNLVOKTSSLDKRESAQEKLEITLYGKSKSCVPWQTCISNT 405
QY 411 ESALPYVVGKMFVDYVFOEDKEMMEELVEGVRAFDIMLEKENEMWDAGTKRKAERAR 470
Db 406 DDALGFALGSLFVKATFDROSKETAEAGMISEIRTAFEAL--GQLVWMDKTRQAKKAD 464
QY 471 AVLAKEYPEEIMNDHVNEDLKAIFSEADYFGNVLTQRTKILASDFEMLKRAVPKTEM 530
Db 465 AITDMIGFPEDEILPEKELDDYDGYEISDSFQNMNLNYSKAVMADOLKRPSPDQW 524
QY 531 FTNPVTYNAFYSTNQIRFPAGELQKPFPGTGYPRSLSYGAIGVYGHFTHGPDNG 590
Db 525 SMPQVNAVYLLPTKNEIYFPAGILQAPRY--ARNHPKALNFGIGVYGMHELTHAFDDG 583
QY 591 RYDKNGNLDPWWSDESEKEKTKCMINQYSNYWKAGLVNKGRTLGENTADGCL 650
Db 584 REYDKNGNLPRWQWONESLAFRNHTACMEQYNY--QVNGERLNGRQTLGENTIDNGCL 641
QY 651 REAFRAYRKWINDRQGLEEPLLPGITFTNNQLEFLSYAHVRCNSYRPEARQVOIGAH 710
Db 642 KAAVNAVYKWL--RKHG--EEQQLPAGVLJTNHQLFEVGFAGVWCVSVRTPESHGELVTDPH 698
QY 711 SPQGFVNGAISNSEEFQKAFNCPNNTNRMGMDSCRLM 749
Db 699 SPARFVLTGLTNSRDLRHFQCPVGPSPMNPQ--QLCEVW 736

RESULT 15
US-10-176-913-420
; Sequence 420, Application US/10176913
; Publication No. US20030022298A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Chen, Jian
; APPLICANT: Desnoyers, Luc
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Pan, James
; APPLICANT: Smith, Victoria
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Zemin
; TITLE OF INVENTION: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC

```

; TITLE OF INVENTION: ACIDS ENCODING THE SAME
; FILE REFERENCE: P3430R1C66
; CURRENT APPLICATION NUMBER: US/10/176,913
; CURRENT FILING DATE: 2002-06-20
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 612
; SEQ ID NO 420
; LENGTH: 736
; TYPE: PRT
; ORGANISM: Homo Saplen
US-10-176-913-420

Query Match

30.9%; Score 1223; DB 9; Length 736;

Best local Similarity 35.2%; Pred. No. 3e-91;
Matches 267; Conservative 145; Mismatches 307; Indels 40; Gaps 18;

QY 2 EAETGSSV--ETGKKANRGRTRIAL-VVFVGTVLGTILF--LVSQGL-LSLQAKQEXCL 55
DB 7 ELGSGSNVGFQKTRQLGSGRTQLELVAGASLLAALLGLCLVALGVQYHRDPSHSTCL 66
QY 56 KPECIEAAAIIISKVNLSDPCDNFERRACDGMISNNPIPEDMPSYGVYPMLRHNDLKL 115
DB 67 TEACIRVAGKILESIDRGVSPCEDFYQSCGGMIRNPLPDGSRKMTFNSLMDQNAIL 126
QY 116 KELLEKSISRRTDEATQAKILYSCMNEKAIEKADAKPLHLIRSPFRMPVLESNIG 175
DB 127 KHLELENT-TFNSSSEADQKTRFYLSCLQYERIELGAQPLRDLI-----EKIG 174
QY 176 P---EGWSEKRPSSLOTLATFRQYNSVPIRLYVSPDDKASNEHLIKDQATLSLAVR 232
DB 175 GWNITGWDODNF--MEVLAVAAGTYRATPEFYIISADSKSSNSNVAIQVDSGLFLPSR 232
QY 233 EDYLDNSTEAKSYRADALYKFEVDVAVLGANSRRAEDMKSVLRLEIKIAEIMIPH-ENR 291
DB 233 DYIL-NRTANEKVLTATLDYMEELGMLGGRTSTRQMQVLELEIQANITVPQDQR 291
QY 292 TSEAMNKKMISLISAMIPOFDWLGKIKVYIDRLYPLKDISPENYVVRVQYFKDLF 351
DB 292 DEEKIYHKMSISELQALAPSDMWEFLSFLSP-----LELSDEPYYVVGMDYLOVS 345
QY 352 RIIGSEKKTIANLYVMRYMSRIPLNLSRROYMLESRYIOGT-TTILPQWDCVNF 410
DB 346 ELIRTEPSTLNNLYLNNLVOKTSSLDPRRESAOKLETLTYGKKSCVPRWOTCISNT 405
QY 411 ESALPYVVGKMFVDYFEQEDKEMMEELVEGVRWAFIDMLEKENEMDAGTKRRAKERAR 470
DB 406 DDAIGFALGSLFVATFDROSKETAEGMISLRTAFEEAL-GQLVMMDEKTRQAKERAD 464
QY 471 AVLAKGVYPEFIANDTVNEDLKAIRSEADYFGNVLTQTKYLAOSDFEFLRKAVPKTEW 530
DB 465 AIYDMIGFPDILEPKKEIDVDYDYEISEDSFQNMNLNYNFSAKVADQLRKPPSRDOW 524
QY 531 FTNPTTNAFYSASTNOIRPAGELQKPFWGTETPRLSYGALGVYIGHFTGFDONG 590
DB 525 SMTPTQYNAIYILPTKNEIVFPAGILQAPFY-ARHHPKALNFGIGVWGHLLTHAFDDG 583
QY 591 RKYDKNGNLDPMWSTSESEKREKTKCMINOYSNYWKAGLNVKGRKTLGENTADNGL 650
DB 584 REYDKEGNLRPMQNESLAFARNHTACMEQYNGY--QVNGERLNGRQTLGENTDNGL 641
QY 651 REAFRAIRKRVINDRQGLEPILPGITFTNNQLEFLSYAHRCNSYRPEARQVOYQAGAH 710
DB 642 KAAVNAKAWL--RKHG-EEQQLPAGVLTNQLTFVGFAQWCVSRTPESSHEGLVTDPH 698
QY 711 SPOFRVNGAISNSEEFOKAFNCPNSTMNGMDCRLM 749
DB 699 SPAFRVLTGLTNSRDLFRHRCGCVSPMNG-QLCEVW 736

Search completed: May 21, 2003, 18:55:13
Job time : 64 secs

GenCore version 5.1.4-p5.4578
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: May 21, 2003, 18:45:44 ; Search time 48 Seconds
(without alignments)
1500.098 Million cell updates/sec

Title: US-09-913-955a-1
Perfect score: 3958
Sequence: 1 MEAFGSSVETGKKNRGR.....AFNCPPNSTMNRMGMSCLRM 749

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

1: PIR_73:*
2: PIR1:*
3: PIR2:*
4: PIR3:*
4: PIR4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1351	34.1	774	2	JC7265
2	1283.5	32.4	750	1	HYHUN
3	1263.5	31.9	750	1	HYRIN
4	1260	31.8	751	1	HYREN
5	1257	31.8	758	2	JC2521
6	1257	31.5	770	2	JC4136
7	1248.5	31.5	758	2	A54667
8	1243.5	31.4	754	2	A53679
9	1241.5	31.4	754	2	A47268
10	1184	29.9	825	2	I46078
11	1119.5	28.3	750	2	D88082
12	1014.5	25.6	766	2	T20003
13	997	25.2	590	2	C88099
14	949	24.0	769	2	T24949
15	814.5	20.6	706	2	F87683
16	778	19.7	734	2	T16182
17	672	17.0	663	2	C70838
18	668	16.9	700	2	B82788
19	646.5	16.3	667	2	C87236
20	606	15.3	1589	2	T22668
21	599.5	15.1	732	1	HYHUK
22	567	14.3	798	2	T28906
23	547.5	13.8	801	2	T31991
24	512.5	12.9	726	2	B88099
25	511.5	12.9	823	2	T28132
26	502	12.7	627	2	F53290
27	495	12.5	627	2	C86850
28	494	12.5	627	2	A47098
29	442	11.2	774	2	T31512

30	420	10.6	649	2	E88098	protein F18A12.6 [
31	417	10.5	630	2	B98058	endopeptidase O (E
32	417	10.5	630	2	F95191	endopeptidase O [i
33	410.5	10.4	534	2	T33020	hypothetical prote
34	379	9.6	684	2	T32024	hypothetical prote
35	365	9.2	684	2	T11548	hypothetical prote
36	350	8.8	651	2	T31513	probable zinc meta
37	335.5	8.5	658	2	T16040	hypothetical prote
38	325.5	8.2	732	2	T32023	hypothetical prote
39	297.5	7.5	817	2	T25758	hypothetical prote
40	287	7.5	570	2	G88098	protein F18A12.3 [
41	291	7.4	734	2	F88098	protein F18A12.4 [
42	195.5	4.9	433	2	T28805	hypothetical prote
43	185.5	4.7	500	2	D88099	protein F18A12.5 [
44	157.5	4.0	198	2	D88098	protein F06D4.5 [i
45	157.5	4.0	198	2	T32025	hypothetical prote

ALIGNMENTS

RESULT 1

JC7265

neprilysin (EC 3.4.24.11) II - rat

C:Species: Rattus norvegicus (Norway rat)

C>Date: 18-Aug-2000 #sequence_revision 18-Aug-2000 #text_change 02-Sep-2000

C:Accession: JC7265

R:Tanjia, O.; Facchinetti, P.; Rose, C.; Bonhomme, M.C.; Gros, C.; Schwartz, J.C.

Biochem. Biophys. Res. Commun. 271, 565-570, 2000

A:Title: Neprilysin II: A putative novel metalloprotease and its isoforms in CNS and

A:Reference number: JC7265

A:Contents: Brain and testis

A:Accession: JC7265

A:Molecule type: mRNA

A:Residues: 1-774 <TAN>

C:Gene: nepril

C:Superfamily: neprilysin

C:Keywords: brain; glycoprotein; hydrolase; metalloprotease; neuropeptide; testis;

Query Match 34.1%; Score 1351; DB 2; Length 774;

Best Local Similarity 38.2%; Pred. No. 1.4e-83;

Matches 289; Conservative 156; Mismatches 266; Indels 46; Gaps 18;

QY	18	GTRALVVF--VGGTL-VICSTILF-----LVSGLSLDQAKOEYCIKPECTEAAATL 67
DB	39	GAIVTIGVFYSIGKQLPLNSLHVSRRHRTVYKRVLRDSSQKSDICTTPSCYIARATL 98
QY	68	SKVNLVDPDNEFRFACDGMISNPIPEDMPSYGYVPMVLRHNVDLKLELEKSSRRR 127
DB	99	QNDQSKKPCDNYOYACGGLRHNVHYPENSRYSVFDLRDELVLKGLVEDSSVQHR 158
QY	128	DTEALQAKTLYSSCKNEKAEKADAPLHIIHRSPFMPVLESNIGEGVWSER--K 184
DB	159	--PAVEKAKTLYRSCMQSVTERKDSPEPLNVL--DWIGGVPVAMDK-----WNETMGK 209
QY	185	FSLIQTATFRGOYSNVSFRLVYVSPDDKASNHILKLDATSLAVREDYLDNSPEAKS 244
DB	210	WELEKRLAVLNSQFNRRVLDLFTIMDDQNSKHVYIIDPITIGMSREYTF--KDSNR 267
QY	245	YRDALYKFNVDYAVL-----LGANSRAEDHMKSVLRLEIKIAELIMPHENTTS--EAY 297
DB	268	VREAVLGFMTSVAMLMRLDNLPGEDVLQGEAAQVLIHETHLANTVPEKRDVATLY 327
QY	298	NKANISLSAM--IPQFDWLGITKKYIDRLYHLKDISSENVVYRVQYFQDLRIIG 355
DB	328	HRKGLIELQERFGKGFKNMTLFTIONVLSVQV---ELAPNEVVYVGGIPLYENLEIID 383
QY	356	SEKRTIANTLVMMYRSPINLSRRQYKWLFEFSRVIQSTTLLOPMQKCVAFISALP 415
DB	384	VFPQITQNTLVRLVLDRIQSLQRFKARVYRKALGTTIEEVRMECSYVSNME 443
QY	416	YVVGKMFVDVYFQEDKKEMAEELVEGVRAFIIDLEKENEMDAGTKRRAKARAVLAK 475

```

Db 444 SAVGLYIKRAFSKDSKSIYSELTEKIRSFVDNDELIN-WMDESKKKAQEKALNIREQ 502
Qy 476 VGYPEFIM--MDTHNEDLKAIFSEADYFEGNVIQTIRKYLQSPDFMIRKAVPEFTWFTN 533
Db 503 IGYPIYLEDNRHRLDEDEYSSLTFSSEDLTFEYNGLNKNKNSRLKLRKREKVDNLTWIG 562
Qy 534 PTTVAFASTASTNOIRFPADELQKPFEPWGTETPRSLSYGAIGVIGHEFTGFDDNGSKY 593
Db 563 AAVNAFAFSPNRNLIVFPAQLQPPFF-SKQDQALNNGGIGMVGITHTGFDDNGRNF 621
Qy 564 DKNGNLDPMWSTSESEKKEKTKCMINOYSNYWKKA-GLNVKGRITGENIADNGGLRE 652
Db 622 DKNGNLDPMWSTSESEKKEKTKCMINOYSNYWKKA-GLNVKGRITGENIADNGGLRE 681
Qy 653 AFRAVRKRWINDROGLEELPLPGITFTNNOLFSTYAHVRCNSYRPEARQVIGAHSP 712
Db 682 AYKALQWL---ASGRDQRLPGILTYAQLFETNYAQWCGSYRPEAFIQSITVDVHSP 738
Qy 713 POFRVNGAISNSEEFOKAFNCPPNSTMNGMDSCLRW 749
Db 739 LKRYLIGSLQNLPGFSEAFHCPRGSPMH-PMNRGRIM 774

```

RESULT 2

```

neprilysin (EC 3.4.24.11) [validated] - human
N:Alternate names: CD10; common acute lymphocytic leukemia antigen; endopeptidase 24.11;
C:Species: Homo sapiens (man)
C:Date: 30-Sep-1992 #sequence, revision 30-Sep-1992 #text, change 08-Dec-2000
C:Accession: A41387; A36173; S05275; JLD084; S00350; S02228
R:ID:Adamo, L.; Shipp, M.A.; Masteller, E.L.; Reinherz, E.L.
Proc. Natl. Acad. Sci. U.S.A. 86, 7103-7107, 1989
A:Title: Organization of the gene encoding common acute lymphoblastic leukemia antigen
A:Reference number: A41387; MUID:8938688; PMID:2528730
A:Accession: A41387
A:Molecule type: DNA
A:Residues: 1-750 <DNA>
A:Cross-references: GB:M26605
A>Note: The authors translated the codon AAC for residues 14 and 72 as Asp
R:Shipp, M.A.; Richardson, N.E.; Sayre, P.H.; Brown, N.R.; Masteller, E.L.; Clayton, L.R
Proc. Natl. Acad. Sci. U.S.A. 85, 4819-4823, 1988
A:Title: Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA)
A:Reference number: A36173; MUID:88263036; PMID:2368607
A:Accession: A36173
A:Molecule type: mRNA
A:Residues: 1-750 <SH1>
A:Cross-references: GB:J03779
A>Note: part of this sequence was confirmed by protein sequencing
R:Jongeneel, C.V.
Submitted to the EMBL Data Library, August 1988
A:Reference number: S05275
A:Accession: S05275
A:Molecule type: mRNA
A:Residues: 1-750 <ION>
A:Cross-references: EMBL:Y00811; NID:929625; PIDN:CA68752.1; PID:929626
R:Lebarte, M.; Vera, S.; Tran, R.; Addis, J.B.; Onizuka, R.J.; Quackenbush, E.J.; Jong
J. Exp. Med. 168, 1247-1253, 1988
A:Title: Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase
A:Reference number: JLD084; MUID:89010526; PMID:29711756
A:Accession: JLD084
A:Molecule type: mRNA
A:Residues: 1-750 <ION>
A:Status: nucleic acid sequence not shown
A:Molecule type: mRNA
A:Residues: 2-191; 211-737 <LET>
A:Cross-references: EMBL:Y00811
R:Note: part of this sequence, including the amino end of the mature protein, was confir
R:McFoy, B.; Khan, W.J.; Seeburg, P.H.; Mason, A.D.; Schorfield, P.R.
FEBS Lett. 223, 206-210, 1988
A:Title: Molecular cloning and amino acid sequence of human enkephalinase (neutral endop
A:Reference number: S00350; MUID:88152222; PMID:3162217
A:Accession: S00350
A:Molecule type: mRNA
A:Residues: 3-750 <MAL>

```

```

A:Cross-references: EMBL:X07166
A>Note: 467-Thr was also found
C:Comment: This enzyme inactivates a variety of peptide hormones, cleaving on the amide
C:Comment: This antigen is an important cell surface marker glycoprotein in the diag
C:Gene: neprilysin
A:Gene: GDB:MME
A:Cross-references: GDB:120190; OMIM:120520
A:Map position: 3q25.1-3q25.2
A:Introns: 54/1; 66/1; 120/1; 147/1; 179/1; 218/3; 240/3; 285/3; 319/3; 365/2; 396/3;
C:Superfamily: neprilysin
C:Keywords: glycoprotein; hydrolase; metalloproteinase; oligopeptidase; surface anti
F:2-750/Product: neprilysin #status experimental <MAT>
F:16-23/Region: stop-transfer sequence
F:29-51/Domain: transmembrane #status predicted <TM>
F:52-750/Domain: extracellular #status predicted <EXT>
F:145; 285; 311; 325; 335; 628/Binding site: carbohydrate (asn) (covalent) #status predict
F:584; 588/Binding site: zinc (His) #status predicted
F:585/Active site: Glu #status predicted

```

```

Query Match 32.4% Score 1283.5; DB 1; Length 750;
Best Local Similarity 35.9%; Pred. No. 5.2e-79;
Matches 272; Conservative 155; Mismatches 285; Indels 45; Gaps 19;

```

```

Qy 13 KKANRGTALVYVGGTIVLTGTFITLVSGGLSLQAKOE--YCKPECTEAAAAILSKV 70
Db 19 KKRQMTPEISLSV--LVLTITVMTALVATVDDGICKSSDCKSAARLIQNM 73
Qy 71 NLSVDCDNFRRACGMSNPNIPDMPSYGYPMRLRNVDLKLKELKESISRRDTE 130
Db 74 DATPECTGFKKACGGMKRNVPETSSRYGFDLRLDELVYAKDLQ--PTEIDIV 131
Qy 131 AIOKATILVSSCNEKAIEKADAKPLHLIRSPFMRPLENIGPEGWSR--KPSL 187
Db 132 AVGKAKATVRSCTNEAIDSRGEPLKTL-PDIQGMVATEN-----WEKYGASMTA 184
Qy 188 LQTLATFRGOYSNVITRLVYSPDOKASNEHLIKDQATLSLAVREDYDINSTAKSYRD 247
Db 185 EKAIQDINSYKGRKVLINFLVGDGDKNSVNHVHIDQPLGRPSR-DYEECTGYEACT 243
Qy 248 ALKFMVDVAVL-----IGANSSRAHEHMKSVLRREITAIIMIPHEHRTSE-AMYKM 300
Db 244 AYVDFMISVARKLRQERLPIDENQALDMKNVMELEKTIANAIAKPEDRNDPMLYKMK 303
Qy 301 NISLSAMT-----POFDMLGIRKVIDTRILPHLKDISPSENVVVRVQYKDFLRL 354
Db 304 TLAQIQNNFSLIEINGKPFQMLNFTNIMSTVNI---STINEDVYVAPELTKLPIL 359
Qy 355 GSERKRTIANYLVWRVYRIPMLSRFQYRMLESRYVIGTTLLPQMDKCVNIESAL 414
Db 360 TKYSARDLQNLMSWRIMDLVSLSTRYKESRNAEFKALYGTSTETATWRCANVYNGNM 419
Qy 415 PYYVGMKFDVYFQEDKRMMEELVGVWATIDMLEKNEEMDAGTRAKAEKARAVLA 474
Db 420 ENAVGRVLYEAAVAGSKHVEDLQALREVFITQLD-DLTWMDAETKRAEKAALKE 478
Qy 475 KVGYP-EFTMNDTHVEDKAIKFESEADYFQVGLVTRKYLQASDFMIRKAVPEFTWFTN 533
Db 479 RIGYPPDIYSNDKLNNELELYNKEDEFENIQLNKAFSQSKQKLKREYDKDQEMJSG 538
Qy 534 PTTVAFASTASTNOIRFPADELQKPFEPWGTETPRSLSYGAIGVIGHEFTGFDDNGSKY 593
Db 539 AAVNAFAFSPNRNLIVFPAQLQPPFF-SAQOSNLNNGGIGMVGITHTGFDDNGRNF 597
Qy 594 DKNGNLDPMWSTSESEKKEKTKCMINOYSNYWKKA-GLNVKGRITGENIADNGGLRE 652
Db 598 NMDGDLVMDWTOOSANFSEQSQCVAYQYGNFSDLAGQHQLINTLGENIADNGGLGQ 657
Qy 653 AFRAVRKRWINDROGLEELPLPGITFTNNOLFSTYAHVRCNSYRPEARQVIGAHSP 712
Db 658 AYRAYQNTI--KNG-EELTLPGDLNKLQFLFLNFAQWCGTGYRPEAYVANSIKITVDVHSP 714
Qy 713 POFRVNGAISNSEEFOKAFNCPPNSTMNGMDSCLRW 749

```

Db 715 GNRRIIGTIONSAPFSEAFHCKRKNSTYNN-PEKCRW 750

RESULT 3

HYPER

neprilysin (EC 3.4.24.11) - rat

N,Alternate names: CD10; common acute lymphocytic leukemia antigen; endopeptidase 24.11;

C:Species: Rattus norvegicus (Norway rat)

C:Date: 30-Sep-1992 #sequence, revision 30-Sep-1992 #text-change 18-Jun-1999

C:Accession: A29295; A33521

R:Malfoy, B.; Schofield, P.R.; Kiang, W.J.; Seeburg, P.H.; Mason, A.J.; Henzel, W.J.

Biochem. Biophys. Res. Commun. 144, 59-66, 1987

A:Title: Molecular cloning and amino acid sequence of rat enkephalinase.

A:Reference number: A29295; MUID:87213218; PMID:3555469

A:Accession: A29295

A:Molecule type: mRNA

A:Residues: 1-750 <MAL>

A:Note: part of this sequence, including the amino end of the mature protein, was confir

R:Bateman Jr., R.C.; Jackson, D.; Slaughtner, C.A.; Umithan, S.; Chai, Y.G.; Moomaw, C.

J. Biol. Chem. 264, 6151-6157, 1989

A:Title: Identification of the active-site arginine in rat neutral endopeptidase 24.11

A:Reference number: A33521; MUID:89197908; PMID:2703483

A:Accession: A33521

A:Molecule type: protein

A:Residues: 95-102, 'X', 104-129 <BAT>

C:Comment: This enzyme inactivates a variety of peptide hormones, cleaving on the amino

neprilysin

C:Superfamily: neprilysin

C:Keywords: glycoprotein; hydrolase; metalloproteinase; oligopeptidase; surface antigen;

F:9-750/Product: neprilysin #status experimental <MAL>

F:16-23/Region: stop-transfer sequence

F:29-51/Domain: transmembrane #status predicted <TMN>

F:752-750/Domain: extracellular #status predicted <EXT>

F:145-285,325,628/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:311/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:584,588/Binding site: zinc (His) #status predicted

F:585/Active site: Glu #status predicted

Query Match 31.9%; Score 1263.5; DB 1; Length 750;

Best Local Similarity 35.7%; Pred. No. 1.2e-77;

Matches 270; Conservative 151; Mismatches 291; Indels 45; Gaps 19;

Db 13 KANGGTRIALVVFVGGTIVLGTILFVSGGLSLQAKOE--YCLAPCEIAAAALISKY 70

19 KKKQMTPLSLSY--LVL--LITVAVTALVATYDGIKSSPCISARLIQNM 73

71 NLSVPCDNFRFACDGMISNNPREDMPISYGVPMLRHNVLDLKELESISRRTDE 130

74 DASAPCDDFFKYACGMLKRVIPETSSRSNFDILDELVLKDVLOE--PKTEIV 131

131 AIOKKILYSCMNEKAIEKADAKLHLIRHSPFRVLESNICEGVSE--RKFSL 187

132 AVOAKATLYRSCINSALDSRGQPLTLTL--PDIGWVASON-----WQDTGTSTWA 184

188 IOTLTFPGOVSNSVIFIRLYVSPDKASNEHLIDQATSLAVEDVLDNSTEAKSYRD 247

185 EKSIQOLNSKYKAVLINEFVGTDKNSTQIHFDQRLGLPSR-DYECTGIYKACT 243

248 ALYKENVDTAVL-----LGANSSRAEDMKSVLRLEIKIAEIMPHENRTSE-AMYKRM 300

244 AVVDMSIVARLRLEORLPIDENQLSLEMMKVMLEKEIANATKPKDRNDPMILYKRM 303

301 NISLSAMI-----PQDMGLGTYIKVVDTRILYPLKDISPENNVAVVPYFKDLFKIL 354

304 TLAKLONNESLEINKSPFSMNFTEIMSTVNI-----NIQNEEVVAVAPETLRKLEIL 359

355 GSEKRTIANYLVMMVYSRIPLNLSRRFQYRLSESVYGGTTLLPQWDCVNFIEEAL 414

360 TKSPDLDONLMSWRFINDIVSSLSRNTKESNARAKALYGTSTSTAWRRCANVNMNM 419

415 PYVVGKMFVYVFOEDKKEEMELVEGVMAFIDMLEKENEMWMAQGYRKRAKARAVLA 474

Db 420 ENAVGLUYEAAFAAGSKSHVEDLLIQIREVFQTLQD-DLTWMDAETKKAEKALAIKE 478

475 KVGYP-EFTMNDTHVEDIKAIKFSADYFGVNLQTRKILASDFEMLKAPKTEMTN 533

479 RIGYDDIISNENKLNNELELYKEEYFENIOMLKFSQSKOLKREKVDKQWISG 538

534 PTYNVAFYSATQIREFPAGELQPFPGWGTETPRSLSYAIGVYGHETFGDNGRKY 593

539 AAVVNAFYSGRNQIYFPGIQLDPFF-SARQSNLSNYGIGVYGHETFGDNGRNF 597

594 DRNGNIDPMWSTSEKFEKTKCMINQYSNYYWKA-GIANYKRTIGENTADNGIRE 652

598 NKDGDLVDMWTQOSANNFKDQSCWYQGNFTWDLAGGSHINGITLADNGIQQ 657

653 AFPAIKRWINDROGDEPLRLPGITTTNNQPLFLSAHRKNSYRPEARQVOIGANSP 712

658 AYRAYONYV--KKNG-EKELPLDLNHRKQLFELNLAQVCGTYREYAVNSIKTDVHSP 714

713 POFVNGAISNSEFOKAFNCNPSTNRQMDSCRLM 749

715 GNRRIIGTIONSAPFADAFCKRKNSTYNN-PCRW 750

RESULT 4

HYPER

neprilysin (EC 3.4.24.11) - rabbit

N,Alternate names: CD10; common acute lymphocytic leukemia antigen; endopeptidase 24.

C:Species: Oryctolagus cuniculus (domestic rabbit)

C:Date: 30-Sep-1992 #sequence, revision 30-Sep-1992 #text-change 18-Jun-1999

C:Accession: A29451; I46872

R:Devall, A.; Lazure, C.; Nault, C.; Le Moual, H.; Seldah, N.G.; Chretien, M.; Kahn,

EMBO J. 6, 1317-1322, 1987

A:Title: Amino acid sequence of rabbit kidney neutral endopeptidase 24.11 (enkephalin

A:Reference number: A29451; MUID:87275825; PMID:2440677

A:Accession: A29451

A:Molecule type: mRNA

A:Residues: 1-751 <DEV>

A:Cross-references: EMBL:X05338

A:Note: part of this sequence, including the amino end of the mature protein, was con

R:Kahn, P.H.; Powell, J.F.; Beaumont, A.; Rogues, B.P.; Mallet, J.J.

Biochem. Biophys. Res. Commun. 145, 488-493, 1987

A:Title: An antibody purified with a lambda gIII fusion protein precipitates enkephal

A:Reference number: I46872; MUID:87241544; PMID:3297057

A:Accession: I46872

A:Status: translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 207-275 <KAR>

A:Cross-references: GB:M16593; NID:g165556; PIDN:AAA53694.1; PID:g165557

C:Comment: This enzyme inactivates a variety of peptide hormones, cleaving on the am

neprilysin

C:Superfamily: neprilysin

C:Keywords: glycoprotein; hydrolase; metalloproteinase; oligopeptidase; surface anti

F:2-751/Product: neprilysin #status experimental <MAL>

F:16-23/Region: stop-transfer sequence

F:29-51/Domain: transmembrane #status predicted <TMN>

F:52-751/Domain: extracellular #status predicted <EXT>

F:145,286,312,326/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:585,589/Binding site: zinc (His) #status predicted

F:586/Active site: Glu #status predicted

F:629/Binding site: carbohydrate (Asn) (covalent) #status experimental

Query Match 31.8%; Score 1260; DB 1; Length 751;

Best Local Similarity 36.0%; Pred. No. 2e-77;

Matches 273; Conservative 149; Mismatches 290; Indels 46; Gaps 20;

Db 13 KANGGTRIALVVFVGGTIVLGTILFVSGGLSLQAKOE--YCLAPCEIAAAALISKY 70

19 KKKQMTPLSLSY--LVL--LITVAVTALVATYDGIKSSPCISARLIQNM 73

71 NLSVPCDNFRFACDGMISNNPREDMPISYGVPMLRHNVLDLKELESISRRTDE 130

74 DATAEPCDDFFKYACGMLKRVIPETSSRSNFDILDELVLKDVLOE--PKTEIV 131

```

RESULT 5
JC2521
endothelin converting enzyme (EC 3.4.24.-) 1, umbilical vein endothelial cell form - human
C|Species: Homo sapiens (man)
C|Date: 17-May-1995 #sequence_revision 14-Jul-1995 #text_change 20-Jun-2000
C|Accession: JC2521
R|Shimada, K.; Matsushita, Y.; Wakabayashi, K.; Takahashi, M.; Matsubara, A.; Iijima, Y
Biochem. Biophys. Res. Commun. 207, 807-812, 1995
A|Title: Cloning and functional expression of human endothelin-converting enzyme cDNA.
A|Reference number: JC2521; MUID:95169128; PMID:7864876
A|Accession: JC2521
A|Molecule type: mRNA
A|Residues: 1-758 <SHIT>
A|Cross-references: GB:D43698; NID:g1197803; PIRN:BA07800.1; PID:g1197804
A|Experimental source: umbilical vein endothelial cells
C|Genetics:
A|Gene: GDB:ECEL1; ECE
A|Cross-references: GDB:698357; OMIM:600423
A|Map position: 1p36.1-1p36.1
C|Superfamily: neprilysin
C|Keywords: alternative splicing; glycoprotein; hydrolase; metalloproteinase; transmembrane
F:57-77|Domain: transmembrane #status predicted <TM>
F:154,175,198,258,304,350,371,527,620,639|Binding site: carbohydrate (Asn) (covalent) #status predicted
F:505,599|Binding site: Glu #status predicted
F:356|Active site: Glu #status predicted

```

Best local Similarity 37.6%; Pred. No. 3-3e-77;
Matches 281; Conservative 126; Mismatches 276; Indels 64; Gaps 21;

```
QY 21 IALVYVGGLVLTGLLEFLVSGLSLQAKOECLEKPECTEIAAAIILSVNLSVDPDNF 80
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 58 VLVVLV-----LAAGLVACLAALGLOYOTRSPVCSLSEACVSVTSLISMSDPVPCGHF 113
QY 81 FRPACGWMISNNIPEDMDESYGVYPMILRHNVLDLTKELLEKTSIRRDORFAIOKAIIS 140
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 114 FSVACGWMKANVPDGHGSMWGFNSLMEHNAQIITHLEENSTAA--SVSEAERKAQVYIR 171
QY 141 SCMEKAIEKADAKPILHLRLHSPPFRMPVLESNIIGEGVSEKRTSLQTLATFRGOYSN 200
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 172 ACMEERIEELRKAPLMEILERLG--GMNI-----TGPMAKDNIQ--DTLOVVAHYRT 221
QY 201 SVYIRLVYSPDDKASNEHLKIDQALSLAVREDYLDNSTEAKSTYDALKYMWDTAVLL 260
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 222 SPFFSYVASDKNSNSNVIQVDSGLSPSDYTL--NKTENEKVLTYGLNVMVLGKLL 280
QY 261 GANSSRA--EHDMSVLRLEKIAELMIPHEMRTSEAM--YKNKISLESLAMIPQDMLGYT 318
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 281 GGDDEFAIRPMQOILDFETALANITIPQEKRDDELIHYKVTALQTLARAINMLP-- 339
QY 319 KAYIDRLPHLKDISEPNVYVRVQYFKDLFRILIGSEKRTKIANYLVWRVYTSRIPLV 378
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 340 ---LNTIFP--VEINESPIVYDYDEYLEQSTLINTDROLLNNYIMTNLYVRTSSEL 394
QY 379 SRNFQYRMLEFSRVIOGT--TTLPLQWDKCVNFTESALPYVGMKMEVDYFQEDKEMME 437
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 395 DQRFQADAEKFMVVMYGTKTCCLPRMKPCVSDPTENNLGALDPMYKAFAPADSSTATE 454
QY 438 LVEGVMAIIDLKENEVMADGTRKAKAKAVALAKYGEFTY-----NDTHV 488
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 455 ILEIKKAEESL--STLKMDEDETRSAKEKADAIYMGIEPNFTMDPKELDVENDYTA 513
QY 489 NEDLKAIKFSADYFCGNVLOTQRKYLQSDFF-----LRKVPKTEMTNTPTYNAPFS 542
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 514 VVDL-----YENAMRF-----FNSKRVATADOLRKAPVNDQSMTPMNAIYS 558
QY 543 ASTNOIRPAGELQKRFEMGTEYPSRLSYGAIGVJGHEFTGFDNNGRKDYDKNGLDPM 602
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 559 PKNEITVFPAGIILQAPFYRRS--PKALNFGGIGVVGHELTAFPDQGREYDKDGNLPM 617
QY 603 MCTESEKKEKTKCMINQSYMYKKKAGLANKGKRTIGENIADNGLEAREAFRAYRKIN 662
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 618 MNSSVYEAKEKROTECVNEYSNY--SVNGEPNGRHTTGENTADNGGKAAARAYQANV-- 674
QY 663 DRROGLEEPLTIGITETNNQTLFFLSYAHRCNSYSPAREQVIGASIPQFPRNGAIS 722
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 675 -KKNGAHNS-LPTLIGLTNNQLEFLFPAQYWCVCVPRPESHGELIINDHSPSFRNYIGLS 732
QY 723 NSEFQAKFNCPPNSTMNRGMDSCRLM 749
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 733 NSKEFSEHRCPPGSPMN--PPHKCEVM 758
      : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 6
JC4136
endothelin converting enzyme (EC 3.4.24.-) 1, renal adenocarcinoma form - human
C:Species: Homo sapiens (man)
C:Date: 31-Aug-1995 #sequence_revision 27-Oct-1995 #text_change 20-Jun-2000
C:Accession: JC4136; S51009; S47269
R:Origins: K.; Moroi, K.; Inagaki, N.; Saito, T.; Masuda, Y.; Masaki, T.; Sano, S.
Biochem. Biophys. Res. Commun. 208, 721-727, 1995
A>Title: Cloning and sequencing of a human endothelin converting enzyme in renal aden
A:Reference number: JC4136; MUID:95209687; PMID:7695628
A:Accession: JC4136
A:Molecule type: mRNA
A:Residues: 1-770 <YOR>
A:Cross-references: GB:D9471; NID:6695404; PIND:BAA08442.1; PID:6695405
A:Experimental source: renal adenocarcinoma cell
A>Note: It is uncertain whether Met-1 or Met-18 is the initiator
R:Schmidt, M.; Kroeber, B.; Jacob, E.; Seuberger, H.; Subkowski, T.; Otter, R.; Meyer
```


FEBS Lett. 356, 238-243, 1994
 A:Title: Molecular characterization of human and bovine endothelin converting enzyme (EC
 A:Reference number: S51009; MUID:95104423; PMID:7805846
 A:Accession: S51009
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 18-770 <SC2>
 A:Cross-references: EMBL:Z55307; NID:9535181; PIDN:CAA84548.1; PID:9535182
 C:Comment: This enzyme is a phosphoramidon-sensitive, membrane-bound metalloprotease.
 C:Genetics:
 A:Gene: GDB:ECEL1; ECE
 A:Cross-references: GDB:698357; OMIM:600423
 A:Map position: 1p36.1-1p36.1
 C:Superfamily: neprilysin
 C:Keywords: alternative splicing; glycoprotein; hydrolase; metalloproteinase; phosphop
 F:69-89/Domain: transmembrane #status predicted <TM>
 F:25/Binding site: phosphate (Thr) (covalent) #status predicted
 F:166,187,210,270,316,362,383,539,632,651/Binding site: carboxylate (Asn) (covalent) #
 F:607,611/Binding site: zinc, catalytic (His) #status predicted
 F:608/Active site: Glu #status predicted

Query Match 31.8%; Score 1257; DB 2; Length 770;
 Best Local Similarity 37.6%; Pred. No. 3,4e-77;
 Matches 281; Conservative 126; Mismatches 276; Indels 64; Gaps 21;

QY 21 IALYFVGTLVLTIFLVSQGLSLQAKQVCLKPCIEAAALISKVLSVPCDNF 80
 DB 70 VLVVLVLAAGVLAALAGVLTQYOTRSPVCLSEACSVTSILSMDPTVPCDF 125
 QY 81 FRFACDGIWNNPIEDMPSYGVYVWLRHNDLKLKELLEKSISRRTDTEAIOKAKILYS 140
 DB 126 FSYAGGMIKANPVDGHSRWGTFSLNMEHQALIKHLENSTA--SVSEAEKRAQYYR 183
 QY 141 SCMNKAIEKADARPLHLIHSFRPWVLESNIGPEVWSEKRSLLQTLATFGQYSN 200
 DB 184 ACMNTRIEELRAKPLMELIERLG-GWNI-----TGPMAKDNFQ--DTLQVVTAAHRT 233
 QY 201 SFVILYSPDDKASNEHLIKLQATLSLAVREDYLDNSTEAKSYRDALYFMVDTAVLL 260
 DB 234 SPFEVYVSADSKNSNSNVIOVDSGLPSRDYLL-NKTENEKVLTOGLYMMVQGLKLL 292
 QY 261 GANSSRA-EHDMKSVLRLEIKIETIMPHENTSEAM-YKNKNISELSAMIPQDMLGYI 318
 DB 293 GGGDEEARPQQOILDEFETALANTITIPQEKRRDELLYHKYTAELQTLAPAIWMLPF- 351
 QY 319 KKVIDIRYLPHLKDISENNVAVRPOYFKDLFRILGSEKRTIANTLYMMVYSRIPNL 378
 DB 352 --LNTITFP--VEINSEPIVYDKEYLEQISTINTTDRCLLNMYIMLVKRTSFL 406
 QY 379 SRFEYRMLEFSRVIOGT-TTLIPQMDKCNFIESALPYVVGKMFVDYFQEDKEMEE 437
 DB 407 DQRFDDADEKFMWVYGTCKTCLPRMKFCVSDTENNLGAFALGPMVKATFADSKSTATE 466
 QY 438 LVEGYRMATIDMLEKENEMDAGTKRKAERAVLAKYGFETM-----NDTHV 488
 DB 467 ILLEIKKAFEEESL-STLKMDEETRKSAKADALYNNIGYENFIMDEKIDKYNDDTA 525
 QY 489 NEDLKAIFSEADYGVNLTQTKRYLAQSDFFM-----LRKAVPTMEFTNPTVNAFYS 542
 DB 526 VPDL-----YFENMRP-----FNSWRVTADOLKRAKPNDDQSMTPPMVNAFYS 570
 QY 543 ASTNOIRPAGELQKPFPMGTETPRSLSYGAIVGHEHTGFDNNRKAQDKNDKNDLPW 602
 DB 571 PKKNITVPAGITQAPFYTRSS-PKALNFGIGVYVGHETLHAFDQGRREYDKDQNLAPW 629
 QY 603 WTESEEFKREKTKCMINQYSNYWKAGLVAKKRTIGENIADNGIGLREAFRAYRKIN 662
 DB 630 WKNSSVEAFKQTECMVQYSNY--SVNGEPEVNGRHTIGENIADNGIGLREAFRAYQNNV- 686
 QY 663 DRQGLEELPLGTFETNNOLFSLYAVHRCNSYRPEARAOVQAGASPPOFRNGAIS 722
 DB 687 -KKNGAHS-LPTGLTNNQLEFLGFAQYWCSTRTPESSHGLITDHPSPSRFYIGSL 744

QY 723 NSEFOKAFNCPNPNSTNRGMDSCRML 749
 DB 745 NSEFSEHRCPPGSPMN-PPRKCEVW 770

RESULT 7

endothelin converting enzyme (EC 3.4.24.-) 1 - bovine
 C:Species: Bos primigenius taurus (cattle)
 C:Date: 28-Oct-1994 #sequence_revision 28-Oct-1994 #text_change 05-Nov-1999
 C:Accession: A54667; JC2448
 R:Xu, D.; Emoto, N.; Glaid, A.; Slaughter, C.; Kaw, S.; dewit, D.; Yanagisawa, M.
 Cell 78, 473-485, 1994
 A:Title: ECE-1, a membrane-bound metalloprotease that catalyzes the proteolytic activ
 A:Reference number: A54667; MUID:94340737; PMID:8062389
 A:Accession: A54667
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-758 <XUA>
 A:Cross-references: XUA:U27342; NID:9897601; PIDN:AAA82928.1; PID:9897602
 R:Ikura, T.; Sawamura, T.; Shiraki, T.; Hosokawa, H.; Kido, T.; Hoshikawa, H.; Shimad
 Biochem. Biophys. Res. Commun. 203, 1417-1422, 1994
 A:Title: CDNA cloning and expression of bovine endothelin converting enzyme.
 A:Reference number: JC2448; MUID:95032010; PMID:7945289
 A:Accession: JC2448
 A:Molecule type: mRNA
 A:Residues: 1-90, 'A', '92-698, 'A', '700-758 <TM>
 A:Cross-references: GBS:G73774; NID:9688289; PIDN:AA832062.1; PID:9688290
 C:Superfamily: neprilysin
 C:Keywords: hydrolase; metalloproteinase; transmembrane protein; zinc
 F:57-77/Domain: transmembrane #status predicted <TM>
 F:595,599/Binding site: zinc, catalytic (His) #status predicted
 F:596/Active site: Glu #status predicted

Query Match 31.5%; Score 1248.5; DB 2; Length 758;
 Best Local Similarity 37.9%; Pred. No. 1.3e-76;
 Matches 282; Conservative 121; Mismatches 281; Indels 61; Gaps 21;

QY 23 LVEFVGTLVLTIFLVSQGLSLQAKQVCLKPCIEAAALISKVLSVPCDNF 82
 DB 57 LVLVLVLAAGVLAALAGVLTQYOTRSPVCLSEACSVTSILSMDPTVPCDF 115
 QY 83 FADGMIWNNPIEDMPSYGVYVWLRHNDLKLKELLEKSISRRTDTEAIOKAKILYS 142
 DB 116 YACGGMKANPVDGHSRWGTFSLNMEHQALIKHLENSTA--SVSEAEKRAQYYRAC 173
 QY 143 MNKAIEKADARPLHLIHSFRPWVLESNIGPEVWSEKRSLLQTLATFGQYSN 202
 DB 174 MNTRIEELRAKPLMELIERLG-GWNI-----TGPMDKNFQ--DTLQVVTSHHTSP 223
 QY 203 FVILYSPDDKASNEHLIKLQATLSLAVREDYLDNSTEAKSYRDALYFMVDTAVLLGA 262
 DB 224 FSVYVSADSKNSNSNVIOVDSGLPSRDYLL-NKTENEKVLTOGLYMMVQGLKLG 282
 QY 263 NS-SRAEDMKSVLRLEIKIETIMPHENTSEAM-YKNKNISELSAMIPQDMLGYIK 320
 DB 283 GAEDTIPRQQOILDEFETALANTITIPQEKRRDELLYHKYTAELQTLAPAIWMLPF--- 339
 QY 321 VIOFRLPHLKDISENNVAVRPOYFKDLFRILGSEKRTIANTLYMMVYSRIPNL 380
 DB 340 -LNTITFP--VEINSEPIVYDKEYLKVSTLINSKCLLNMYIMLVKRTSFL 396
 QY 381 RFQYRMLEFSRVIOGT-TTLIPQMDKCNFIESALPYVVGKMFVDYFQEDKEMEE 439
 DB 397 RFQDADKFMWVYGTCKTCLPRMKFCVSDTENNLGAFALGPMVKATFADSKNINASEII 456
 QY 440 EGYRMATIDMLEKENEMDAGTKRKAERAVLAKYGFETM-----NDTHV 490
 DB 457 LEIKKAFEEESL-STLKMDEETRKSAKADALYNNIGYENFIMDEKIDKYNDDTA 515
 QY 491 DKAIRKSEADYGVNLTQTKRYLAQSDFFM-----LRKAVPTMEFTNPTVNAFYS 544
 DB 516 DL-----YFENMRP-----FNSWRVTADOLKRAKPNDDQSMTPPMVNAFYS 560

[illegible]

```

Query Match: 31.4% Score 1241.5; DB 2; Length 754;
Best Local Similarity 37.9% Pred.No. 3.7e-76;
Matches 282; Conservative 120; Mismatches 282; Indels 61; Gaps

QY 23 LVVFGGTLVLTIFLVSGGLSLDQAKOECLKPECIEAAMAILSKVNLVSPDCDNFR 82
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 53 LVVLV-ALTAALVACLAVLGIGYQRTSPVSCISEACISVTSLSMDPTVPCQDFET 111
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 83 FADCGMISNPEDIDMPGSGVGYWMLRHNDLKLKELLEISIRRDTEALQAKALLVSSC 142
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 112 YAGGGMKAPVVDGDSRNGTFSNMEHQAILKHLEENST--SVSEERKDQGYNAC 169
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 143 MNEKALEKADPLILHLNHSFRMPVLVLSNIGPEGVSEERFSLQTLATPFGYSNSV 202
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 170 MNEFRLEELKAKPLAMELIELGL-GWNI-----TGPMDKXQFG--DTLQVYTSYTHNSP 219
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 203 FIKLYVSPDDKASNEHILKLDQATSLAVREDYLDNSTEAKSYRDALYKFWYDRAVILGA 262
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 220 FEFVYVSADSKSNSNSNVIVDQSGILGSPRDYLL-NKTEENEKVLGTYLNVYMQGLKILGG 278
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 263 NS-SRAEHMDKSVLRLEIKIAELMIPHERNSTSEAM-YNKMNSTSETSAIMIQPDMLGKIK 320
      : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 279 GADDTLRPQMQLDDETLALANITTPQEKRRDEELIYHKVYIAAEIQTALPAINMLPF-- 335
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

QY 321 VIDTRLYPHLKDISPSENVVVRVPOYFKDLFRILGSEERKTIYANLVVMRYVSRIPLNLSR 380
      : ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

Db 336 -LNTIETP--VEINSEPIVIYDKKEYLSKSVSTLINSTDKCLINMIMNLYKRTSSFLDQ 392

QY 381 RFOYMLSESRVIOGT--TTLPLQMDKCVNFIESALPYVVGKMFVDVYEQEDKREKMEELV 439

Db 393 RQDDADEKFMVMTKTKTCLPRMKFCVSDIENTIGLFGMPFVATPAEDSKNIASRTI 452

QY 440 EGVWAFIDMLEKENEMDAGTKRRAKARAVLAKVGPFFIM-----NDTHVNE 490

Db 453 LEIKKAFSEEST--STLKAMDEDTKRSKAKKADAIYNNIGIPNIPKELDKVNDIYTAVP 511

QY 491 DLKAIKFSADYEGVVLQTRKYLQASDFEW-----LKRKAVTMDPTNPTVNAFYSAS 544

Db 512 DL-----YFNAMR-----FNSWRYTADQLKRAKRDQMSKTPPVNAYIYPT 556

QY 545 TNOIRPAGELQKPFMGTEYPRSLSYGAIYVGHFTGFDNNGKRYKNDPDMWS 604

Db 557 KNEIYVPAIILQAPFYTRSS--PNAINFSGIGVVGHELT HARDDQGREYDKGNLRPMWK 615

QY 605 TSESEKFKTKYCMINQYSNYWKKAAGLVKGRKRLGENIADNGSLREAFKRYKINDR 664

Db 616 NSSVEAFKQOTACMEQYQY--SVNGEPVNGRHTLGENIADNGSLKAAVRAVQMWV--K 671

QY 665 RQGLEPLPGITFTNNQFLSYAHVRCNSYRPEARQVOIGASHPPQFRVNGAISNS 724

Db 672 KNGAEQ--TIFTLGTRNNQFLSYAHVRCNSYRPEARQVOIGASHPPQFRVNGAISNS 730

QY 725 EEFQAFNCPNPSTNKGMDSCRLW 749

Db 731 KEFSEHFHCPGSPMN--PHKCEVW 754

RESULT 10

146078

endochelin converting enzyme (EC 3.4.24.-) 2 - bovine (fragment)

C:Species: Bos primigenius taurus (cattle)

C:Date: 16-Aug-1996 #sequence_revision 16-Aug-1996 #text_change 20-Sep-1999

C:Accession: I46078

R:Biochem. N.; Yanagisawa, M.

J. Biol. Chem. 270, 15262-15268, 1995

A:Title: Endochelin converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive me

A:Reference number: A57042; MUID:95318093; PMID:7797512

C:Accession: I46078

A:Status: Preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-825 <EMO>

A:Cross-references: EMBL:027341; NID:9897599; PID:9897600

C:Genetics:

A:Gene: ECE-2

C:Superfamily: neprilysin

C:Keywords: hydrolase; metalloproteinase

Query Match 29.9%; Score 1184; DB 2; Length 825;

Best Local Similarity 35.1%; Pred. No. 3.4e-72;

Matches 265; Conservative 138; Mismatches 313; Indels 38; Gaps 18;

QY 4 ETGSSVETGKANKRTRIALVVGGLVGLTILF--LVSOGL--LSLOAKOEYCLKEPCI 60

Db 102 EAGRRKRTSRILGHTQLEVL--AGVSLLAALLGLGLVALGVYHNDPSHSTCTFACI 160

QY 61 EAAAILSKVNLVSDPCDNFPRACDGMISNPIEDMPSYGYPIWRHNVDLKLELLE 120

Db 161 RVAKRIIESLDRGVSPCEDEFQFSCGMIRNPLPDGRSMNNSNSLMDNOALKHLLE 220

QY 121 KSIRRRDTEIAOKAKILYSSCMNEKAKERADAKPLHLIRHSPFMPVLESNIG--PE 177

Db 221 NT--FNSSESEKRTQRPYISCLDVERIEELGA---HALRD-----LIDKIGGNVT 268

QY 178 GVSEKRFSLQTLATFERGOYSNVEFTRLYVSPDKASNEHILKLDQATISLAVREYLD 237

Db 269 GPMQODN--MEVLKAVAGVTRAPFPFLVYVSADSKSNSNIIOVDSGLFLPSRDYLL-- 325

QY 238 NSTEAKSRDLKFFMVDTAVLGLANSRAHDMKSVLRLEIKTAELMIPH--EKRTSEAM 296

Db 326 NRTANKEVLTAVLDYMEELMGLGGQPTSTRQOMROYLEIOLANITVPOQDRDEKRI 385

QY 297 YNNKNISELSAMTPQDMLOGIKVIDTRLYPHKDISPENNVVAVPOYFKLFRILIS 356

Db 386 YHKMSIHELALAPASMDMLEFSLSP-----LELGSDEPVVYGTDLQGVSELINR 439

QY 357 ERKTIANYLVWRVYSRINLSRFOYRWLEFSRVIOGT--TTLPLQMDKCVNFIESALP 415

Db 440 TEPVNLNLYLWNLVQTTSSLDHREFSADKLELTLYGKTKCTPRMOCISINTDIALG 499

QY 416 YVVGKMFVDVYEQEDKREKMEELVEGVWMAFIDMLEKENEMDAGTKRRAKARAVLAK 475

Db 500 FALGSLFPAKTFDQSKSEIAGMISEIRVAFEEAL--SHLVMDKTEKQAKERADAIYDM 558

QY 476 VGYEPIFMDTHVEDLKAIFSEADYFGVNLQTRKYLQASDFEWLTKAVPTKEMFTNP 535

Db 559 IGFDFTLEPKELDDVYDGYEVSSEDFQNNLNYNSAKVMADQLKPPSRQMSKTPQ 618

QY 536 TVNMFYASTQIRPAGELQKPFMGTEYPRSLSYGAIYVGHFTGFDNNGKRYDK 595

Db 619 TVNAYILPTKNEIYFPAIILQAPFY--TGNHPQALNFGSIGVVGHELT HARDDQGREYDK 677

QY 596 NGNIDPMWSTSESEKFKTKYCMINQYSNYWKKAAGLVKGRKRLGENIADNGSLKAAFR 655

Db 678 EGNLRPMQONSILAFRHTIACIEQYQY--QVNGEKRLQTLGENIADNGSLKAAFR 735

QY 656 AYRKVINDRQGLEPLPGITFTNNQFLSYAHVRCNSYRPEARQVOIGASHPPQFRV 715

Db 736 AYKAMV--RKHG--EQQLPAGVGLNHLQFLYFGFQVWMSVTPRESSHGLTDPHSAPF 792

QY 716 RVNGAISNSEEFQAFNCPNPSTNKGMDSCRLW 749

Db 793 RVLGTLNSRDPLRHFGCGPVGSPMNSG--QLCEVW 825

RESULT 11

D88082

protein T05A8.4 [imported] - Caenorhabditis elegans

C:Species: Caenorhabditis elegans

C:Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 24-May-2001

C:Accession: D88082

R:Anonymous; The C. elegans Sequencing Consortium.

Science 282, 2012-2018, 1998

A:Title: Genome sequence of the nematode C. elegans: a platform for investigating bio

A:Reference number: A75000; MUID:99069613; PMID:9851916

A:Note: see websites genome.wustl.edu/gsc/C.elegans/ and www.sanger.ac.uk/Projects/C-

A:Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999;

A:Accession: D88082

A:Status: Preliminary

A:Molecule type: DNA

A:Residues: 1-750 <STO>

A:Cross-references: GB:chr_II; PIDN:AB95021.1; PID:92746865; GSPDB:GN00020; CESP:T05A

C:Genetics:

A:Gene: T05A8.4

A:Map position: 2

C:Superfamily: neprilysin

Query Match 28.3%; Score 1119.5; DB 2; Length 750;

Best Local Similarity 32.4%; Pred. No. 7e-66;

Matches 250; Conservative 150; Mismatches 324; Indels 47; Gaps 15;

QY 2 EAETGSSVETGKANKRTR--IALVVGGLVGLTILF--LVSOGL--LSLOAKOEYCLKEPCI 57

Db 4 DEEDGTTKSPG--SHWTRIMAILILILILVILGAIYF---YINWKSSDVCLSP 56

QY 58 ECTEAAAILSKVNLVSDPCDNFPRACDGMISNPIEDMPSYGYPIWRHNVDLKLE 117

Db 57 GCITKIVSLISSNNSVDPDCEDEFQFACGOWIKGHIIPDARSVSNFENLGGDLFAKLE 116

QY 118 LT--EKISIRRRDTEIAOKAKILYSSCMNEKAKERADAKPLHLIRHSPFMPVLESNIGP 176

Db 117 LLDENDEPYDETSAVGAKAYFYNLCLINSEIILDNRTTFDEYVK--SFGGWPSLGHOMKP 175

```

OY 177 EEWSEKRFSLIQLIATFRQOYSVFLRILYVSDDKASENHIKLDOATLSLAVREYU 236
Db 176 DA-----SIEMLYADWNAFEKADSEFKATVPQDDKNSORRHVLIIDQPLINTAFADFY 228
OY 237 DNSTEAKSYRDALKFEMVDYTVLLGAUSSRAEDHMKSVLLEIKIAEIMPHENRSEAE 295
Db 229 AAENE-----RMAVYQILRDVLIILDAORTRATIDAKTIIDFETALNITMADEHRDIAE 285
OY 236 MTKNMNISLSAMIPQDWMJGYIKRVIDTRLPLKDISPEN--VVRVPOYFCKLFRI 353
Db 286 LYTTLTGEMRRSLPHFNMPLFEFRMKDKLHEKNGKRITPDNTVEVYVGYELRRLDVL 345
OY 354 LGSEKKRTIAYLYMVRVY-SRIPNLSRRQYKMLESKRYIGTITLLPQMDKCNFTES 412
Db 346 IPQDNRILYLVLECMCFEFTMTLKDLPDPALITFEFKYKLTIMNOKYRWGICVTRINS 405
OY 413 ALPYVGKMFVDYFQEDKEMMELEVEGRMAFIMLEKENEMMDAGTKRRAKEARAY 472
Db 406 LMPAATSAIYKKNFHDEAKQVDEMSLIMESFVLLISE-DWLTKEKTKQYRAKQVNM 464
OY 473 LAKGYEPBELMNDTHVEDLKAIFSEBDFGNVLOTRYKLAQSDFFEMKRAKVPKTEMT 532
Db 465 KRIKGYEDYLMDPAVANNEXKTEFKVYPGHYQKFSFYBQYORDVLERTEADEBRWYA 524
OY 533 NPTVNAFYASASTQIR-----PAGELQKPFPMGTEYPRISUSYGAIVY 578
Db 525 GAAVNAFYSPNTEISKFLGTLTQRFKFSVPFAGILO-PVYSKDPFSSNMGIGIYI 583
OY 579 GHEFTHFDDNNGRKRYDNGMLDPMWQSESEKREKTKRKMINOYSNYMKRAGLVNKKR 638
Db 584 GHETTHFDDRGRLYDNLGIRQWMDNATISKFEHKAQCTIEKOYSYSLYDQIDMJOINKS 643
OY 639 TLGENIADNGGLEAFRAYRKMIINDRQGLEEPLTIGITFNNNOJFSLSYAHRNSYRP 698
Db 644 TKGENIADNGGLKQAVRAYKYY---EKRSRPRRLDPGVULTHDQLEFLNTAQIMCGTAMD 700
OY 699 EAAREVQIOIAHSPQOFRYNGAISNEEFQAKNCPNPSTNRMGDSGLW 749
Db 701 KEMLRKRTSHSPGPIRYKGLPSNSYDPAKKNYENPGSSOM-PRKKRYV 750

```

RESULT 12

hypothetical protein ZK20.6 - *Caenorhabditis elegans*
C:Species: *Caenorhabditis elegans*
C:Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 21-Jan-2000
C:Accession: T20003; I27775
R:Gajadsky, S.
submitted to the EMBL Data Library, March 1996
A:Reference number: 219209
A:Accession: T20003
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-766 <MI>
A:Cross-references: EMBL:Z69902; PIDN:CAA93770.1; GSPDB:GN00020; CESP:ZK20.6
A:Experimental source: clone C47D12
R:Gajadsky, S.
submitted to the EMBL Data Library, March 1996
A:Reference number: Z20417
A:Accession: T27775
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-766 <MI>
A:Cross-references: EMBL:Z69904, PIDN:CAA93782.1; GSPDB:GN00020; CESP:ZK20.6
A:Experimental source: clone ZK20
C:Genetics:
A:Gene: CESP:ZK20.6
A:Map position: 2
A:Introns: 11/1; 334/3; 439/1; 692/2; 734/2
C:Superfamily: neprilysin

Query Match	25.6%;	Score 1014.5;	DB 2;	Length 766;
Best Local Similarity	31.8%;	Pred. No. 9.6e-61;		

Matches 223; Conservative 157; Mismatches 292; Indels 29; Gaps 17;

```

QY 61 EAAAIILSTKNLVSDPCDNFEKACDGMISNNPILDEMPYSGVYPMILRHNDLKTLELLE 120
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 83 EASLLÖKSLNTSLDPCDDFFEVYCRAMVSHPLPDLTSTSOFTATREKLAEMRLYLE 142
QY 121 KSISSRDETAIOAKILLYSSCMEKAIEKADAPLHLILRHSPFRWLVESNIGPEGVW 180
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 143 DMS-IPTSISILIKOIVTMCMDTEKHNNAVGADELJEKTKTYG-IPVHNE-----KW 195
QY 181 SERKESLÖJLAFERGOYSVFIRLVSPDDASNHILIKLOATSL--AREEDVLN 238
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 196 RESTFDLTLLSMTIQSDVSEFPDGPADSRSVSRLLSPQSGIGLQYSTRDYLLDE 255
QY 239 ---STEAKSYR--ALYKEMVDATVLLGANSRAEHDMKVLRLEKIAEIMPHENRT 292
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 256 KKYEKOMKAKRYKTIGKVRYYTEDAG-MAVNESKIESDVDEIIAEKEMQÖLLVAEDRR 314
QY 293 S-DAMTNKMNISLMSMIQFMDLGYIKKYIDRLRPLHLKDISESENVVVRQYERDLF 351
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 315 NYTKLVNRREFDLKEYSITDMKKTLSTTPFLVHSYK-TNPS--IISDVEYÖLOKM 371
QY 352 RIGSERKTIANYLVWRMYRSRIPNLSRFQYRMLESFVIOGTTLPLPOMQCVNIE 411
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 372 TLLQNTDPRLVTVILLRMAGMSQÖELKKYEDLQÖEFAQMGRQROPRMWDQCVSSAG 431
QY 412 SALPYVVGKAFVDYIOEDKKEEMELVEGVMAFTDMLERENEMDAGTKRRAKAR 471
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 432 GKLSVAGSMYAKYEDNAKNTTLDIMTDLOEAFRNMNH-ANDMADAETKRYALEKADQ 490
QY 472 VLAQVYPEFIMNDVTENNDLKAIKFSEADYEGENVLÖTKRYLAQSPFWLR--KAVPKIE 529
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 491 MKQIOYPRFILLNDEKLDWMYKGLGAPEDSISÖLVE-KSIOMRNNFYRRLLEPRNRE 549
QY 530 WFTNPTTVAEYSASTNQIRPAGELÖKPEFMGTEVPRSLSYGALGVIOGHETFGDN 589
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 550 FISSAVVVAEYFSPRTNALAFAPAGILQPPF-DARPPKALNYGGAGAVIGHETHFDPT 608
QY 590 GKRYYKNGLDPMWSESESEKREKTKCMINQYSNYMMKAGLVNKGKTLGENTADNG 649
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 609 GQÖFDNVGMLRPMWDNTTSSKFNERQÖCILEYADVKLKGTLRLNGKLOEENTINDNG 668
QY 650 LNEAFRAYRWINDRROGLEEPLLPQI-TFTNQÖLFELSYAHVRCNSYPRPEARQVQIG 708
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 669 IKAÖKFAKYSY--EKHGQÖEARLPQESLITNEQÖLFVYQADVWGAKPRFKITILLTD 726
QY 709 AHSPPQFRNGALNSSEÖKAFENCPNPSTNMRGMDSCILW 749
   ::::: ::::: ::::: ::::: ::::: ::::: ::::: ::::: :::::
Db 727 PHSPTARNAVYLINQÖPEAEKCPAGSPNM-PTKRQCVW 766

```

RESULT 13

protein F18A12.8 [imported] - *Caenorhabditis elegans*
C.Species: *Caenorhabditis elegans*
C.Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 10-May-2001
C.Accession: C88099
Randomness: The C. elegans Sequencing Consortium.
Science 282, 2012-2016, 1998
A.Title: Genome sequence of the nematode *C. elegans*: a platform for investigating bid
A.Reference numbers: A15000; MUID:99069613; PMID:9851916
A.Note: see websites genome.wustl.edu/gsc/C_elegans/ and www.sanger.ac.uk/Projects/C_
A.Note: published errata appeared in Science 283, 35, 1999; Science 283, 2103, 1999;
A.Accession: C88099
A.Status: preliminary
A.Molecule type: DNA
A.Residues: 1-590 <SMD>
A.Cross-references: GB:chr-IT; PIDN:AB66079.1; PID:G2315629; GSPDB:GN00020; CESP:F18A
C.Genetics:
A.Gene: F18A12.8
A.Map position: 2

Query Match 25.28; Score 997; DB 2; Length 590;

Best Local Similarity 34.8%; Pred. No. 9.9e-60;
Matches 214; Conservative 120; Mismatches 237; Indels 44; Gaps 14;

QY 154 KLLHLRLSPRPVLESGNIGPEGVSRKSLQTLATFPGQVSNVYRLIYSPDK 213
Db 1 RLPLETLELG-EMPLDEN-----WDKTKFNTSLVNSRRDGVVFFOLYIYASK 53
QY 214 ASNEHLIKDAQTLIA-VREDYLDNSTEAKSYRDALYKFWVDVAVLL--GANSRABH- 269
Db 54 NTSRNLFLDQSTLALGRTIRYIANTILFSSHMTAIRKYLKQIHLKTLTDGNTLRSSE 113
QY 270 ---DMKSVLRLEIKIAEIMIPH-ENRTSEAMYNKMNISELAMIPOFDMGIIKIVIDTR 325
Db 114 MNADIEKIDFEIETAKIIVADERNNRTLYNKRQIDOLYVNLPOVWV----- 163
QY 326 LPHLKDLSPE-----NVVVRVPOYFEDLFRILIGSEKKTIANIYLVWRYMSRIP 376
Db 164 --PFOSTAPSDTLPHFNETEIIICEIEYLQHVSELEKTDVGLTYVLMRVVQSNVR 221
QY 377 NLSRRFOYFMLEFSRVIOGTTTLTPQMDKCVNFIESALPYVVGKMFVDYFQEDKEMME 436
Db 222 YDEREDFKODFLKVMGQOSPPRMKDCAYPSTVPLAAGALIYQAHQESDKHEAL 281
QY 437 ELVEGVRAAFIDMLEKENEMDAGTKRAKERAVALAKVGPPEFIMDTHVEDLKAIK 496
Db 282 RIMHMLNRSFADLV-RQNDMDDEETKAVALEKANSMINNIGPYDVTNLPKLDKQYLGIS 340
QY 497 FSEADYFGVNLQTKRYLQOS-DEFMLKRAVPKTEWFTNPTTANAYASASTQIRPAGEL 555
Db 341 ISDSDFYIYKMSVYVWMSREFQKLPEDKHEEDISPAVVANYSPEKNAITPPAGIL 400
QY 556 QRPFFGTEYPRSLSYGAIGVIGHEFTGFQDNNGRYKDKNGLDPMWSTESSEKFEKKT 615
Db 401 QPFFSGT-FPRAVYVGAIGVIGHEITHGFPDQSGQYDKDGNLNMWSESSLSFDRR 459
QY 616 KCMINQSYVYKKAAGLVKGRITLGENIADNGLEAFRAYRKMIINDROGLEBPLPG 675
Db 460 RCIVEQYGVYVPTKTNFRVNGKLTQGENIADNGVKEAQAQYKVTENG--EERPLPG 516
QY 676 I-TFTNNOLFELSYAHVRCNSYRPEARBOVQIGAHSPQPFVYNAISNSEQFAFNC 734
Db 517 LQOYITQEQLEFVSVAHFVWGKKEAAMQOVLTDHSPVFRVIGVLSMMAFADYVRCP 576
QY 735 PNSTNRGMDSCRLW 749
Db 577 RNAPVNPD-HKCIW 590

RESULT 14

T24949
hypothetical protein T16A9.4 - *Caenorhabditis elegans*
C:Species: *Caenorhabditis elegans*
C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 21-Jan-2000
C:Accession: T24949
R:McMurray, A.
submitted to the EMBL Data Library, July 1996
A:Reference number: z19959
A:Accession: T24949
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: DNA
A:Residues: 1-769 <W1>
A:Cross-references: EMBL:Z77135; P1DN:CA00879.1; GSPDB:GN00023; CESP:T16A9.4
A:Experimental source: clone T16A9
C:Genetics:
A:Gene: CESP:T16A9.4
A:Map position: 5
A:introns: 15/2; 59/1; 105/3; 202/1; 336/3; 371/3; 393/1; 424/2; 457/3; 571/1; 637/2; 67
C:Superfamily: neprilysin

Query Match 24.0%; Score 949; DB 2; Length 769;
Best Local Similarity 30.6%; Pred. No. 2.7e-56;
Matches 224; Conservative 147; Mismatches 277; Indels 84; Gaps 22;

QY 54 CLKPECIAAAAILSKVNLGYVPCDNFPRACDGMISNNIPEDMPSYGVYVWLRHNV-- 111
Db 86 CTSRECYRIAGFLAENLSKINPCEDYFEACCGVGNKMLPANKP-----LRHISD 138
QY 112 ----DIKLELLKESISRRDTEAIK----AKILYSSCMNEKALEKADAPLHLIR 161
Db 139 VQSRNKKVQSMLOSPIS-----ANEKPMVDKAVKGYQCLDEBELESIGVEAMRDIK 192
QY 162 HSPFRVYVLESGNIGPEGVSRKSLQTLATFPGQVSNVYRLIYSPDKASNEH 218
Db 193 RIG-GWPLEDGDQWQ--WSHWEQIALVNLNLGV-----NAVILEMAATHDPSNSSRS 244
QY 219 ILKIDQATLSLAVEDYLD--NSTEAKSYRDALYKFWVDVAVLLGANSRAEDMSVLR 276
Db 245 VIELDQPKWAGSRYPILSGANDPMLNFT-----TLKMTKVALGADPALAEKEMNEAME 300
QY 277 LEIKI---AEIMIPHENRTSEAMYNKMNISELAMIPOFDMGIIKIVIDTRLYPHLKD 332
Db 301 FELKIVNSADWV---RDPERNGNFELMQLKSVPEFINFERYKTV-----FKELVA 352
QY 333 ISPEENVVVRVPOYFEDLFRILIGSEKKTIANIYLVWRYMSRIPNLSRRFOYFMLEFSRV 392
Db 353 LSPNHVYIVREIDYVGIQHVLOSTPKRVLANIYMSRLVQGSFSPFLPPSAREPFOFKAN 412
QY 393 IQGTTTLTP--QMDKCVNFIESALPYVVGKMFVDYFQEDK-KEMBELEGVRAAFIDM 449
Db 413 QTGMEFNSPPDRMEDCVTLISVIMDMVGRFLVFNFEKERAKMKMELISYLNKEIRQ 472
QY 450 LEKENEMDAGTKRAKERAVALAKVGPPEFIMDTHVEDLKAIKFSEADYFGVNLQ 509
Db 473 LH-VLDWMDDEETRRRAISKAMIEYKSGFPVLFENDTMEKN-----WGMILKP 520
QY 510 KRYLAQ-----SDFMLKRAVPKTEWFTNPTTANAYASASTQIRPAGELQK 558
Db 521 REYLHLITRYKLVFTTELLRLDQPDRSKMWQSPQVAYVAPANNEMIFPAGINQFP 560
QY 559 FFMGTEYPRSLSYGAIGVIGHEFTGFQDNNGRYKDKNGLDPMWSTESSEKFEKTKM 618
Db 581 FL-TLGYPNYITTYGMVAGVIGHEVSHAFDDQGGYDENGKLNMDWMDTEKEKTEKTRCF 639
QY 619 INQYSNYVYKKAAGLVKGRITLGENIADNGLEAFRAYRKMIINDROGLEBPLPGI-T 677
Db 640 VROYENHVEADIDHNGQLSLGENIADNGVKAFAFNAKAM-KSNYTGISEPALGCFQGN 698
QY 678 FTNNOLFELSYAHVRCNSYRPEARBOVQIGAHSPQPFVYNAISNSEQFAFNCPPNS 737
Db 699 FTSOQMFPLAVANNWCSLVKPKHYITLTDVAPSKYRAMIPLQNRPEFAKAFQCPG 758
QY 738 TNNRGMDSCRLW 749
Db 759 PMNPER-KCQYW 769

RESULT 15

F87683
peptidase M13 family protein [imported] - *Caulobacter crescentus*
C:Species: *Caulobacter crescentus*
C>Date: 20-Apr-2001 #sequence_revision 20-Apr-2001 #text_change 10-May-2001
C:Accession: F87683
R:Neiman, W.C.; Feldblyum, T.V.; Paulsen, I.T.; Nelson, K.E.; Eisen, J.; Heidelberg, B.; Laub, M.T.; Deboy, R.T.; Dodson, R.J.; Durkin, A.S.; Gwinn, M.L.; Haft, D.H.; Ko n, J.; Ermolaeva, M.; White, O.; Salzberg, S.L.; Shapiro, L.; Venter, J.C.; Fraser, C
Proc. Natl. Acad. Sci. U.S.A. 98, 4136-4141, 2001
A:Title: Complete Genome Sequence of *Caulobacter crescentus*.
A:Reference number: A87249; M01D:21173698; PMID:11235647
A:Accession: F87683
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-706 <SNO>
A:Cross-references: GB:AE005673; MID:G13425232; P1DN:AAK25466.1; GSPDB:GN00148
C:Genetics:
A:Gene: CC3504
C:Superfamily: neprilysin

Query Match	20.6%;	Score 814.5;	DB 2;	Length 706;
Best Local Similarity	30.6%;	Pred. No. 3.1e-47;		
Matches 229;	Conservative 109;	Mismatches 316;	Indels 95;	Gaps 20;

[illegible]

Search completed: May 21, 2003, 18:50:01
Job time : 52 secs